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The Role of Metallothionein and Zinc Signaling in CD4+ T cell Activation and 
Differentiation 
James M. Rice, PhD 
University of Connecticut, 2014 
 
Metallothioneins (MTs) are small-molecular weight, high cysteine content 
proteins that bind and release zinc ions in response to redox signaling and oxidative 
stress.  Although the precise cellular functions of MTs remain elusive, their upregulation 
in CD4+ T cells following activation and during inflammation implicates their role in 
modulating immune responses. To understand the role of MT in CD4+ T cells, MT 
expression and [Zn2+] were characterized under different cytokine environments during 
primary and secondary activation. Increased MT expression correlates with a higher 
intracellular [Zn2+] following activation, suggesting a potential mechanism of increased 
MT expression and a role for MT in the differentiation of the CD4+ Tr1 effector 
phenotype.  
CD4+ T cells that do not express MT (MT-KO) exhibit a weaker increase in 
intracellular labile [Zn2+] following exposure to extracellular ROS or following T cell 
receptor activation compared with congenic wildtype controls (MT-WT). However, 
oxidation of ROS sensitive probes is equivalent in the presence or absence of MT, 
suggesting MT provides a redox sensitive mobilizable zinc reservoir but does not affect 
the total redox buffering capacity. These results suggest a role for MT in modifying 
intracellular signal transduction in CD4+ T cells by increasing intracellular [Zn2+] 
following ROS production.  
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Chapter 1  
Introduction  
 Over the last decade, significant progress has been made in elucidating the roles 
of biological labile zinc and its effect on intracellular signal transduction. Because 
intracellular concentrations of labile zinc ions (hereafter referred to as [Zn2+]) are 
maintained in the picomolar (pM) range in lymphocytes, investigating changes in [Zn2+] 
was not possible until the development of suitable high-affinity fluorescent sensors. 
Following the widespread use of these sensors to investigate immune cell signaling, a 
paradigm of cellular fluctuations in [Zn2+] as an important cellular signal has emerged. 
These fluctuations are associated with activation and cytokine receptor signaling and 
have significant and measurable effects on cell proliferation.  
The spatial and temporal organization of zinc signals varies between cell types 
and signal origin. In CD4+ T cells, zinc influx into the cytosol from both extracellular and 
vesicular spaces has been observed, resulting in an increase in cytoplasmic [Zn2+]. This 
increase overlaps with cytosolic activation of phosphorylation dependent signaling 
networks, including MAPK and JAK/STAT pathways. Small increases ( >1 nM) in 
cytoplasmic [Zn2+] have the potential to modify these signaling networks by inhibiting 
phosphatase activity. Inhibition of phosphatases that are considered negative regulators 
of CD4+ T cell signaling by zinc, including SHP-1 and MKP-1, are thought to be 
important regulatory checkpoints for cell proliferation.  
The following work explores a novel mechanism for increased cytoplasmic [Zn2+] 
in CD4+ T cells that is independent of trans-membrane zinc movement through ion 
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transporters. Cytoplasmic pools of metallothioneins (collectively referred to as MT) 
serve as a redox mobilizable reservoir of zinc ions. The unique biochemistry of MT 
allows for the conversion of reactive oxygen species (ROS) into an increased 
cytoplasmic [Zn2+], therefore converting a redox signal into a zinc signal. This can occur 
even in the overall reducing environment of the cytoplasm because of the low redox 
potential afforded to MT by its high cysteine content. The recent observations of ROS 
and RNS signals in CD4+ T cells following activation provide a potential mechanism by 
which zinc release from cytoplasmic could affect intracellular signaling networks. 
 
The central hypothesis in this thesis is metallothionein provides a redox 
mobilizable zinc reservoir in CD4+ T cells following activation that affects intracellular 
signal transduction. This will be broken down into the following testable hypotheses: 
1. MT is expressed in effector CD4+ T cells  
2. CD4+ T cells that express MT exhibit a greater increase in intracellular [Zn2+] 
following exposure to ROS compared to congenic MT knockout controls 
3. CD4+ T cells that express MT exhibit a greater increase in intracellular [Zn2+] 
following T cell activation compared to congenic MT knockout controls 
4. The increased zinc signal associated with MT expression increases activation 
of the p38 MAPK pathway in CD4+ T cells 
5. MT gene dose affects IL-10 secretion from CD4+ T cells via regulation of 
intracellular [Zn2+] 
 
1.1 Thesis Overview 
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Chapter 1 provides a general review of metallothionein (MT) and its various 
biological functions with an emphasis on expression in CD4+ T cells. This includes 
regulation of MT expression at the genetic level (transcriptional, post-transcriptional, 
epigenetic) and protein level (translation, degradation, trafficking). This is followed by a 
review of MT structure and how that contributes to its unique position at the intersection 
of redox and zinc signaling in biology. This is followed by a review of CD4+ T cells and 
their contribution to adaptive immune responses through clonal expansion and 
differentiation. The role of labile [Zn2+] in modifying CD4+ T cell signaling pathways 
following activation is discussed and a role for MT in modulating the labile [Zn2+]  is 
proposed.  
Chapter 2 describes the materials and methods used in the experiments 
described in this thesis. These include descriptions of the mouse models and the culture 
conditions used to generate the Tr1 and TH0 CD4+ T cell phenotypes. Establishing a 
condition of robust MT expression in MT-WT CD4+ T cells using the Tr1 phenotype will 
allow experimental investigation into the effects of MT by comparing wildtype Tr1 cells 
with Tr1 cells from congenic MT knockout mice (MT-KO). Specific reagents and 
protocols are referenced. 
Chapter 3 establishes the experimental foundation of how intracellular [Zn2+] is 
measured in CD4+ T cells in vitro. This includes methods to manipulate intracellular 
[Zn2+] using zinc specific chelators or ionophores as well as control of intracellular [Zn2+] 
through addition of antioxidants or an extracellular [Zn2+]. The subcellular localization of  
Zn2+ and the effect of MT gene dose on that localization is investigated by confocal 
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microscopy. Finally, the sensitivity of the p38 MAPK pathway to intracellular [Zn2+] in 
CD4+ T cells is demonstrated by western blot and flow cytometry. 
Chapter 4 explores the effects of MT on the fluctuation of intracellular [Zn2+] and 
MT expression in naïve CD4+ T cells following primary activation through the T cell 
receptor (TCR). This is done in the presence (Tr1 inducing conditions) or absence (TH0 
inducing conditions) of IL-27. The effect of MT gene dose on the redox mobilizable zinc 
pool and total redox buffering capacity in Tr1 cells is then investigated. 
Chapter 5 examines the effects of MT on intracellular labile [Zn2+] and effector 
function during reactivation of  Tr1 cells. This includes the generation of ROS signals 
following TcR mediated activation and the subsequent increase in intracellular labile 
[Zn2+]. The effect of this increase in intracellular labile [Zn2+] on the p38 MAPK pathway 
and IL-10/ IFN-gamma secretion in Tr1 cells is then explored. Finally, the effect of MT 
gene dose on in vivo adaptive immune responses is assessed by isotyping the IgG 
response to type II collagen and by comparing the Treg frequency with CD4+ T cell 
populations with MT gene dose.  
Chapter 6 brings together a discussion of the experimental results and how they 
suggest a role for MT as a reservoir of redox mobilizable intracellular labile zinc in CD4+ 
T cell activation. Finally, future directions for continuing to investigate the impact of MT 
on intracellular labile zinc signaling are proposed. 
 
1.2  Metallothionein 
Metallothioneins (collectively referred to as MT) are small-molecular weight, high 
cysteine content proteins that are ubiquitously expressed in most mammalian cells.  
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Although the precise cellular functions of MTs remain elusive, their upregulation in 
response to increases in metal or reactive oxygen species (ROS) or pro-inflammatory 
cytokines1 suggests an important role during cellular stress responses. These 
conditions are present during adaptive immune responses where extracellular cytokines 
and intracellular redox and zinc ion signaling events precede the proliferation and 
differentiation of CD4+ T cells. The unique biochemistry of MTs allows for the binding 
and release of zinc ions in response to redox signaling and may therefore play a role in 
shaping adaptive immune responses by directly influencing these signaling pathways. 
 Significant experimental evidence indicates that MTs are immuno-modulatory in 
both autoimmune disease and infection models, although the mechanisms underlying 
these effects remain poorly understood. Generally, inflammation and disease severity 
are increased in CD4+ T cell mediated autoimmune disease models in MT knockout 
mice (MTKO) compared with wildtype controls 2,3. However, MT expression is 
associated with increased inflammation in models of autoimmune inflammatory colitis 4 
and EAE when CD4+ T  cells are adoptively transferred5. These divergent 
immunological consequences suggest that the effects of MT on the adaptive immune 
response are context dependent.  
Intracellular zinc signaling has recently emerged as an important component of T 
cell activation and differentiation 6 and may play a role in MT mediated 
immunomodulation. Nanomolar increases in intracellular labile [Zn2+] can have 
significant effects on signaling pathways originating from the T cell receptor 7, cytokine 
receptors 8 or toll-like receptors 9. Increases in intracellular [Zn2+] inhibit distinct sets of 
intracellular kinases 10 11 and phosphatases 12 13,14 that alter STAT and MAPK signaling 
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networks and affect transcription factor activity. Regulating the concentration of labile 
intracellular zinc, therefore, has the potential to dramatically impact the development of 
CD4+ T cell effector function 15-17 and ultimately immune function and disease pathology.  
 MTs have the ability to bind and release zinc under physiologically relevant 
conditions and, along with cell specific Zn importers and exporters, are part of a network 
that regulates intracellular [Zn2+] . The intracellular pool of MT is comprised of oxidized, 
reduced and zinc bound forms 18 19 whose dynamic equilibrium is positioned to release 
Zn in response to intracellular ROS generation and subsequently increase intracellular 
labile [Zn2+] . Zn release is possible even in the reducing environment of the cytoplasm 
through reactions with selenium redox catalysts20. The 20 vicinal cysteine residues of 
MT impart a very low redox potential (-366 mV) which directs its preferential oxidation 
before other free thiols like GSH 21. Additionally, three of the seven Zn binding sites of 
MT have an affinity for Zn (logK = 10 – 7.7)22 that allow Zn to be released and affect 
enzyme activity and signaling cascades6. These properties uniquely position MT to 
transduce ROS signals into Zn signals within the narrow range of redox and Zn 
fluctuations that occur during CD4+ T cell activation. 
In this report, the relevant state of the field for measuring intracellular labile [Zn2+] 
and [MT] and the development of protocols for measurement in lymphocytes is 
reviewed. Development of these methods forms the experimental foundation for 
investigating fluctuations in intracellular labile [Zn2+] and MT during primary CD4+ T cell 
activation and differentiation into effector phenotypes. Furthermore, insight into the 
contribution of MT in this process will be gained by using an MT-KO model that does not 
express functional MT1 or MT2 proteins. Experimental manipulation of labile [Zn2+] will 
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also be investigated to determine the effect of MT gene dose on zinc mediated 
regulation of p38 MAPK activation and IL-10 and IFN-gamma secretion during 
secondary activation of CD4+ T effector cell subsets. Finally, the broader 
immunomodulatory effects of MT will be examined by observing the humoral responses 
to type II collagen immunization as part of a mouse model of inflammatory autoimmune 
arthritis.  
 
1.2.1 History and Occurrence  
The first MTs were first isolated in 1957 from a equine kidney cortex after 
cadmium exposure 23 and is the only protein known to contain this metal 24. The 
designation of metallothioneins, as its name suggests, comes from the combination of 
the high cysteine content and the ability to bind metals. MTs were originally 
characterized by the following characteristics: molecular weight of 6-7 kDa; high metal 
content: characteristic amino acid composition (high cysteine content, no aromatic or 
histidine residues); unique distribution of cysteine residues; and unique spectroscopic 
signatures associated with metal-thiolate bonds. At the First International Meeting on 
Metallothionein and Other Low Molecular Weight Metal-binding Proteins in 1978, the 
definition of metallothionein was adopted and any protein satisfying several of the 
criteria can be classified as MT. This classification strategy was revised in 1999 and is 
currently based on phylogenetic relationships between the protein and the nucleotide 
sequences of different isoforms25. The focus of Part 1 of this thesis will be to outline the 
unique structure of MTs and how that structure contributes to redox and zinc binding 
functions. 
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Metallothioneins, as defined above, can be found in both eukaryotes and 
prokaryotes and all vertebrate and invertebrate phyla except coelenterate (marine 
jellyfish). A comprehensive list of all the metallothioneins is beyond the scope of this 
thesis but for a review and comprehensive list of MT expression systems in different 
living systems see 26. In mammals, 4 distinct isoforms of MT are expressed, of which 
MT-1 and MT-2 are the most abundant and are the only isoforms classes expressed in 
lymphocytes.  MT1 and MT2 will be only isoforms discussed in this thesis and hereafter  
will be referred to collectively as MT. MT-1 and MT-2 differ by only a single negative 
charge that separates them during ion exchange chromatography, which led to the first 
distinction between MT1 and MT2. Within the MT-1 and MT-2 charge groups, many 
mammals (but not mice) express multiple isoforms with the same charge but distinct 
structures (see genetic organization below). MT-3 is found primarily in the brain and 
neurons 27 although its mRNA is expressed in the tongue, stomach, heart, kidney and 
reproductive tissues 28,29. MT-4 is the least studied of the 4 isoforms and has been 
detected primarily in squamous epithelia 30.  
Constitutive levels of MT expression can be found in most cell types, with certain 
tissues containing high levels of MT and others expressing significant less. In31 adult 
monkeys, for example, the hierarchy of concentrations in tissues are kidney > liver > 
pancreas > intestine > testes > lung > heart 32. There is considerable variation between 
species in concentrations of MTs in various tissues. For example, hepatic levels of MT 
ranges from 400 – 700µg MT per gram of liver tissue in humans, ~200 µg / g in 
monkeys, and 10µg / g in mice 33. These amounts vary with differences in age, state of 
development, dietary regime, and other unidentified factors, underscoring the regulation 
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of MT as a dynamic component of tissues and cells that is under various regulatory 
controls.  
Determining the presence and concentration of MT in blood cells and, in 
particular, lymphocytes is challenging because of the lower level of expression when 
compared with the liver or kidney. In general, MT protein concentrations in leukocytes 
are measured by Cd/ Hemoglobin Affinity assay, immunoassay (such as immunoblot or 
ELISA), or by immunofluorescence. Baseline estimates of MT expression place resting 
levels in human T lymphocytes at ~1.21nM with 4 times higher levels in B 
lymphocytes34. Activation of lymphocytes by mitogens, or exposure to inducing agents 
including Zn, Cd, or dexamethasone (a glucocorticoid analog) strongly induces the 
expression of MT in human lymphocytes. After 2 or 6 days in culture with extracellular 
ZnCl [125µM], T cell expression of MT increased 3-fold and 10-fold, respectively34. In 
mice, MT expression in lymphocytes and hepatic tissue is lower than in humans. MT 
protein levels are virtually undetectable in mouse splenocytes without induction. 
However, upon culture with Zn or stimulation with the T cell mitogen concanavalin A, 
MT is rapidly induced and can be measured by immunoblot in concentrations around 
1.81nM and .381nM, respectively 35. Interestingly, pathways of MT induction by 
mitogens or zinc are interrelated and can be a point of regulation during T cell 
proliferation 36.  
 
1.2.2  Genetic organization  
There are several distinct differences in the phylogenetic organization of MTs 
between humans and rodents. Rodents express 4 functional MT genes (Mt1, Mt2, Mt3, 
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and Mt4), which are clustered on chromosome 8. Humans express these 4 isoforms but 
have additional copies of Mt1 and Mt2, and all functional MT genes are clustered on 
chromosome 16 (16q13). In humans, there are 13 total copies of Mt1, 2 copies of Mt2, 
and one copy each of Mt3 and Mt4. Of the 17 MT genes, 10 encode functional proteins 
(MT-1a, MT-1b, MT-1e, MT-1f, MT-1g, MT-1h, MT-1x, MT-2a, MT-3, MT-4) while 7 are 
classified as non-processed pseudogenes (Mt1c, Mt1d, Mt1i, Mt1j, Mt1k, Mt1l, Mt2b) 
according to the RCSB protein data bank (www.rcsb.org). For a thorough review see 37. 
The MT-1 and MT-2 genes show a significant degree of sequence homology between 
mouse and human (Figure 1). All 20 cysteine residues between MT-1 and MT-2 in 
mouse and human proteins are perfectly conserved. Additionally, MT-1 and MT-2 from 
many species including human, mouse, rat, rabbit, dog, horse and fish are all cross 
reactive with anti-MT antibody (clone UC1MT) (http://www.abcam.com/metallothionein-
antibody-uc1mt-ab12228.html)38demonstrating their shared antigenic structure. Taken 
together, these observations provide a reasonable basis for making inferences on the 
functions of human MTs based on mouse models.  
 To study the effects of MT in living systems, MT gene dose was manipulated in 
mice. Strains of mice that do not express (MT-KO) or overexpress MT (MT-TGN) were 
created and compared with congenic wildtype controls (MT-WT) in prospective studies 
to examine the role of MT in CD4+ T cell activation and differentiation. To create a 
functional MT knockout strain, targeted disruption of the metallothionein I and II genes 
(Mt1 and Mt2) was achieved on a 129/SvCPJ background 39. To create a functionally 
overexpressing strain (MT-TGN), 112 additional copies of Mt1 (56 on each 
chromosome) along with distal regulatory elements (cis- and trans-) from the mouse MT 
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locus were cloned and introduced onto the 129/SvCPJ mouse background40. Both of the 
congenic strains described, hereafter, were produced by 8–9 generations of 
backcrossing these mice to the C57BL/6J background strain, followed by incrossing of 
the heterozygotes to produce homozygotes for each construct. According to the 
equation for the fraction of loci that are still heterozygous at the Nth generation [(1/2)N-1] 
the amount of residual donor genetic material that may contribute to observed 
phenotypic differences after 8–9 backcrosses is between 0.2 and 0.4% 41.  
 
1.2.3  Basal Expression and Induction of MT Transcription 
MT gene transcription is induced by many endogenous factors including metals, 
cytokines, oxidants, and glucocorticoids and exogenous factors including bacterial 
lipopolysaccharides (LPS) and mitogens including concanavalin A (for review see 37,42). 
MT is upregulated under normal, healthy conditions in proliferating cells and under 
stressful conditions including infection, inflammation, and heavy metal toxicity, Because 
of the latter, MT is considered in many contexts to be a stress response protein 
because of its relatively fast induction (<2 hours) and small molecular weight; features it 
shares with other stress response proteins including heat shock proteins (HSPs). When 
MT is found in the extracellular environment it can even be considered a danger signal 
and can influence immune cell chemotaxis and the pathogenesis of inflammatory 
autoimmune colitis 4. 
All MT genes in both mice and humans share similar regulatory elements that 
control their transcription. However, the preferential induction of certain MT isoforms 
under particular conditions indicates a high degree of regulatory control. In mice, for 
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example, metals and glucocorticoids equally induce MT-1 and MT-243,44. In humans, 
metals induce all MT isoforms but preferentially induce MT-2a with 5 times greater 
efficiency that MT-1. Glucocorticoids induce MT-2a and MT-1e45 but not the other MT-1 
isoforms and with the same bias towards MT-2a. It is important to note that the 
presence of multiple copies of MT1 genes as a result of gene duplication in humans has 
allowed for the mutation and evolution of the regulatory elements upstream of each 
gene copy, resulting in induction and expression patterns in humans that are cell and 
tissue specific. The multiple isoforms of MT1 and MT2 encoded by these genes, 
however, are so close in structure and sequence homology that they are considered 
functionally equivalent with regard to binding and releasing Zn. Furthermore, while MT1 
expression patterns may differ between human cell types, the pattern of expression in 
mouse and human lymphocytes is the same. This includes the metal dependent 
coordinate regulation of MT-1 and MT-2 genes, which further supports using mice as a 
model system for studying MT post induction in lymphocytes. Below is a brief overview 
of MT expression and induction in humans and mice with a focus on lymphocytes. 
The transcriptional regulation of MT genes is reflected in its physiological 
occurrence in response to metal stress and inflammation and the relevant regulatory 
elements underlying its induction are conserved between mice and humans. Directly 
upstream (cis-) of MT genes, in order of proximity to the transcriptional start site and 
strength of positive regulation are: metal response elements (MREs); antioxidant 
response elements (AREs); binding sequences for signal transducers and activators of 
transcription (STATs) which are part of extracellular receptor signaling pathways; and 
glucocorticoid response elements (GREs). Catecholamines and glucagon act via 
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second-messenger systems (Ca2+ and cAMP dependent protein kinases) and induce 
expression via trans- acting nuclear factors. For a comprehensive review, see 46. The 
contribution of each of the regulatory elements is cell specific and can be synergistic, 
especially between non-metal induction pathways.  
 
Basal MT Expression 
Basal expression of MT genes is achieved through the presence of conserved 
TATA boxes that are 25 bp upstream of MT genes in all but 5 human MT1 isoforms 
(MT1E, MT1F, MT1H, MT1J and MT1M). GC boxes are found in all MT promoters 
(human and mouse) and are often clustered close together near the transcription start 
site. This acts as a binding motif for Sp1 factors and can synergistically stimulate 
transcription. AP-2 related basal level enhancer sequences are found in most human 
MTs as well and can result in MT overexpression and acquired resistance to cisplatin47. 
Other important regulatory elements of basal MT expression in both mice and humans 
include general transcription factor II (TFII-I) and upstream stimulatory factor (USF) 
binding to an upstream E box which overlaps with the antioxidant response elements 
(AREs). Finally, metal response elements contribute to basal MT expression, primarily 
through a low level of constitutive metal transcription factor 1 (MTF-1) binding 48. 
 
Induction by metals 
The most potent inducers of MT expression are metals. In human peripheral 
lymphocytes, induction by metals has been demonstrated for Zn2+, Cd2+, Hg2+, Cu2+, 
and Ni2+, but not Sn2+, Pb2+, Fe2+, Co2+ and Mn2+ 49. Metal induced MT synthesis is 
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mediated via cis-acting metal response elements (MREs) which are found in multiple 
copies in the promoter region of MT genes in both humans and mice and act as binding 
sites for MTF-1. MTF-1 binds to multiple, non-identical MRE sequences and a 7 bp core 
sequence (TGCRCNC) that is present in the promoter of MT genes. This variation of 
MTF-1 binding allows MT transcription to be differentially regulated by different metals50.  
 MTF-1 activity is intrinsically regulated by multiple factors. It is a multiple zinc 
finger protein and Zn is an important co-factor of MTF-1 activity. Upon Zn binding, MTF-
1 changes into an active conformation that effectively binds MREs and induces MT 
transcription. The activity of MTF-1 also relies on the CREB binding protein (CBP) and 
E1A binding protein, which are implicated in regulation of interferon-gamma production 
in human CD4+ T cells15 and regulatory T cell activation and signaling51. Oxidative 
stress has been found to activate MT52, suggesting Zn release from cellular thiols upon 
oxidation may contribute to an important Zn signal that influences the cellular 
transcriptome.  Because the amino acid sequence of MTF-1 is 93% identical between 
mouse and human, the role of MTF-1 in mouse studies can be considered to be a good 
model for human systems. 
There are many proteins that act as transcription factors capable of binding 
MREs and positively affecting Mt gene transcription during induction. Many of these 
proteins are, themselves, induced by Zn2+ and are part of a regulatory loop that 
increases MT synthesis to maintain labile [Zn2+] homeostasis. These include metal 
response element binding factor-I (MBF-1)53, zinc activated protein (ZAP)54, zinc 
regulated factor (ZiRF1)55 among others. Many of these proteins have been observed in 
certain cell types and not others, suggesting that the regulation of zinc signaling is cell 
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type specific. In lymphocytes, the cell type that is the focus of this thesis, the most 
important signaling pathway for metal induction of MT is MTF-1. 
Cd2+ and Zn2+ are the most potent inducers 56 of MT in all systems and can 
induce maximum MT expression in lymphocytes. Because Cd2+ and all other metals 
known to induce MT except for Zn2+ and Cu2+ are not biologically relevant under normal 
conditions, the remainder of this review will focus on Zn as the primary and most potent 
metal inducer of MT. Additionally, Cd2+ induction of MT is mediated, in part, through 
displacement of Zn from cellular ligands which confers a zinc signal, similar to induction 
by zinc itself. Of note, normal physiological concentrations of Cu2+ do not induce MT 
synthesis and therefore Zn can be considered the only relevant MT inducing metal. 
Because Zn signaling is an important regulatory component of many T cell processes, 
including but not limited to activation or exposure to oxidative stress (see Part 2 of the 
Introduction), the regulation of MT expression by Zn2+ should not be considered only in 
the context of environmental or nutritional excesses or deprivation, but rather as an 
important component of many signaling pathways. 
 
Induction by stress, inflammation, and infection 
 When circulating CD4+ T cell populations. When these extravasate through the 
blood vessels into sites of inflammation or infection, they become exposed high local 
concentrations of inflammatory mediators and oxidative stress, which are both strong 
inducers of MT synthesis. It is important to remember this temporal and spatial 
organization of CD4+ T cell exposure to MT inducing conditions when evaluating in vitro 
models of CD4+ T cell function. In general, activated and expanded T cell populations 
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that have exited secondary lymphoid tissues have been activated and expanded and 
have higher basal expression of MT than naïve cells. These populations also express 
higher levels of VCAM and other extracellular receptors that facilitate their chemotaxis 
into sites of infection and inflammation where they are likely to experience higher 
concentrations of molecular signals that further induce MT. This is in contrast to 
increased MT synthesis in naïve CD4+ T cells that are exposed to increased systemic 
levels of cortisol or IL-6 in the peripheral blood, for example.  
Transcriptional activation of MT genes following exposure to glucocorticoids (ex. 
cortisol), reactive oxygen species (ROS), and reactive nitrogen species (RNS) is 
independent of signaling through an extracellular receptor because these signals enter 
the cell through simple diffusion. This is in contrast to signaling though membrane-
bound receptors where signals from many receptors are transduced via second 
messengers (cAMP, cGMP, g proteins, etc.) and the integration of these transduced 
signals results in transcriptional activation.  
Glucocorticoids (GCs) and the synthetic glucocorticoid receptor agonist 
dexamethasone are strong inducers of MT in lymphocytes. In this receptor-ligand 
interaction, the cytosolic GC receptor binds cortisol that has diffused into the cell and 
becomes an active transcription factor capable of binding to GREs and upregulating 
transcription (for review see 57). The human MT2A gene contains one GRE while murine 
MT1 and MT2 genes contain two tandem copies approximately 7 kb and 1 kb upstream, 
respectively. Consequently, GC induced expression of MT2A is significantly greater 
than MT1 in humans. In mice, the two isoforms are induced equally58.  
Transcription of MT genes following exposure to ROS is a consequence of the 
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activation of Nrf2 and upstream stimulatory factor (USF) and their subsequent binding to 
antioxidant response elements (AREs). AREs have been found upstream of murine 
MT1 and human MT1G genes, the products of which are expressed following exposure 
to hydrogen peroxide or chemicals that induce oxidative stress59. An alternative 
pathway for induction by ROS has been demonstrated by the increased binding activity 
of MTF1 in cells treated with hydrogen peroxide 60, which is due to an increase in zinc 
redistribution in the cell following oxidation of cellular thiol ligands. Nitric oxide induces 
MT transcription in a similar manner. Exogenous addition or endogenous production 
(via inducible nitric oxide synthase) leads to zinc release and subsequent transcription 
of MT1 and MT2 genes 61,62 through MTF-1 activation. Alternatively, NO causes the 
nitrosylation of Keap-1 which actives Nrf2 and activates transcription via binding to 
AREs63. 
The fourth pathway of induction of MT transcription includes signaling through 
extracellular cytokine receptors. The four cytokines most strongly associated with MT 
induction are all considered pro-inflammatory and are secreted by immune cell 
populations in the context of infection and inflammation. These include IL-6, TNF-alpha, 
IL-1alpha and IL-1beta. IL-1 signaling is most likely mediated through glucocorticoids64. 
IL-6 signaling is achieved through activation and dimerization of signal transducer and 
activator of transcription 3(STAT3)65. These transcription factors bind IL-6 response 
elements (IL6RE) located in the 800 bp region upstream of all human and mouse MT1 
genes between GREs and AREs. Interestingly, there is a synergistic effect of IL-6 and 
GCs on MT1 induction, most likely due to the close proximity of IL6REs and GREs in 
the promoter region66. The heterogeneity of cytokine receptor expression on different 
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cells types and during different stages of cell activation results in pleiotropic cytokine 
mediated effects. TNF-alpha, in particular, which signals through TNFR1 and TNFR2, 
gives rise to different intracellular signaling pathways that are pro-apoptotic or pro-
inflammatory, respectively. The cell dependent effects of TNF-alpha are evidenced by 
MT expression where MT-2 is preferentially induced in the liver and MT-1 is 
preferentially induced in the heart and lungs67 following TNF-alpha exposure. 
Interestingly, MT expression in tissues following induction by IL-6 and TNF-alpha 
correlates with a marked decrease in plasma [Zn2+] as part of an acute phase response 
to infection. 
Inhibition of MT transcription also provides an important regulatory control for 
gene expression. Nuclear Factor 1 (NF1) suppresses both the constitutive and metal-
induced activation of the MT1 promoter in both humans and mice68 by binding to the 
MRE-c element. Dephosphorylation of the transcription factor C/EBPα following 
PI3K/AKT signaling is another mechanism of inhibition of MT expression. Trans- acting 
elements have been observed to be inhibited by a zinc binding transcription blocker 
PZ120, now called ZBTB1169.  
 
Epigenetic Regulation 
Epigenetic regulation of MT genes is achieved through methylation of promoter 
regions in certain cell types or through modification of chromatin structure31. In contrast 
to unmodified regulatory elements, methylation of the 5 position of cytosine residues 
that occur as part of CpG dinucleotides can reduce associated gene expression. In MT 
promoter regions, CpG islands (defined as a region of DNA that is >60% CpG) have 
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been observed and are known to be hypermethylated in certain cancer cell types 70. 
Chromatin modification is thought to also affect MT gene accessibility because addition 
of sodium butyrate, which is known to generate DNAse I hypersensitive sites, increases 
MT mRNA levels and renders the genes hypersensitive to metal induction71,72. In 
lymphoid cells, removal of DNA methylation by azacitidine treatment increases 
expression of MT-1F and MT-1G in response to zinc and MT-2A in response to 
dexamethasone, indicating a level of epigenetic repression that influences cell specific 
expression31. Given the high degree of chromatin remodeling that occurs during CD4+ T 
cell activation and differentiation, chromatin structure may also play a role in lymphoid 
effector phenotype specific MT expression. 
Although many mechanisms of MT gene specific activation and repression are 
cell type specific, they illustrate the complex nature of transcriptional regulation of MT 
genes. The organization and structure of the cis- and trans- regulatory elements 
suggests a level of regulation that is intimately involved with inflammatory immune 
processes and is tightly controlled by the interplay between zinc, ROS/RNS, and 
inflammatory cytokines. In lymphocytes, all of the following regulatory mechanisms 
contribute to MT expression. Hypermethylation of the MT-1 gene promoter in the 
thymus, for example, limits MT expression in immature thymocytes44,73 but this 
repression is removed upon entry into the periphery. Zinc signaling, cytokine signaling, 
redox signaling, and chromatin remodeling are all essential components of CD4+ T cell 
activation, differentiation, and development and are all intimately related to MT induction 
and feedback loops. Understanding the role of MT in influencing CD4+ T cell 
differentiation relies upon an understanding of how different inducing conditions 
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contribute to the pool of intracellular MT and sets the stage for MT mediated effects on 
cell activation and signaling.  
  
1.2.4  Translation, Degradation and Trafficking 
Translation 
There is strong evidence of post-transcriptional control of MT mRNA that is both 
metal and isoform specific74,75. Zn concentration affects the rate of Mt1 and Mt2 mRNA 
turnover and recruitment of MT1 mRNA transcripts to the polysomes where the protein 
is synthesized76. Even though more MT2 mRNA is expressed in most human cells, a 
greater proportion of MT1 mRNA is associated with polysomes suggesting it is 
translated more efficiently. This difference in post-transcriptional control is a central 
reason MT mRNA levels are often not reflected by MT protein concentration within cells. 
This discrepancy emphasizes the need to measure protein levels in addition to RT PCR 
techniques that measure mRNA. 
 
Post-Translational Modifications 
 The most common and well studied post translational modification is the binding 
of metal ions, which happens immediately after the protein is translated, and, to some 
extent, during translation itself. On human MT1 and MT2, there are 2 sites of potential 
phosphorylation (serine 6 and 12), 2 potential sites for acetylation (lysine 22 and 51) 
and 1 site for ubiquitination (lysine 43). Of these sites, only the K43 site is conserved 
between mouse and human. Acetylated and non-acetylated forms of MT2 both occur in 
relatively equal proportions in the human liver and plasma 77 but the biological 
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significance of this modification is not known. Furthermore, interactions between MT 
and glutathione78 and ATP 79 have also been observed. 
 
Degradation 
The total cytosolic concentration of MT is a function of both its rate of expression 
and degradation. MT degradation takes place primarily in the lysosomes via the 
proteolytic action of cathepsins B and/or L80,81. On a more limited basis, MT degradation 
occurs in the cytoplasm via neutral, soluble proteases82. The rate of MT degradation is 
both metal and redox dependent and isoform specific. Metal bound MTs have a much 
longer half life ex vivo, in vivo, and in vitro than MTs that are not bound to metals 
(apoMTs) 83-85. The type of metal bound and the degree of metal binding saturation are 
affected by the metal status of the organism as well as the redox poise of the cells 
themselves. Furthermore, other factors that affect MT-metal binding affinity, including 
pH, indirectly affect MT stability and degradation by affecting metal binding. This is a 
may be a contributing factor to lysosomal degradation of zinc bound MT, where the pH 
is significantly lower (3.6 – 5 vs. 7.2), being the predominant MT degradation pathway. 
Regarding isoform specific proteolysis, the alpha-domain of MT-1 and the beta domain 
of MT-2, but no other combinations, have been found in the liver form zinc treated rats86. 
This suggests that the different metal clusters of MT-1 and MT-2 may have different 
proteolytic degradation pathways, providing further control over the cell and tissue 
specific accumulation of the two isoforms beyond transcriptional and post-transcriptional 
regulation. It should be noted that the mechanisms described above were observed in 
cell and tissue systems that express large amounts of MT upon exposure to heavy 
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metals or zinc. In this way, MT is a primary metal detoxifying agent and a central player 
in the physiology underlying resistance of organisms to heavy metal toxicity. The focus 
of this thesis, however, will only cover fluctuations in zinc that occur within a normal 
physiological range and only in lymphocytes. It is important to remember that the 
degradation of large amounts of MT in liver cells following exposure to cadmium might 
not be an entirely relevant model for the degradation of MT in lymphocytes, where it is 
primary lysosomal and not significantly different for MT-1 and MT-2. 
 
Nuclear Trafficking 
MT is usually a cytoplasmic protein but exhibits preferential nuclear localization 
under several conditions. These include malignant tumor growth, fetal liver, in high 
glucose medium, and in proliferating and differentiating cells. Consequently, nuclear MT 
localization can be considered cell cycle and proliferation stimulus dependent. MT lacks 
a traditional nuclear localization signal (NLS) that would traffic the protein to the nucleus. 
Similar to calmodulin, which also lacks a NLS, MT transport into the nucleus is affected 
by wheat-germ agglutinin (WGA) treatment (which binds GlcNAc, glycosylated residues) 
and by ATP depletion87. Interestingly, there is conflicting data regarding temperature 
and MT nuclear transport. In SCC25 (squamous cell carcinoma) cells, temperature did 
not affect MT nuclear localization 88, while in HL-60 (lymphoblast) cells it prevented the 
protective effects of MT from taking place in the nucleus21 indicating that the binding of 
MT to its receptor, but not the translocation process itself is energy dependent. This is 
different from the classical NLS-bearing protein translocation mechanism and indicates 
MT binds a nuclear translocation mechanism in an ATP dependent manner, and then 
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enters the nucleus by diffusion89. Evidence for this proposed mechanism is 
strengthened by the fact that MT is not retained in the nucleus after flushing with buffer. 
Further investigation has led to the discovery that MT nuclear localization requires the 
oxidation of a cytosolic accessory protein for efficient translocation90, an effect which is 
prevented by excess glutathione. Taken together, this data suggests that MT is targeted 
to the nucleus by passive diffusion and retention with a non-diffusible nuclear binding 
partner, a process that would be compatible with a proposed role for MT that is closely 
associated with DNA replication. In the context of T cell activation and proliferation, 
increases in intracellular [Zn2+] and [ROS] precede induction and sub cellular 
localization of MT to the nucleus, where it presumably plays a role in preventing errors 
in DNA replication by acting as an antioxidant. Increased expression of MT during CD4+ 
T helper cell effector differentiation could therefore prime CD4+ T cells for increased 
proliferative capacity.  
 
Secretion 
Extracellular pools of MT are observed in serum 91,92, urine93, bronchoalveolar94 
and prostatic fluids95, liver sinusoids and renal tubules96, pancreatic ducts97 and milk98. 
They are also considered an important extracellular danger signal with chemotactic 
properties that affect immune cell trafficking in the context of autoimmune colitis4. The 
mechanism by which MT leaves the cytoplasm is unknown but the high concentrations 
found in secretions and extracellular spaces, absent signs of necrosis or tissue damage, 
indicate that there is a biological mechanism responsible. Additionally, MT was found to 
be secreted from adipocytes in culture, and was observed in the supernatant before 
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other secreted proteins including leptin which strongly suggests it is actively secreted 
from cells. The vast majority of MT (>93% in rat liver) is translated on polysomes99. 
Most extracellular proteins have an N-terminal secretion signal (SS) that directs mRNA 
to the endoplasmic reticulum (ER) for co translational translocation and vesicle 
secretion via the Golgi apparatus. However, there exist many directed small molecular 
weight protein secretion mechanisms that lack this SS, including those for IL-1 alpha 
and IL-1 beta and HSPs. Like these proteins, MT may be secreted through lysosomal 
secretion pathways, exosomes, exovesicular membrane blebbing 100-102or move directly 
across the membrane as is observed with IL-1103.  
 
Uptake from the Extracellular Environment 
Extracellular MT can also be taken up by cells, as has been demonstrated in 
renal proximal tubules104 and hepatocellular carcinomas cells (HepG2). This process 
appears to be dependent on surface expression of megalin105 in the case of renal cells 
and on binding to albumin followed by clathrin-mediated endocytosis in HepG2 cells. In 
lymphocytes, MT has been found to bind to the extracellular membrane but not be 
endocytosed (unpublished data) and effect lymphocyte chemotaxis, most likely through 
a G protein coupled receptor mediated mechanism106. In summary, MT is primarily a 
cytosolic protein that is trafficked to the nucleus during DNA replication as part of 
proliferation and is secreted from certain cell types following stress exposure. The focus, 
hereafter, will be on the cytoplasmic role of MT where it is predominantly found in 
lymphocytes.  
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1.2.5  Structure 
  The introduction to MT structure presented below will focus on MT-1 and MT-2 
in humans and mice (hereafter referred to as MT), which are structurally very similar 
and homologous in terms cysteine residues and zinc binding properties. The unique 
structure of MT is, in many ways, unlike any other mammalian protein.  
 The primary sequence of MTs is comprised of 61-62 amino acids (MW ~6kD) 
including 20 cysteine residues (except for MT-1B which has 21), 6-8 lysines, 7-10 
serines, and a single acetylated methionine at the amino terminus. In general, MT is rich 
in the disorder producing amino acids (G, S, P) and has very few aliphatic amino acids 
(I, V, L) and no aromatic amino acids, both of which are order producing 
(http://www.rcsb.org/pdb/explore.do?structureId=1mhu)107 (Figure 1). The MT1 isoforms 
are separated from the MT2 isoform during ion exchange chromatography based on the 
negative charge of MT-2 at position 11 where due to an aspartate residue. The human 
MT1 isoforms differ from each other by 3-13 amino acids 108 (Figure 2a and 2b). There 
is currently speculation in the field about whether the small differences in primary 
sequence between MT-1 and MT-2 isoforms impart a functional difference on the 
protein. The conservation of all 20 cysteines between all isoforms and the presence of 
similar amino acids at the other positions, however, suggests the primary function of 
metal binding and release also remains conserved and is not significantly different 
between the 2 isoforms. 
 The intrinsically disordered apo-metallothoinein (T) with no metal ligands 
occupies a large conformational space. This is evidenced by the lack of a clear band 
during SDS PAGE experiments using a reduced version of the protein. 109. MT devoid of 
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metal ligands is only found in vitro, however, and MT isolated from biological samples is 
always bound with metal ligands. The affinity for divalent metal cation ligands comes 
exclusively from the 20 vicinal cysteine residues. These residues occur primarily in cys-
cys, cys-x-cys, and cys-x-y-cys motifs. The free thiol R group of cysteines form thiolate 
bonds with divalent cations, most notably zinc and copper. In lymphocytes, in the 
absence of exposure to toxic heavy metals, zinc is the only metal found in a complex 
with MT 34.  
 Folding of the MT polypeptide chain around Zn2+ ions organizes the structure into 
two domains: a C-terminal alpha domain and an N-terminal beta domain, which 
resembles a barbell. The alpha domain contains 11 cysteine residues that can bind up 
to 4 Zn2+ ions. The beta domain contains 9 cysteine residues that can bind up to 3 Zn2+ 
ions. In the reducing environment of the cytoplasm, thiol groups (-SH) exist primarily as 
reduced sulfur atoms (S-) and are capable of forming an ionic bond with cationic metals 
called a thiolate bond. In MT, Zn2+ ions are bound via thiolate bonds in a tetrahedral 
geometry (4 thiols per Zn2+). Zinc-thiolate bonds are organized into two types: bridging 
and terminal. Thiols that interact with 2 Zn2+ ions are considered bridging and thiols that 
interact with one Zn2+ ion are considered terminal (See Figure 3). The alpha domain of 
MT contains 5 bridging and 6 terminal thiols; the beta domain contains 3 bridging and 6 
terminal thiols. The alpha domain does not share a structural similarity to any other 
known protein while the beta domain shares some homology with histone lysine methyl 
transferases110,111. The cysteine residues and their coordinate Zn2+ ions are clustered, 
which results from the tertiary structure of the two domains putting cysteine residues in 
contact with Zn2+  ions in an order that is independent of primary sequence. 
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1.2.6  Redox Reactivity and Zinc Binding 
 Zinc is commonly used as a structural cofactor for protein folding and it is 
estimated that 3% of the nearly 19,000 human genes encode proteins with structural 
zinc sites with cysteine ligation112. In zinc finger motifs, where very tight zinc binding is 
preferential, combinations of nitrogen (histidine), oxygen (glutamate/aspartate) and 
sulfur (cysteine) are employed to form zinc binding motifs where the affinity is high (Kd < 
10-12 ex. zinc finger domains) and is less reactive to oxidation113. In proteins that are 
subject to more dynamic regulation, where moderate affinity for zinc and a higher 
reactivity with oxidants is preferential, there are a higher proportion of cysteines in zinc 
coordination environments. This principle is illustrated in the Kelch domain of Keap1 
protein binding to Nrf2 through coordination of a Zn2+ ion. Upon exposure to oxidants, 
cysteine ligands of Keap1 are preferentially oxidized, releasing Nrf2 to translocate to the 
nucleus and upregulate genes involved in antioxidant defense114, including MTs.  
 The latter group of proteins with zinc finger motifs can be divided further into 
redox sensors and redox transducers. Redox effects are expressed at several levels in 
a signaling cascade through redox sensors: 1. Oxidative activation of matrix 
metalloproteins that proteolytically process receptors; 2. Regulation of 
phosphatase/kinase activity to affect phosphorylation state of proteins; 3. Interface of 
protein-protein binding interactions; 4. Regulation of transcription factor activity.20. MTs 
are hypothesized to be redox transducers, meaning they convert redox signals into zinc 
signals through oxidation of cysteine ligands and concomitant release of bound Zinc. In 
this way, the activity of MT after oxidation is not the important component of the 
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signaling cascade but rather, the effect of the released Zn2+ ions becomes the important 
cellular signal. Because intracellular [Zn2+] is so low, even picomolar fluctuations caused 
by the release of free Zn2+ ions can act as a cellular signal in this manner.  
Thiols or thiolates (-SH / S-, or S-metal, respectively) react with electrophiles and 
become oxidized in the process. In general, thiolates have a lower pKa than thiols and 
are more reactive than sulfhydryls to oxidation, alkylation, and nitrosylation18. Generally, 
within the relatively narrow redox potential of mammalian cells, higher order oxidation of 
thiols (loss of 2 electrons) leading to sulfinic, and sulfonic acid are unlikely20. Instead, 
lower order reversible oxidation reactions resulting in disulfide bond formation are more 
likely115. Thus far, disulfides are the only oxidation states identified as the result of sulfur 
ligand oxidation in Zn-S sties.  
 In reactions of MT with biological oxidants, the presence of so many vicinal thiol 
groups imparts an extremely low redox potential (-366mV) 79 and makes higher order 
oxidation events even less likely. The reactivity of zinc bound thiolates to oxidation 
follows this order: Zn-S4 > Zn-S3 > Zn-S2 > Zn-S. The underlying reason for this seems 
to be that the Zn2+ ions coordinate the sulfur atoms of sulfhydryl groups so they are in 
the correct orientation for disulfide bond formation before they are oxidized116. However, 
Zn2+ binding also affects entropic factors by electrostatically screening reduced thiols 
and protecting them from oxidation. Furthermore, H-bonding drastically affects the 
reactivity of sulfurs in proteins. Because different types of intramolecular forces affect 
Zn coordination environments, proteins can be “fine-tuned” to act as precise redox-zinc 
switches that change conformation and activity only at specific thresholds. Furthermore, 
parameters like temperature, pH, [Zn2+], redox potential, and the nature of the oxidant 
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can all affect the threshold of zinc release/binding and allow redox-zinc switch proteins 
to react appropriately under different intracellular conditions. For example, the capacity 
of biological disulfides to release zinc from MT varies considerably. Cystamine release 
93% of bound Zinc while oxidized glutathione (GSSG) releases 20% at the same molar 
concentration117. 
The combination of all of the factors affecting Zn-S binding in proteins makes 
empirical prediction of thiolate reactivity (and subsequent release of zinc) in a particular 
protein very difficult. For this reason, the 7 zinc binding sites in MT were originally 
thought to have a high affinity for MT 118 even though it is evident from 113Cd NMR 
spectra that all seven zinc ions exist in unique environments within MT119. It has 
recently been revealed, however, that MTs have four sites with high affinity (logK=11.8), 
two sites with moderate affinity (logK=10) and one site with even lower affinity 
(logK=7.7) at pH 7.0 120. In reality, however, the relationship between zinc and MT in 
biological systems is more complicated and dynamic than a distribution of static logK 
values would suggest, especially in the context of redox signaling. It is important to note, 
that the binding sites with lower affinity prevent MT from being a thermodynamic sink for 
metal chelation, which is the case with Cd2+. Instead, MT has the ability to transfer zinc 
to apoforms of zinc enzymes that have inherently lower stability constants for zinc121. 
Furthermore, this transfer is aided by the presence of both reduced glutathione (GSH) 
and oxidized glutathione (GSSG), when they are present together as a redox couple79. 
There are 3 distinct states of the sulfhydryl side chains of the cysteine residues; 
metal bound, reduced or oxidized. Metallothionein (MT) refers to the protein products of 
Mt genes that, once translated, are in a complex with metal ions. Thionein (T) refers to 
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apo- (metal removed) form of metallothionein, which can be further, differentiated by the 
redox status, reduced (TR) or oxidized (TO). Due to the dynamic nature of MT zinc 
binding and the redox state of intracellular proteins, single MT polypeptides may contain 
all 3 types of sulfhydryl groups simultaneously. Furthermore, intra- and inter MT zinc 
transfer happens rapidly 122 so it is not practical to consider any of the cysteine residues 
in a biological pool of MT to be in a static state. The 3 states of MT exist in a dynamic 
equilibrium that is reflected by their relative ratio in biological tissues or cells. Recent 
advances in chemical modification strategies have allowed the 3 states of MT to be 
measured simultaneously and, therefore, their relative ratios deduced. In both liver cells 
and tissue homogenate the ratio of T/MT is around 30%, which correlates with five of 
the seven metal binding sites being occupied by zinc123. Within the non-metal bound 
fraction of cysteine ligands, the ratio of TR t: TO is 2.75 : 1 in the liver and 1.5 : 1 in T29 
human epithelial cells in culture, which most likely reflects the exposure of cells in 
culture to a higher partial pressure of O2 and the resulting increased oxidative stress. 
Interestingly, introduction of a Ras oncogene that causes oxidative stress124 increased 
the total amount of MT expressed by 20% but decreased the ratio of TR : TO (1:3). As 
the MT metal bound and reduced ligands were oxidized, the total ratio of T/MT also 
increased from 20% to 27%123.  The observation that MT is not zinc saturated under 
cellular conditions underscores its position at the precipice of zinc and redox regulation 
in the cell and place it in a position to quickly respond to changes in redox or zinc status. 
The interaction of biological oxidants with MTs is of particular importance in 
understanding the role of MT in modulating redox status. ROS and RNS have ability to 
react directly with MT to oxidize the protein and release Zn2+125. ROS species including 
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superoxide radical, hydroxyl radical126, and peroxides21 all interact directly with 
sulfhydryl groups on MT to form disulfides. In the case of RNS, nitric oxide also reacts 
directly with MT127, or reacts with superoxide to form peroxynitrite, one of the most 
potent biological catalyst for MT zinc release that has been reported 128. The result of 
this reaction can be glutathionation125, S-nitrosylation129, transnitrosation130, or disulfide 
formation131. Because the redox potential of MT is so low, it can also react with 
biological disulfides including GSH-GSSG, a process which is aided by catalytic 
selenols132. Furthermore, MT redox status is intimately associated with other redox pairs 
including thioredoxin133. The kinetics of reactions between biological disulfides and 
oxidants and MT are influenced by the concentration of enzymes including protein 
disulfide isomerase (DsbA)121, glutathione peroxidase122, and sulfhydryl oxidase134 
among others. The relative availability of these enzymes is believed to be responsible 
for the maintenance of differences in redox potential of different redox pairs within the 
cytosol. 
 
1.2.7  Proposed Biological Roles of MT 
 MT has been referred to as a Sphinx 135 because of the difficulty in deciphering 
its elusive biological roles. More than 50 years of research have elucidated many 
immunological contexts in which MT appears to play a role. The biological roles of MT 
can be distinguished by their intracellular and extracellular modes of action. 
Extracellular pools of MT (reviewed previously 35,136,137 ) have been shown to be potent 
mediators of leukocyte chemotaxis106,138, CD8+ T cell cytotoxic function139, CD4+ T cell 
differentiation2, dendritic cell function140, T-dependent humoral responses 141, and 
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others. MT is hypothesized to modulate immune activity through interference with 
chemokine signaling or by acting as potent antioxidant and interfering with the positive 
feedback loop involving oxidative stress and inflammation.  
The intracellular role of mammalian MT and its position at the juncture between 
redox and zinc metabolism has been well studied under normal and pathological 
conditions in various tissue and cell types. The very low redox potential and preferential 
oxidation of MT by ROS and RNS implicate MT in modulation of redox signaling 
pathways. In this way, oxidative signals generated by membrane bound enzymes142, 
cytosolic enzymes143, or mitochondrial enzymes144 would be dampened in the presence 
of MT. MT’s role as a negative regulator of oxidative signaling is reinforced by the 
presence of ARE elements in the MT promoter regions and strong induction of MT by 
oxidative stress. In addition to modifying the redox state of proteins, MT may directly 
interact with certain transcription factors including NF-κB and affect their DNA binding 
activity145,146. 
Of all the proposed mechanisms of MT mediated immunomodulation, MT’s role 
in the management of intracellular labile [Zn2+] may be the most notable. When 
considering the cumulative in vitro biochemical observations of MT function, evidence 
points to an integral, but context dependent, role in zinc homeostasis. On one hand, MT 
acts as a signal transducer that is preferentially oxidized (even in the presence of 
millimolar GSH) and releases a transient zinc signal. In the absence of an oxidative 
signal, MT acts as a general zinc buffer, binding and donating free zinc as part of metal 
homeostasis. Even during relative redox and zinc homeostasis, MT stabilizes the 
transition state between apo and metal bound forms of zinc proteins, thus facilitating 
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and regulating the use of zinc as a regulatory co-factor. The implications of this zinc 
mediated regulation of biological systems are immense and far reaching and have been 
the focus of several recent comprehensive reviews 18,133,147-149. These interactions are 
not mutually exclusive, and depending on the MT concentration, cell type, and 
environmental context, particular mechanisms may play a more significant role in 
immunomodulation. 
One of the most intriguing observations is the association of MT and its purported 
role in autoimmunity and inflammation. The positive feedback loop between 
inflammation and oxidative stress is well characterized, and in this context, exogenous 
addition or induction of MT appears to provide a potent redox buffer for the 
detoxification of potentially harmful ROS and RNS species. MT has been implicated in 
protection from several autoimmune diseases including collagen induced arthritis2,150,151, 
type 1 diabetes152, experimental autoimmune encephalomyelitis3,153, and others. 
However, recent evidence suggests that disruption of endogenous production of MT 
using a genetic MT knockout can also prevent the onset of autoimmune disease, 
specifically EAE5. Further investigation into the responsible mechanism revealed that 
the development of immunosuppressive Type 1 regulatory T cells (Tr1) was increased 
in the knockout model, suggesting that MT plays a role in CD4+ T cell development. 
Because this effect occurred both in vivo and in vitro, in the absence of antigen 
presenting or accessory cells, it is likely that intracellular CD4+ T cell signaling following 
activation was influenced by MT gene dose.  
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1.3  Role of CD4+ T Cells in Adaptive Immune Responses 
 A core component of adaptive immunity is the integration of signals that 
accompany the recognition of non-self molecular patterns and translating them into a 
beneficial response. This process is exemplified in CD4+ T cells where parallel 
recognition of antigen and extracellular stimuli direct cell development into distinct 
effector phenotypes which go on to mediate appropriate adaptive immune responses. 
 
1.3.1  CD4+ T Cell Activation 
For circulating naïve CD4+ T cells that have exited the thymus, primary activation 
occurs following recognition of foreign or non-self peptides through the T cell receptor 
(TcR). Each unique TcR binds to an associated major histocompatibility complex II 
(MHC) molecule with a specific antigenic peptide (Signal 1). During this cellular binding 
event, other surface proteins on the antigen presenting cell (APC) and CD4+ T cell 
interact including B7.1 (CD80) or B7.2 (CD86) on the APC and CD28 on the T cell 
(Signal 2). B7 expression on APCs is upregulated after exposure to pathogen 
associated molecular patterns (PAMPs) including LPS 154or LTA155. The presence of B7 
on the APC stimulates the activation of phosphoinositide 3-kinase (PI3K) and Akt based 
signaling pathway in T cells. Together, pathways downstream of Signal 1 and Signal 2 
converge to result in CD4+ T cell activation and proliferation. In the absence of PAMPs, 
APCs do not express elevated levels of B7, which upon recognition of peptide/MHC by 
the TcR, results in Signal 1 without Signal 2 and T cell anergy or apoptosis 156,157.  In 
this way, T cells can respond to the same antigenic peptide very differently, depending 
on co-stimulatory signals expressed by the APC. 
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Successful activation of primary CD4+ T cells usually occurs in secondary 
lymphoid tissues following an interaction with a pathogen activated dendritic cell158. In 
addition to Signal 1 and Signal 2, CD4+ T cells receive extracellular signals from both 
the contact APC and the extracellular environment. CD4+ T cells express inducible 
costimulator molecules including ICOS, CD27, and CD154, and CD137 among others 
that all bind with cognate membrane-bound co-activating molecules on the surface of 
dendritic cells. Conversely, after a period of T cell activation, CD28 on the T cell surface 
is replaced by expression of CTLA-4, which activates an inhibitory pathway. This signal 
is transduced through SHP-2 and prevents T cell over-activation and influences the 
activation phenotype of the APC through an interaction with CD80 or CD86.  
The process of T cell activation is complex and is an area of intense investigation. 
For the purposes of this introduction, the general mechanisms of T cell activation will be 
reviewed with an emphasis on the interactions that have the potential for MT mediated 
regulation. The series of events between the time the TcR recognizes its cognate 
peptide/MHC (Signal 1) and downstream gene regulation involve several parallel 
pathways initiate T cell activation. Upon recognition of the peptide/MHC complex by the 
TcR, intracellular phosphatases and kinases are brought within close proximity of one 
another and reach a density threshold. Subsequent phosphorylation of ITAMs on the 
intracellular domains of CD3 and ZAP70 triggers phosphorylation of LAT and activation 
of phospholipase-C (PLC), a crucial step in the signaling cascade and an area of 
integration with CD28 signaling (Signal 2). Activation of PLC cleaves 
phosphatidylinositol biphosphate (PIP2) to yield diacyl glycerol (DAG) and inositol 
trisphosphate (IP3).  IP3 leads to a calcium signal that is a requirement for T cell 
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activation and underscores the importance of ionic signaling cascades in T cell 
activation. DAG recruits protein kinase C (PKC), for which MT2a is an observed 
substrate159, and RasGRP which in turn activates Ras. Ras then activates the mitogen-
activated protein kinase (MAPK) cascade that terminates with activation of several 
transcription factors, most notably AP-1 and NF-κB.  
During the signaling through the T cell receptor (Signal 1) and CD28 (Signal 2), T 
cells also receive signals from extracellular cytokines (Signal 3).  Cytokines signal 
through hetero-dimeric receptors on the plasma membrane, many of which use a γ 
common chain (IL-2, IL-4, IL-7, IL-9, IL-15) or β common chain (IL-3, IL-5 GM-CSF). 
Other heterodimeric cytokine receptors use unique chains for recognition and signaling 
(IL-13, IFN-γ, IL-10). These receptors signal through janus kinases (JAKs) that activate 
signal transducers and activators of transcription (STATs). Activated STATs may 
translocate to the nucleus and affect gene transcription or, in the case of STAT5, also 
activate MAPKs160.  
MAPKs fall into 3 families: c-Jun N-terminal kinases (JNKs), extracellular-signal 
regulated kinases (ERKs), and p38 mitogen-activated protein kinases (p38). Integration 
of STAT and MAPK signaling networks during and following TcR and CD28 
engagement set the foundation for differentiation and CD4+ effector T cell 
development161. Interestingly, p38 MAPK activity is increased following exposure to 
ROS 162, zinc 13, and glucocorticoids 163 and pro-inflammatory cytokines164, all of which 
are important inducers of MT expression in CD4+ T  cells. This observation suggests 
negative feedback loops that may be important mechanisms of MT mediated 
immunomodulation in CD4+ T cells. In the absence of MT, signaling through p38 MAPK 
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pathways would be sustained for longer periods of time, affecting activation of AP-1 and 
NF-κB and potentially cell differentiation and cytokine secretion.   
The primary molecular mechanism underlying the propagation of Signal 1, Signal 
2 and Signal 3 are the phosphorylation and dephosphorylation of signaling proteins, 
including signaling kinases and phosphatases themselves. This conservation of 
mechanism allows multiple signaling cascades to be regulated by zinc or redox status165. 
Increases in zinc, in general, inhibit cellular phosphatases which tends to increase 
phosphorylation and activation of signaling kinases in T cells 166. Control of intracellular 
[Zn2+], therefore, allows T cells to tune the threshold of signaling activation following 
Signals 1 and 2. Both zinc 12,167 and reactive oxygen species168 are highly regulated 
during CD4+ T  cell activation and are under the direct influence of intracellular MT 
concentration and redox status, placing this protein at a central position for influencing T 
cell signaling. In addition to global regulation of phosphatase activity, it is important to 
note that intracellular phosphatases are differentially regulated by zinc and ROS and 
inhibitory concentrations of zinc (IC50) can vary by several orders of magnitude. 
Therefore, small decreases in ROS, and concomitant increases in labile zinc after 
oxidation of MT, could have a targeted effect on particular substrates including p38 
MAPK, without needing to affect global phosphorylation patterns.  
 
1.3.2  CD4+ T Cell Differentiation and Development of Effector 
Phenotypes 
Successful activation of naïve CD4+ T cells in vitro results in proliferation and 
differentiation into an effector phenotype. This is marked by changes in expression of 
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surface markers of activation including CD44169, CD62L, CD69, and CD25, and CD45 
170
. The effector function of differentiated CD4+ T cells is influenced, primarily, by 
soluble cytokines that are present during the initial activation event (Signal 3)171. CD4+ T 
effector cells fall into general categories and new categories are still being discovered.  
Of these categories, the 4 most well studied effector populations in vivo include Th1, 
Th2, Th17, and iTreg while stimulation of naïve CD4+ T cells in vitro without additional 
stimulation through cytokine receptors leads to a TH0 effector phenotype (Figure 1.4). 
These categories are generally defined by effector cytokine production and master 
transcription factor profiles. For a more thorough review see 172. 
 The dichotomy of the TH1 and TH2 groups were first discovered in murine cells 
and represent the most well studied paradigm of naïve CD4+ T cell fate decisions173.  
Robust IL-2 and IFN-gamma secretion, in addition to many cells secreting TNF-alpha, 
characterize TH1 cells. IL-12 signaling during initial activation results in expression of 
the master TH1 transcription factor Tbet and controls the Th1 cell fate decision174,175.  
TH2 cells, on the other hand, are characterized by secretion of IL-4, IL-5, and IL-13 176 
and expression of the GATA-3 transcription factor.  These cells are induced by IL-4 as 
part of a positive feedback loop that enhances TH2 responses177. The fate choice for 
TH1/TH2 is reinforced by the repression of transcription factor expression, where 
expression of one reciprocally inhibits expression of the other. This allows for 
coordinated cellular responses to immune challenges. In the case of TH1, this involves 
intracellular infections, whereas TH2 responses are required to clear extracellular 
bacteria and parasites such as helminthes.  
A parallel dichotomy in CD4+ cell fate lineage appears between Th17 and 
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inducible regulatory T cell (iTreg) CD4+ cell lineages, which have been defined more 
recently.  Th17 cells are characterized by their robust secretion of IL-17a, IL-17f, and IL-
22178 and the RORγt transcription factor. iTregs are characterized by secretion of IL-10 
and TGF-β and expression of the FoxP3 transcription factor179. The dichotomy between 
these cells is defined by their functions, where IL-17 is responsible for controlling some 
extracellular bacteria and fungi and promotes inflammatory conditions while iTregs 
suppress T cell function and inflammation180. Furthermore, the conditions that induce 
these phenotypes are similar but distinct. The presence of TGF-β and IL-6 during 
primary activation result in the development of Th17 cells while TGF-β alone results in 
development of iTregs. 
An alternative IL-10 secreting CD4+ T cell subset is the in vitro or in vivo derived 
T regulatory Type 1 (Tr1) subset (Figure 1.4) These cells are similar to iTreg because 
they secrete IL-10 and are immunosuppressive, but do not require the expression of 
FoxP3 181,182. These cells can be induced by immunosuppressive drugs183, certain 
soluble proteins184 and peptide antigens185, or by chronic stimulation186. Alternatively, 
Tr1 cells are induced in the presence of IL-27 during primary activation 187 and are an 
excellent model for studying the immunosuppressive functions of IL-10 producing 
cells5,188.  
 
1.3.3  The Role of Labile [Zn2+] in T Cell Signaling and Effector 
Function 
Of the nutritionally essential transition metal ions, zinc ions have the most 
prevalent role in regulating protein strucutre189. The vast majority of biological zinc  is 
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sequestered in proteins due to the high affinity of sulfur and other negatively charged 
atoms for zinc. This explains why total intracellular zinc concentration is in the range of 
a few hundred micromolar, while free or labile zinc concentration is only a few hundred 
picomolar. Interestingly, every metal ion in its “free” state is kept at a concentration that 
is commensurate with its binding affinity 190. The compartmentalization of zinc is an 
important aspect of zinc biology and underlies the foundation of using zinc ions as 
molecular signals that affect cell behavior.  
 Briefly, zinc homeostasis in cells is achieved through the dynamic process of 
continuous export and import. Two families of proteins are implicated in the transport of 
zinc across membranes: the ZnT family (solute-linked carrier 30, SLC30A) is 
responsible for zinc export out of the cytosol while the Zip family (Zrt- and Irt-like 
proteins, SLC39A) is responsible for zinc import into the cytosol. For review see 191. 
Cellular zinc homeostasis, on a smaller scale, is maintained through zinc buffering and 
muffling192. Specifically, these processes describe the binding and release of zinc from 
proteins and their transport into intracellular vesicles as strategies to maintain zinc 
homeostasis; both of these processes have been observed in lymphocytes8,13,15. MT is 
implicated in both of these processes, and is considered the most important intracellular 
zinc buffering mechanism19,133. 
  Over the past 2 decades, significant but indirect evidence for the role of 
intracellular labile [Zn2+] in CD4+ T cell signaling has been observed. Unlike calcium 
ionic signaling, zinc ionic signaling events are difficult to measure because intracellular 
[Zn2+] in human and mouse lymphocytes is a few hundred pM, which is about 3 orders 
of magnitude lower than calcium. Only recently have fluorescent probes been 
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developed that are capable of reliably measuring changes in labile [Zn2+] during T cell 
activation193 194. However, since their acceptance as a research tool, the zinc probe 
Fluozin-3 (Invitrogen) has allowed the precise quantification of intracellular labile [Zn2+] 
in cells in vitro and revealed a dynamic role for zinc in the regulation of T cell activation. 
 Zinc signaling can be temporally divided into two groups: early signals and late 
signals148. (Figure 5) Late signals involve transcriptional regulation of Zip (SLC39A) and 
ZnT (SLC30A) proteins and take place on the order of 30 minutes to hours after the 
initiating signal. Early zinc signals take place on the order of seconds to minutes and 
involve rapid mobilization of zinc from intracellular vesicles, extracellular space, or from 
zinc bound to cytosolic proteins including metallothionein. In CD4+ T cells, both types of 
signals are associated with T cell activation. Late zinc signals include increased 
intracellular [Zn2+] that is associated with the development of a lymphoblast phenotype 
and subsequent proliferation 36 and increased expression of Zip8 in T cell lysosomes15. 
Early zinc signals include influx from the extracellular environment after peptide/MHC 
recognition on an activated APC7, release of Zn2+ from lysosomes following IL-2 8 or IL-
1 beta195 cytokine signaling, or release of Zn2+ from metallothionein following exposure 
to heavy metals or oxidative stress194. The ability to induce zinc signals and, 
alternatively to terminate zinc signals, is negatively associated with increased age and 
is considered to be an important factor in decreased immune function in the elderly36,196-
198
.  
 The reported effect of increased extracellular [Zn2+] on T cell activation and 
function varies greatly. Increasing extracellular [Zn2+] to 100µM alone is associated with 
increased T cell proliferation199. Increasing extracellular [Zn2+] from 3-75µM during T cell 
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activation with APCs loaded with superantigen7 is also associated with increased 
proliferation.  However, studies using alternative mitogens including pokeweed mitogen 
(PWM), anti-CD3 antibodies16 or concanavalin A (ConA) 17 reported reduced 
proliferation upon addition of ZnCl [100µM]. Additionally, strong zinc signals are 
associated with increased T cell apoptosis through regulation of Bim 200 and increased 
cytotoxicity following oxidative stress201,202. These conflicting reports underscore the 
context dependent nature of the effects of intracellular Zn on proliferation. It is important 
to note that these studies described above explored artificially high in vitro [Zn2+] that is 
unlikely to be experienced by T cells in vivo. This makes interpretations of the biological 
significance of these observations less straightforward.  
 Another general paradigm that emerges from the large body of research 
involving the effects of zinc on T cell function includes the requirement of intracellular 
[Zn2+] within a narrow window. In the case of dietary zinc deficiency, and resulting 
decreases in intracellular [Zn2+], development of the Th1 phenotype6,203 and secretion of 
IFN-γ204 are impaired. This is the general mechanism of immunosuppression attributed 
to the relationship between zinc deficiency and viral infection205. However, like the 
studies described previously, dietary zinc deficiency is an extreme condition and the 
mechanisms underlying the influence of a severe cellular zinc deficit on immune 
function are likely different than those employed by zinc during “normal” cellular 
zincexposure. 
In cases where zinc has been studied in a more concentration relevant context, 
increasing intracellular [Zn2+] in vitro while maintaining viability still decreases production 
of cytokines including IL-10 and IL-1716 while increasing IL-2195. These effects are 
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dependent on modulation of MAPK pathways by free Zn2+, as described earlier. For 
example, MEK and ERK are both found to be activated in response to increased 
intracellular [Zn2+]  following IL-2 signaling 8, which results in increased expression of 
the transcription factor c-fos. This is due to zinc-mediated inhibition of MEK and ERK 
dephosphorylating protein phosphatases. Of the MAPK family, p38 is the most sensitive 
to changes in intracellular Zn in CD4+ T lymphocytes during TcR signaling13 and its 
increased activation by zinc is also attributed to inhibition of a MAPK-phosphatase206. 
This zinc-mediated effect on MAPK activity occurs within a physiologically relevant 
[Zn2+] and affects IFN-gamma transcription and secretion as well as inhibitory activity of 
Treg207,208. It is therefore a likely mechanism for regulation of cytokine secretion and 
mediation of inflammation209. The mechanism underlying inhibition of phosphatase 
activity by zinc has recently been described in detail12,167. Interestingly, the regulation of 
protein tyrosine phosphatases by zinc overlaps considerably with the intracellular [Zn2+] 
affected by MT expression and oxidation.  
In addition to MAPK, zinc affects cytokine secretion by reducing the activation of 
STAT311. Induction of IL-10+ Tr1 cells by IL-27 requires the activation of STAT3210, 
which is increased in MT deficient lymphocytes5 and is responsible for increased IL-10 
expression compared with wildtype controls. However, the mechanism responsible for 
increased activation of STAT3 and subsequent increase in IL-10 expression in MT-KO 
mice remains unknown. One hypothesis is that a reduced intracellular zinc signal 
following T cell activation in MT-KO mice allows for a greater increase in STAT3 
activation. This is supported by studies describing the presence of ROS during T cell 
activation211 and the association of MT with higher concentrations of oxidant released 
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labile zinc212. 
 
1.3.4  CD4+ T cell mediated effects on humoral immune responses 
 Effector CD4+ T cells influence both cell mediated and humoral immune 
responses. The coordination of effective immune responses to different classes of 
pathogens requires CD4+ T cells to integrate extracellular signals during differentiation 
of effector cells. Once cell fate has been decided and effector function has been gained, 
CD4+ T cells are poised to appropriately influence the activation both innate and 
adaptive immune cells through contact dependent and independent mechanisms. For 
adaptive humoral responses, CD4+ T cells influence B cell activation subsequent 
antibody secretion through both cell contact independent (ex. cytokine signals)213 and 
cell contact dependent signals (ex. CD40L) 214. During B cell activation and 
differentiation into an antibody secreting plasma cell, B cells commonly switch the class 
of antibody they secrete from membrane bound IgD to soluble IgG. The cytokine 
environment controlled primarily by CD4+ T cells influences the sub-type of IgG class. 
In this way, TH1 mediated immune responses are associated with higher levels of 
serum IgG2a 215 while TH2 responses are associated with higher levels of serum 
IgG1177. Alternatively, higher levels of TGF-beta associated with Treg mediated immune 
responses result in a higher level of IgG2b216. By measuring the IgG subtype of the 
humoral response to a specific antigen, it is therefore possible to draw conclusions 
about the cytokine environment and predominant type of CD4+ T cell response.  
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Figure 1.1 Human metallothionein 2A (Mt2a) shares a high degree of 
sequence homology with mouse metallothionein 2 (Mt2) and 
metallothionein 1 (Mt1) 
 
Human Mt2a vs. mouse Mt2 
 
Human Mt2a vs. mouse Mt1
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Figure 1.2 Human Metallothionein Gene Comparison 
 
A.  
                               Human MT Isoform Sequence Comparison 
 
 
 
 
B.  
           Number of amino acid variations within human MT-1 isoforms 
 
 A  B E  F G  H R M X  Y 
A 0 10 5 9 7 8 6 11 10 11 
B  0 5 9 9 8 7 8 8 10 
E   0 4 4 6 3 8 7 8 
F     0 4 8 7 10 10 10 
G     0 6 5 10 8 10 
H       0 7 11 7 12 
R       0 10 9 10 
M        0 10 6 
X         0 13 
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Figure 1.3 Zinc Binding Motifs of Metallothionein 
 
  
 
 Beta Domain of Human MT2      Alpha Domain of Human MT2 
 
 
 
Adapted from 20 
 
  
N-terminal beta domain of MT C-terminal alpha domain of 
MT 
Bridging Thiolate 
Terminal Thiolate 
 
 
 48
Figure 1.4 CD4+ T Cell Differentiation 
 
 
 
 
Adapted from 160 
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Figure 1.5 Early and Late Zinc Signaling 
 
 
 
 
 
Adapted from 148 
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Chapter 2 
 
Materials and Methods 
 
2.1. Mouse Strains 
All in vitro and in vivo studies were performed using mice bred and housed at the 
University of Connecticut in accordance with the University of Connecticut Institutional 
Animal Care and Use Committee (IACUC) guidelines. The congenic MT-1/2 knockout 
mice and the congenic MT1 transgenic mice were derived from the original strain 
constructs (129S7/SvEvBrd-Mt1tm1Bri Mt2tm1Bri /J [12] and STOCK Tg(Mt1)174Bri/J 
40
 that had been obtained from the Jackson Laboratory (Bar Harbor, ME). The Jackson 
Laboratory provided Genotyping protocols for the selection of heterozygotes at each 
generation. Both of the congenic strains were produced by 8–9 generations of 
backcrossing to the C57BL/6J background strain, followed by incrossing of the 
heterozygotes to produce homozygotes for each construct. According to the equation 
for the fraction of loci that are still heterozygous at the Nth generation [(1/2)^(N-1)], the 
amount of residual donor genetic material that may contribute to observed phenotypic 
differences after 8–9 back- crosses is between 0.2 and 0.4%41. Strain production was 
done at the University of Connecticut, where these strains are maintained. (C57BL/6J, 
abbreviated WT; C57BL/6-Mt1tm1Bri Mt2tm1Bri , abbreviated MTKO; and C57BL/6- 
Tg(Mt1)174Bri, abbreviated MTTGN) mice were age and sex matched for each 
independent set of experiments. Mice between 9 and 24 weeks were used for all 
studies. Mouse genotype was confirmed by PCR prior to beginning studies.  
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2.2. Cell Culture and Treatment 
 
2.2.1 Cell Isolation 
For PBMC isolation, ~200µL of blood was collected by sub mandibular bleed into 
lithium heparin lined BD Microtainer tubes (BD Biosciences). Blood from 3-4 mice was 
pooled to create one sample. Blood was then mixed 1:1 with DMEM and layered over 
2mL of Histopaque 1083 (Sigma) and spun at 300g for 30 minutes with no brake. The 
PBMC layer was removed and washed 2x in DMEM “Benchtop” Media (see recipe 
below). 
 For buffy coat isolation, ~50µL of blood was collected by retro orbital bleed into 
heparinized Micro-Hematocrit Capillary tubes (Fisher Scientific) and spun at 300g for 20 
minutes. Tubes were cut below the bufficoat line and cells were expelled into DMEM 
“benchtop” media before use. 
For splenocyte isolation, mice described in section 2.1 were euthanized by 
cervical dislocation. Spleens were removed aseptically and single cell suspensions 
were created using frosted glass slides (Corning #2948) and passing resulting cells 
through an 18 gauge needle (2x) and through a 70µM cell strainer (Fisher Scientific) 
into DMEM benchtop media.  
For mouse CD4+ T cell isolation, cells were isolated using a negative selection 
magnetic isolation column (Miltenyi Biotec) according to manufacturer instructions. 
The Jurkat E6 CD4+ T cell line was obtained from the American Type Culture Collection 
(ATCC #TIB-152). The CH7C17 CD4+ T  cell line has been described previously217. 
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Cells were counted using a hemocytometer or Z2 coulter counter (Beckman 
Coulter) using the limits TU: 12 and TL: 5 for viable lymphocytes. 
 
2.2.2 Media 
The Jurkat E6 CD4+ T  cell line was obtained from the American Type Culture 
Collection Benchtop Media: During isolation or for prolonged treatment outside of a CO2 
incubator, mouse cells were kept in DMEM containing 4.5g/L glucose, sodium pyruvate 
and 2mM L glutamine (Gibco) supplemented with 10% FBS (Hyclone), 25mM HEPES 
buffer, 1% penicillin/streptomycin (Gibco) and 50µM 2-mercaptoethanol. 
Mouse Cell Culture Media: Mouse cells were cultured in DMEM containing 4.5g/L 
glucose, sodium pyruvate and 2mM L glutamine (Gibco) supplemented with 10% FBS 
(Hyclone), 1% non-essential amino acids (GIbco), 1% penicillin/streptomycin (Gibco) 
and 50µM 2-mercaptoethanol. Cells were kept in 96 or 24 well tissue culture treated 
plates (Fisher) at 1 x 106 cells/mL for CD4+ T cell culture and 2x106 cells/mL for 
splenocyte culture at 37 °C and 5% CO2. 
Jurkat Cell Culture Media: Cell lines were maintained in RPMI 1640 (Invitrogen) 
supplemented with 10% FBS (Atlanta Biologicals) and 4 mM l-glutamine, 
Penicillin/Streptomycin, and 25 mM HEPES buffer (Fisher Scientific) at 37 °C and 5% 
CO2. 
 
2.2.3 Cell Activation and Differentiation  
Mouse CD4+ T cell differentiation: To induce TH0 cells, mouse splenocytes or 
CD4+ T  cells were incubated in 24 well plates coated with 1µg/mL anti-CD3 (Biolegend) 
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and 1µg/mL soluble anti-CD28 (biolegend). For Tr1 cells 50ng/mL of IL-27 (R&D 
systems) was added according to 5. For Th1 cells, 20ng/mL IL-2, 20ng/mL IL-12, and 
10µg/mL anti-IL-4 (R&D systems) was added. For Th2 cells, 20 ng/mL IL-2, 100 ng/mL 
IL-4, 10µg/mL anti-IL-12 (R&D systems) was added. After 5 days, cells were counted 
and resuspended @ 1x106 cells/mL in 75% new media (rested) for 2 days.  
Mouse CD4+ T cell re-stimulation: Rested cells were plated at 1x10^6 cells/mL in 
fresh media in 24 well plates coated with 5µg/mL anti-CD3 (Biolegend). For zinc 
experiments, filter sterilized ZnSO4 [50mM] (Sigma) in 0.85% NaCl was diluted in media 
to indicated [Zn2+]. TPEN (N,N,N′,N′-Tetrakis(2-pyridylmethyl) ethylenediamine) [20mM] 
in DMSO was added to 0.85% NaCl to indicated concentration. After indicated time 
points, cells were spun down (300g) and supernatant was stored at -80OC until analysis. 
Jurkat T cell differentiation: Jurkat E6 CD4+ T  cells were stimulated with 
immobilized anti-CD3 (2 µg/ml) and soluble anti-CD28 (5 µg/ml) in the presence of IL-12 
(5 ng/ml) and IFN-gamma (2 ng/ml) for 48 h (TH1 inducing conditions), or immobilized 
anti-CD3 (2 µg/ml) and soluble anti-CD28 (5 µg/ml) plus IL-4 (5 ng/ml) and IL-10 
(10 ng/ml) for 48 h (TH2 inducing conditions). 
 
2.2.4 Treatments 
For metal treatment, CdCl2 (Sigma), Hg(OAc)2 (Sigma), ZnSO4 (Sigma) were 
diluted in 0.85% NaCl at [50mM] and diluted in media to appropriate final concentrations. 
 For cell activation treatments, Phorbol 12-myristate 13-acetate (PMA) (Roche), 
was reconstituted in DMSO to 1mM per manufacturer’s instructions and diluted in media 
immediately before use. Phytohemaglutanin (PHA) (Roche) and concanavalin A (ConA) 
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(Sigma) was diluted in PBS to 1mg/mL and diluted in media immediately before use. 
For cytokine treatments, recombinant CCL2 (also called MCP-1) and anti-CCL2 
were part of a duoset sandwich immunoassay kit (R&D systems) and stock 
concentrations were created and stored per manufacturers instructions. Mouse IL-1 
beta, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12, IFN-gamma, and TNF-alpha recombinant 
proteins were all part of duoset kits (R&D systems). 
For ROS, RNS, and antioxidant treatments, H2O2 (30% w/v) (Sigma) was diluted 
in PBS before use (See section 2.3.2). 3,3-Bis(aminoethyl)-1-hydroxy-2-oxo-1-triazene 
(NOC-18) (Sigma) was diluted in 0.85% NaCl to 100µM immediately before use. To 
release a bolus of NO, HCl (1M) was added to NOC-18 in a dropwise manner until pH 
3.0 was reached, then brought up to pH 7.4 before being diluted for use. 2,2'-
dithiodipyridine (DTDP) (Sigma) was diluted in PBS to 100µM before being diluted in 
media. N-acetylcysteine (NAC) was diluted in 0.85% NaCl and pH to 7.4 with NaOH 
(1M) before use. 
For zinc treatments, 2-Mercaptopyridine N-oxide sodium salt (Pyrithione) (Sigma) 
was diluted in 0.85% NaCl to 50mM before being diluted before use. N,N,N′,N′-
Tetrakis(2-pyridylmethyl) ethylenediamine) (TPEN) in DMSO [20mM] was diluted to 
indicated concentration. 
 
2.2.5 Buffer Recipes  
(H2O for all buffers was purified using Nanopure system, 18mΩ) 
 
1. NP-40 Lysis Buffer  
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0.5% NP-40 (v/v): EDTA [1mM] 
 
2. Complete Buffer “C” 
9.375 mL Buffer C. : 1 Roche mini tab :10µL DTT [1M] : 50µL PMSF 
[100mM] : 500µL Na-beta-glycerophosphate [1M] : 25µL NaF [400mM] : 
100µL Na-ortho-vanadate [100mM] 
 
3. FACS Buffer 
PBS (pH 7.4) : 5% FBS 
 
4. Staining Buffer 
PBS (pH 7.4) : 0.2% BSA : 0.09% NaN3 
 
5. (2x) Laemmli Buffer with 2-Mercaptoethanol 
4% SDS : 120mM Tris-Cl (pH 6.8) : 20% glycerol : 0.02% Bromophenol 
Blue : 5% 2-Mercaptoethanol 
 
6. SDS-PAGE Running Buffer 
3.25g Tris Base : 14.35g Glycine: 0.1% SDS : 1 L ddH20 
 
7. PBS (pH 7.2) 
160g NaCl: 4g KCl : 4g KH2PO4 : 23g NaH2PO4 : 20L ddH2O 
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8. PBS-T (pH 7.2) 
160g NaCl : 4g KCl : 4g KH2PO4 : 23g NaH2PO4 : 4g NaN3 : 5mL Tween-
20 : 20L ddH2O 
 
9. Incomplete Freund’s Adjuvant 
Heavy Weight Mineral Oil: 10% (v/v) Arlacel A 
 
10. Complete Freund’s Adjuvant 
100mg M. tuberculosis: 30mL Incomplete Freund’s Adjuvant 
 
2.3 Quantification of Intracellular Labile [Zn2+]  
 
2.3.1 Resting Levels  
Mouse and human cells were loaded with 0.5µM Fluozin-3 AM (Invitrogen) in 
benchtop media for 30 minutes at 37OC and 5% CO2 according to manufacturer’s 
protocol. Cells were spun and resuspended in benchtop media alone and incubated for 
an additional 30 min. Cells were spun again and resuspended in ice cold benchtop 
media and stained with antibodies against surface markers for 20 minutes on ice (see 
section 2.4). Cells were then washed 2x with FACS buffer (PBS pH 7.4 + 5% FBS + 
0.05% NaN3) and resuspended in 400µL benchtop media + 3µg/mL propidium iodide. 
Cells were then aliquoted into 3 5mL polypropylene tubes (100, 100 and 200µL) and 
kept on ice until analysis. 10 minutes prior to analysis, 100µL of cell sample was mixed 
with 100µL of [100µM] pyrithione + [200µM] ZnSO4 in FACS buffer to generate an Fmax 
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sample. Similarly, 10 minutes prior to analysis the other 100µL aliquot of cell sample 
was mixed with 100µL of [100µM] TPEN in FACS buffer to generate an Fmin sample. 
Untreated sample was used to generate the F sample. The geometric mean of each 
population in the FITC channel was used to generate F, Fmax, and Fmin 
measurements. To determine intracellular [Zn2+]  the following formula was used: Zn2+ 
[pM] = 15000 x (F – Fmin) / (Fmax – F), adapted from 194. 
To determine effects of treatment induced Zn release at indicated time points, 
cells were loaded with Fluozin-3 AM as described. After loading, cells were incubated 
with appropriate treatment for 30-60 min. Cells were then washed 1x with media and 
placed on ice for surface staining. 
 
2.3.2 Kinetic Zn2+ Release Following Treatment 
For kinetic experiments, cells were loaded and stained as described (see 2.3.1). 
1x10^6 cells were resuspended in 800µL of media and kept on ice until analysis. 5 min 
prior to analysis, cells and treatment (400µL diluted to 2x concentration in media) were 
warmed in a water bath. Cells alone were analyzed for 3-5 minutes to determine a (F) 
baseline measurement. Cell sample was then removed and 400µL of cell sample was 
added to 400µL of 2x treatment and immediately placed back on the cytometer for an 
additional 15-20 minutes. 
 
2.3.3 0-3 Hour Treatment 
Cells were resuspended in a 96 well plate with appropriate treatment for 
indicated amount of time. Cells were then removed, spun down (250g for 5 min) and 
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resuspended in 0.5µM Fluozin-3 AM in media for 15 minutes. Cells were then spun 
again and resuspended in media + surface marker antibodies on ice for 15 min. Cells 
were then washed 1x with media and resuspended in media + PI and kept on ice until 
analysis. 
For detection of Zn release and ROS production during restimulation, see 
protocols adapted from 218. Briefly, cells were coated with anti-CD3 (553058, BD 
Biosciences) [5µg/mL] on ice for 30 min. Cells were then washed in FACS buffer (PBS 
+ 5% FBS, pH 7.4) and resuspended in pre-warmed media containing anti-hamster IgG 
(01-22-06, KPL Bio) [10µg/mL] for indicated period of time . During the last 15 minutes 
of incubation, Fluozin-3 AM [1µM] was added to load the cells before spinning and 
staining on ice for surface markers (see 2.4.1) 
 
2.4 Immuno-phenotyping 
 
2.4.1 Surface Marker Staining 
anti-mouse antibodies: anti-CD4-alexafluor647 (557681, BD biosciences), anti-
CD4-FITC (553729, BD biosciences), anti-CD4-PE (553730, BD biosciences), anti-
CD4-PerCP (553052, BD Biosciences), anti-CD8-PerCP (553036, BD Biosciences), 
anti-CD8-APC (553035, BD Biosciences), anti-CD8-PE (553033, BD Biosciences), anti-
CD45R-PE (1665-09, Southern Biotech) anti-CD45R-alexafluor647 (557683, BD 
Biosciences), anti-CD25a-PE Cy7 (552880, BD Biosciences) anti-CD25-alexafluor647 
(563598, BD Biosciences), anti-CD19-PE (553786, BC Biosciences) 
anti-human antibodies: anti-CD3 (MAB100, R&D systems), anti-CD3-biotin 
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(555331, BD Biosciences), anti-CD28 (555726, BD Biosciences), anti-CD4 (MAB379, 
R&D systems), anti-CD4-alexafluor647 (51-0048, Ebioscience) 
 
2.4.2 Intracellular MT Staining 
The UC1MT hybridoma 141 was grown and IgG was purified by LC using protein 
A/G according to lab protocols. For immunophenotyping, IgG was labeled with 
alexafluor647 using a NHS-alexafluor647 labeling kit according to manufacturers 
instructions (A20006, Life Technologies). After surface marker antibody staining, cells 
were fixed and permeabilized using the “Fix and Perm Cell Permeabilization Kit” 
(GAS004, Invitrogen) according to manufacturer’s instructions. Approximately 1.6µg of 
UC1MT-alexafluor647 antibody per 500,000 cells was used for intracellular staining. 
Mouse-MOPC21-alexafluor647 (400130, Biolegend) was used as isotype control. Cells 
were analyzed in FACS buffer (0.2% BSA in PBS + 0.09% NaN3, pH 7.4) 
 
2.4.3 Intracellular p38 Staining 
Cells were fixed with 2% paraformaldehyde (Sigma) at 37C for 10 min and then 
brought to room temp. Cells were permeabilized in 90% methanol in staining buffer 
(according to Cell Signaling Phospho Staining Protocol) and stored overnight at -20OC. 
Cells were stained with anti-phospho p38 (9211S, Cell Signaling) or anti-total p38 (9212, 
Cell Signaling), or isotype control rabbit anti-OVA (AB1225, Chemicon). Anti-rabbit IgG-
FITC (554020, BD Biosciences) was used as a secondary antibody. Cells were 
analyzed in FACS buffer (0.2% BSA in PBS + 0.09% NaN3, pH 7.4) 
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2.4.4 Intracellular FoxP3 Staining 
PBMC from mice were isolated over a Histopaque 1083 gradient and used for 
FoxP3 staining. Cells were fixed, permeabilized, and stained using the Alexafluor647 
anti-mouse/rat/human FOXP3 Flow Kit (320021, Biolegend) according to 
manufacturer’s protocols. Additionally cells were stained with anti-CD4-FITC and anti-
CD25a PE Cy7 for measurement of Treg cell populations by flow cytometry.  
 
2.4.5 Flow Cytometry 
Cell fluorescence measurements were made on a FacsCalibur Flow Cytometer 
(BD Biosciences). Cells were analyzed using FlowJo v9 software (TreeStar). All cells 
were gated on FSC-SSC and PI negative to ensure uniform analysis of live cell 
populations. For Zn measurements, cells were analyzed in PBS + 10% FBS or 
benchtop media (using DMEM without phenol red) 
 
2.4.6 Confocal Microscopy 
Confocal microscopy images were taken with a Nikon A1R Laser Scanning 
Confocal Microscope (63x objective) or an Andor Revolution Spinning Disk Confocal 
Microscope (63x objective). Cells were kept at 37OC in a humidified chamber during 
image acquisition. Images were processed using ImageJ software. 
 
2.5 Redox Measurements 
  
2.5.1 Intracellular ROS Production 
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ROS production was measured by loading cells with CM-H2DCFDA (C6827, Life 
Technologies) according to manufacturer’s protocols or according to protocols 
described in 218. Treatment with 200µM H2O2 for 20 minutes was used as a positive 
control for oxidation. Fluorescence was measured by flow cytometry (see 2.4.4) 
 
2.5.2 Intracellular Free Thiol Concentration 
Total free thiol measurements were made using a SpectraMax Plate Reader and 
SoftMaxPro software (Molecular Devices, Sunnyvale, CA) according to 219. CPM (7-
Diethylamino-3-(4'-Maleimidylphenyl)-4-Methylcoumarin) was acquired from Life 
Technologies (D-346). To generate a free thiol standard curve, reduced glutathione 
(039K1054, Sigma) was reconstituted immediately before use. Briefly, cells were 
counted and cells were lysed in a nonidet P-40 based lysis buffer (NP-40 0.5% v/v, 
EDTA 1mM). Cell lysates were assayed for total protein concentration using a micro 
BCA kit (23235, Pierce). GSH standard curve in PBS (10µM – 10nM) and cell lysate 
samples were assayed in triplicate. 
 
 
2.6 SDS-PAGE / p38 Western Blotting 
After treatment, cells were spun down and frozen on dry ice and stored at -80OC. 
Cell pellets were resuspended in 25µL complete Buffer “C” (see section 2.2.5). Cell 
lysates were assayed by Bradford Assay (500-020, BioRad) to determine protein 
concentration. For each lane, load 24µg of cell lysate in Laemmli Buffer (1x) (preheated 
to 95OC for 5min and cooled) into lanes of a 3% acrylamide stacking / 10% acrylamide 
 62
separating gel using the BioRad SDS-PAGE box in Running Buffer. Run gel at 150mV 
(DC) for 1 hour. Transfer gel to PVDF membrane using iBlot system (Life Technologies) 
according to manufacturers protocols. For total p38, block membrane with 5% non-fat 
dry milk in TBS-T and probe using anti-p38 (9212, Cell Signaling) according to 
manufacturers protocols. For phospho-p38 block membrane in 5% BSA and probe 
using anti-phospho p38 (9211S, Cell Signaling) according to manufacturers protocols. 
Anti-rabbit-HRP (s-2054, Santa Cruz) was used as secondary antibody. 
Chemiluminescent detection was achieved using SuperSignal West Pico Kit (34079, 
Pierce) and a Kodak 2000MM image station.  For reference, Full Range Rainbow 
Molecular Weight Marker was used (GE Lifesciences). 
 
2.7 Biomarker Quantification by ELISA 
All ELISAs were conducted using Immulon H2B plates and were read on a 
SpectaMax 2 Plate reader at 405nM – 540nM for reference correction of HRP substrate 
and 450nM for AP substrates. Plates were washed in between steps using an ELX 405 
automatic plate washer and PBS-T wash buffer. 
 
2.7.1 Mouse Cytokines 
Mouse cytokine quantification by ELISA was accomplished using duoset 
matched pair antibodies for IL-10 (DY417, R&D systems), IFN-gamma (DY485, R&D 
systems) and streptavidin HRP substrate detection. 
 
2.7.2 Human Cytokines 
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Human cytokine quantification by ELISA was accomplished using duoset 
matched pair antibodies for IL-2 (DY202, R&D systems), IFN-gamma (DY285, R&D 
systems) and TNF-alpha (DY210, R&D systems) and streptavidin HRP substrate 
detection. 
 
2.7.3 Mouse IgG 
 Detection of mouse IgGs were accomplished by serial dilutions (1:4) of serum 
(1:100 – 1:6400) in PBS. The following capture antibodies were used: anti-mouse IgG 
(31168, Pierce), anti-mouse IgG1 (1070-01, Southern Biotechnology), anti-mouse 
IgG2a (103-01, Southern Biotechnology), anti-mouse IgG2b (104-01, Southern 
Biotechnology). Anti-collagen specific IgG was captured using plate bound type II 
chicken collagen [5µg/mL] in 0.05 M Tris-HCl/ 0.2M NaCl. Mouse IgG was detected 
using anti-mouse IgG – AP (1030-04, Southern Biotechnology). 
 
2.7.4 Human anti-CCP antibody 
 Anti-CCP autoantibody was measured from human serum of 48 individuals 
collected by the New York State Department of Health, Wadsworth Center. Serum was 
stored at -80O C until testing. Samples were analyzed by an anti-CCP autoantibody 
ELISA kit (FCCP 100, Euro Diagnostica) using manufacturer’s protocols. For 
comparison with SPCE based measurements, cyclic citrullinated peptide (H-
HQCHQESTXGRSRGRCGRSGS-NH2) was synthesized by Abgent and detected with 
anti-human IgG-biotin (H10315, Invitrogen) and streptavidin-alexafluor647 (S1374, Life 
Technologies). 
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2.9 SPR / SPCE Assays 
 
2.9.1 SPR and SPCE Instrumentation and Sensor Chips 
The GCSPRI instrument used in these studies is an engineering prototype of the 
8500 Flexchip Analyzer (HTS Biosystems, Hopkinton, MA) and has been described 
previously (Unfricht et al., 2005). GCSRPI sensor chips were provided by Ciencia, Inc. 
(East Hartford, CT). Assays requiring both GCSPRI and fluorescent measurements 
were made with a second generation GCSPRI/SPCE dual mode instrument designed 
and built by Ciencia, Inc. (East Hartford, CT). The second generation instrument is 
based on the same SPR principle as the 8500 Flexchip, but operates at a shorter 
wavelength that is compatible with the excitation of Alexa fluor 647 (Invitrogen, Carlsbad, 
CA) and CellTrace Far Red DDAO-SE (Invitrogen, Carlsbad, CA). 
 
2.9.2  GCSPRI Sensor Chip Modification and Printing 
Gold sensor chips were washed with 70% ethanol and rinsed with water (18 MΩ) 
and dried under a stream of filtered air. For dithiobis-succinimidyl propionate (DSP) 
surface modifications, DSP (Thermo Fisher, Rockford, IL) was resuspended in dimethyl 
sulfoxide (DMSO) at 4 mg ml−1 and contacted to the gold surface for 30 min. Chips were 
washed exhaustively with DMSO and water (18 MΩ) and immediately used for printing. 
2-(pyridinyldithio) ethylcarbamoyl dextran (PDEC dextran) surface modifications were 
performed as previously reported (Li et al., 2008). Before printing on PDEC dextran 
surfaces, inter-heavy chain disulfide bonds of antibodies were reduced with 1 mM 
dithiothreiotol (DTT) for 8 h to expose sulfhydryl groups for covalent immobilization. For 
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neutravidin surface modifications, cleaned sensor chips were incubated with a solution 
of 1 mM 1,9 nonanedithiol (Sigma–Aldrich, St. Louis, MO) in ethanol for 2 h and then 
washed extensively with ethanol. Chips were then incubated with 0.3 mg ml−1 
maleimide-activated neutravidin (Thermo Fisher, Rockford, IL) in PBS for 1 h and then 
washed exhaustively with water (18 MΩ) and dried under a stream of filtered air. All 
surface modifications were made at 25 °C. 
Microarrays were printed on sensor chips using the OmniGrid Micro robotic 
spotter (Genomic Solutions, Ann Arbor, MI) or a SpotBot II robotic spotter (TeleChem 
International, Inc., Sunnyvale, CA) and an ArrayIt Stealth micro spotting pin, size 
SMP7B (255 µm spot diameter, 3.1 nL delivery volume) (TeleChem International, Inc., 
Sunnyvale, CA). Chips were maintained in high humidity (75–85%) at 25 °C during 
spotting and allowed to incubate for an additional 1 h in high humidity after spotting. 
Chips were then removed and fitted with a 0.02″ thick, double-sided adhesive gasket 
and 1/8″ thick glass window to form a 50 µl flow cell over the printed array. Once printed, 
chips were stored desiccated at 4 °C for up to 4 days before use. 
 
2.9.3 Antibodies and General Reagents 
Anti-human cytokine antibody matched pair sets for interleukin-2 (IL-2), 
interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha) were 
purchased as duosets from R&D systems (Minneapolis, MN). Mouse anti-human CD3ɛ 
and anti-human CD28 antibodies were purchased from BD Biosciences Pharminogen 
(San Diego, CA). Biotinylated mouse anti-human CD3 was purchased from Becton-
Dickinson (Franklin Lakes, NJ). Superblock (in PBS) blocking agent was purchased 
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from Thermo Scientific (Rockford, IL). Bovine serum albumin (BSA) was purchased 
from Fisher Scientific Company (Morris Plains, NJ). BSA was biotinylated using 
polyethylene oxide–maleimide–biotin from Pierce (Rockford, IL) and diluted to 
500 µg/ml in PBS for use on reference ROIs. CellTrace Far Red 9H-(1,3-dichloro-9,9-
dimethylacridin-2-one-7-yl) succinimidyl ester (DDAO-SE) was used for fluorescent cell 
labeling and streptavidin Alexa fluor 647 were purchased from Invitrogen (Carlsbad, CA). 
For mouse cytokine microarrays, sensor chips were contacted with 
dithiobis(succinimidyl propionate) (22585, ThermoScientific) [4mg/mL] in DMSO for 30 
min and washed exhaustively with DMSO and water before printing. Arrays were printed 
as described in section 2.11.2. For analyte detection, the following sandwich 
immunoassay sets were used: IL-ra (DY480, R&D systems), IL-1beta (DY401, R&D 
systems), IL-2 (DY402, R&D systems), IL-4 (DY404, R&D systems), IL-5 (DY 405, R&D 
systems), IL-6 (DY406, R&D systems), IL-10 (DY417, R&D systems), IL-12p70 (DY419, 
R&D systems), IL-13 (DY413, R&D systems), IL-17 (DY421. R&D systems), IL-18 
(DO47-3 + DO48-6, MBL International) IL-33 (DY3626, R&D systems), CCL-2 (DY479, 
R&D systems), CD40L (DY1163, R&D systems), IFN-gamma (DY485, R&D systems), 
Osteopontin (DY441, R&D systems), TNF-alpha (DY410, R&D systems) 
 
2.9.4 Peptide-MHC Monomer Complexes 
The influenza hemaglutanin peptide abbreviated HA (PKYVKQNTLKLAT), and 
the tetanus toxin control peptide abbreviated TT (QYIKANSKFIGITE), presented in the 
context of DR1 (DRA*0101, DRB1*0101) have been previously described (Stone et al., 
2005 and Zavala-Ruiz et al., 2004). Briefly, recombinant MHC proteins were prepared 
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by standard methods (Cameron et al., 2002). Soluble HLA–DR1 including a uniquely 
reactive cysteine engineered at the C terminus of the alpha chain was produced in 
Schneider S2 insect cells, and was chemically modified with polyethylene oxide–
maleimide–biotin (Pierce, Rockford, IL). 
 
2.9.5 Assay Procedure 
Sensor chips were blocked by flushing 5 ml of Superblock (Pierce, Rockford, IL) 
or 2% BSA in PBS over the chip and allowing the blocking agent to incubate for 10 min. 
This step was repeated once. Next, 5 ml of complete RPMI 1640 with 10% FBS was 
flushed over the chip and allowed to incubate for 30 min. This step was repeated once. 
Cells were resuspended to 2 × 106 cells ml−1 in complete RPMI 1640 with 10% FBS 
before analysis. Complete RPMI 1640 10% FBS was passed over the chip surface for 5 
to15 min at 200 µl min−1 to establish a baseline SPR angle measurement. Three ml of 
sample was recirculated at 200 µl min−1 for 15–30 min to allow for cell binding. Non-
specifically bound cells were minimized by following the cell suspension exposure with a 
wash step consisting of complete RPMI 1640 media 10% FBS at passed over the chip 
at 1 ml min−1 for 10 min. For cytokine production assays, cells were allowed to incubate 
on the chip for 3 h before exposure to lysis buffer (20 mM Tris, 100 mM NaCl, 1 mM 
EDTA, 0.5% Triton X100, pH 7.4) for 5 min followed by a wash with PBS plus 0.0025% 
Tween20 plus 0.0002% NaN3 (PBST) at 500 µl min−1 for 5 min. 2 ml of 0.1% BSA in 
PBST containing a cocktail of secondary matched-pair detection antibodies at 
recommended ELISA concentrations (R&D Systems, Minneapolis, MN) was recirculated 
over the chip at 500 µl min−1 for 60 min, followed by a wash with PBST at 500 µl min−1 
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for 5 min, followed by streptavidin-Alexa fluor 647 in PBST at 800 ng/ml for 20 min and 
a final 10 min wash step with PBST before measuring fluorescence using SPCE. Chips 
were kept at a constant 37 °C for the duration of all experiments. 
 
2.9 Collagen Induced Arthritis (CIA) Model 
Induction of the Collagen Induced Arthritis model in C57Bl/6 mice was 
accomplished using protocols described in 220. Protocols were approved by UConn 
IACUC (protocol number A08-065). 
 
2.9.1 Pilot Study 
7 male C57BL/6 mice (mean age 25 weeks) and 7 female C57BL/6 mice (mean 
age 29 weeks) were injected 2x with 50µL intradermal injections at the base of the tail 
with Chicken Type II Collagen (C9301, Sigma) in complete Freund’s Adjuvant (CFA) 
(Treatment Group) . Alternately, 3 male and 1 female mouse were injected with CFA 
alone (Vehicle Control group). The Treatment Group was given a secondary booster 
injection 2 weeks later with Chicken Type II Collagen in incomplete Freund’s Adjuvant 
(IFA). Mice were monitored and scored for inflammation in the hind paws over the 3 
month course of the study. Blood samples were collected before immunization and at 
days +4, +16, +43, +55, and +80 post immunization. Mice were euthanized at day +55 
or day +80 and spleens, inguinal lymph nodes, PBMCs and serum were isolated for 
further analysis. 
 
2.9.2 Influence of MT on CIA progression Study 
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13 male C57BL/6 (MT-WT), 13 male MT-KO, and 10 male MT-TGN mice were 
immunized as described above (see section 2.10.1) Additionally, 3 mice from each 
group were treated with vehicle control. Changes to above protocol including addition of 
sterile PBS to primary immunization (which precipitates collagen into a salt), and 2 
additional booster immunizations at 14 days and 58 days. 
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Chapter 3   
Measuring Intracellular [Zn2+] in Immune Cells  
in vitro 
3.1 Introduction 
Total intracellular [Zn2+] in eukaryotic cells is usually in the range of a few 
hundred micromolar221. Lysis of cells and removal of the zinc with low pH and heating 
allows the careful analysis of total intracellular zinc. However, the physiologically 
relevant concentrations associated with zinc signaling, where transient changes affect 
cellular processes, are much lower. In T cells, important signaling pathways including 
activation of Akt following IL-2 signaling, for example, are affected when intracellular 
labile [Zn2+] is increased from 200 to 590pM 222. Because of the vast repertoire of zinc 
binding motifs, zinc has the potential to affect protein structure and function across a 
significant concentration range. However, fluctuations within normal healthy immune 
cells during activation and signaling usually include an increase in intracellular [Zn2+] 
from 200 pM up to about 1 nM. Interestingly, this is within the theoretical range of 
regulation by metallothionein (MT), given cytosolic concentrations of MT34 in 
lymphocytes and MT’s affinity for Zn2+ (log K = 11 – 8)120. Within this range, zinc 
mediated regulation occurs via 4 distinct mechanisms in lymphocytes: 1. Structural 
changes and transcription factor activation (ex. MTF-1) 2. Inter-molecular binding and 
activity (ex. CD4/LcK) 3. Enzyme activation (ex. PKC); Enzyme inhibition (ex. PTPase). 
Of particular importance in T cell signaling is the inhibition of protein tyrosine 
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phosphatases223. The vast majority of structural zinc in zinc finger transcription factors is 
not significantly affected in this range of fluctuation because these motifs are already 
saturated with zinc, given their high binding affinity (logK = 13-11). Likewise, activation 
of metalloproteases, which requires high nanomolar [Zn2+] 224, would not be affected by 
these picomolar shifts (Figure 3.1) 
 
3.2 Measuring Intracellular Labile [Zn2+]  
There are many factors to consider when choosing a fluorescent zinc chemo-
sensor including optical ex/em wavelengths, affinity for metal, specificity for a zinc, 
different excitation spectra from metal bound or free sensor for ratio-metric comparison, 
activity in large pH range, etc. Many of the currently available zinc sensors have been 
recently reviewed225. Briefly, an ideal zinc sensor is nonfluorescent in the free-base form 
and highly fluorescent when coordinated to zinc. Furthermore, for determination of 
intracellular concentration, the sensor must be cell-permeable and, ideally, retained 
inside the cell after crossing the membrane. Various zinc sensors meet some but not all 
of the necessary qualifications for measuring picomolar shifts in intracellular [Zn2+] in 
vitro131. However, the need for high specificity, high affinity sensor prevents this 
investigation using established zinc sensors including Zinquin (Kd zinc =7µM)226 227and 
Newport Green (Kd zinc = 1-3µM)228 . 
 The precise measurement of intracellular labile [Zn2+] in immune cells has only 
recently become possible with the development of the high affinity fluorescent sensor 
Fluozin-3 and its acetoxymethyl ester derivative Fluozin-3 AM (Figure 3.2) The high 
affinity (Kd zinc = 15nM) of this sensor allow changes in [Zn2+] below 100 pM to be 
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measured. Furthermore, this sensor is highly specific and is not perturbed by high levels 
of intracellular Mg2+ or Ca2+229 which is of particular importance in T cell activation 
where an influx of Ca2+ is a necessary requirement 230. Furthermore, Fluozin-3 is 
relatively unaffected by low pH or oxidants 231 which is important for studying zinc in 
lysosomes or its release following oxidative stress. 
One of the drawbacks of Fluozin-3 is its lack of ratio-metric properties, meaning 
the total amount of free dye that is not complexed with zinc cannot be determined using 
a different excitation wavelength like other sensors (ex. Fura-2). This can be overcome 
experimentally by exposing cells to complete chelation or complete saturation with zinc 
194
 to generate a minimum fluorescent signal (Fmin) or a maximum fluorescent signal 
(Fmax), respectively. Using these parameters, the intracellular [Zn2+] can then be 
interpreted based on the relationship of Fmin and Fmax to the unperturbed fluorescent 
signal (F) and the known dissociation constant of Fluozin-3 (Kd=15nM) using the 
equation: 
Equation 1: 
Intracellular [Zn2+]  = Kd * (F-Fmin) / (Fmax –F) 194 
 To generate the Fmin signal, an excess of the cell permeant zinc specific 
chelator TPEN is added to the cell sample at least 10 min prior to analysis. Minimum 
Flouzin-3 fluorescence, measured in the FL-1 or GFP channel of the FACScalibur flow 
cytometer, is reached within 1 min of TPEN [10µM] addition194 to cells in complete cell 
culture media. To ensure fluorescent minimum is reached, samples are incubated for at 
least 10 min with 50µM TPEN in PBS/media (1:1). It is important to note, if extracellular 
[Zn2+] in the experimental system is exceptionally high (100µM ZnSO4 treatment, for 
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example) the concentration of TPEN must be increased accordingly. The 10min 
incubation at 50µM is considered a good standard for cells in normal culture media and 
does not affect signal from propidium iodide or forward/side scatter properties, 
indicating this treatment does not interfere with membrane integrity. 
 To generate the Fmax signal, the Fluozin-3 fluorescent probe must be saturated 
with Zn2+ ions, which occurs at about 5µM ZnSO4 at pH 7.2 in isotonic buffer 19 as a 
reference. To accomplish this, an excess of ZnSO4 [200µM] is added to the media 
containing cells along with the zinc specific ionophore pyrithione [50µM] and incubated 
with the cells for at least 10 minutes. Fmax is achieved within 1-2 minutes using these 
conditions with CD4+ T cells (Figure 3.5) and can be achieved with as little as 1µM 
pyrithione and 50µM ZnSO4194. Therefore, the use of 2-10 fold excess ensures Fmax is 
achieved reproducibly.  
 The protocol for determining the best method for Fluzoin-3 loading and sensor 
saturation/chelation was part of a systematic, iterative process to ensure the method 
used had as little effect as possible on the measurement. Literature 7,194 and 
manufacturer’s protocols often call for long incubations with ionophore and chelator at 
37OC. However, this causes a change in the distribution of fluorescent signal and 
scatter properties in immune cells from both Fmax and Fmin conditions. This also leads 
to greater inter-assay variation for the same population of cells measured multiple times 
in parallel (data not shown). To avoid this variation, the method of 10 min incubations on 
ice directly before measurement was developed to produce populations with scatter 
properties that were the same as untreated cells. 
The method described above was applied to freshly-isolated peripheral blood 
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mononuclear cells (PBMCs) from a C57BL/6 mouse. PBMCs were isolated from 
heparinized whole blood by density centrifugation and loaded with Fluozin-3 AM. Cells 
were then stained with anti-CD4-alexafluor647 antibody and propidium iodide (PI). The 
cell sample was split into 3 aliquots: one aliquot was treated with Zn/pyrithione (Fmax); 
one aliquot was treated with TPEN (Fmin) ; one aliquot was left untreated (F). 
Lymphocyte FSC/SSC and PI negative gates were applied and the resulting Fluozin-3 
fluorescence for the three samples is shown in Figure 3.3. The geometric mean of each 
population was then determined and used as the relevant value in Equation 1. For this 
sample, the CD4+ T cell population had an average intracellular [Zn2+] of 202 pM, which 
is within the reported normal distribution for murine CD4+ T cells.  
 To determine the optimal concentration of Fluozin-3 AM to use in subsequent 
experiments, the effect of sensor incubation concentration on the resulting fluorescent 
signal (F) was measured in Figure 3.4. Increasing the Fluozin-3 AM concentration 
above [1µM] did not significantly affect cellular fluorescence. When fluorescent 
compensation between several fluorophores is required, the negative and positive 
stained populations must fit completely within the scale of fluorescence that is 
measured on the cytometer (for example, 104 fluorescent units on the FACScalibur). 
This will be a requirement for when multiple cell populations from the same sample 
need to be identified (CD4+, CD8+ CD25+, CD19+, CD45R+, etc.). In order to get the 
unlabeled and Fmax populations both within this range on the FL-1 channel, it is 
necessary to use a concentration of Fluozin-3 AM that is 0.5µM or lower. Additionally, 
the least amount of probe necessary to generate sufficient signal is always preferred 
because excess probe can have a zinc buffering effect on the cellular system19. For 
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these reasons, a concentration of 0.5µM was generally used for all experiments. 
 To measure the effect of influx of extracellular [Zn2+] on Fluozin-3 fluorescence, 
CD4+ T cells were loaded with Fluozin-3 and treated with different concentrations of 
extracellular ZnSO4 and pyrithione (Figure 3.5). In the absence of pyrithione (magenta 
line), adding up to 50µM ZnSO4did not increase fluorescence in the 30 minute time 
window of incubation, evidencing the ability of cells to maintain steep 
extracellular/intracellular zinc gradients. Addition of pyrithione alone (teal line) did 
increase intracellular fluorescence, indicating the residual zinc in either the pyrithione 
preparation or the 1% fetal bovine serum (FBS) was enough to increase intracellular 
labile [Zn2+] when ionophore was added. Increasing [Zn2+] from 400 nM to 50µM 
increased fluorescence, indicating the probe was not saturated, even when 10µM 
ZnSO4 was added (red line). This was likely due to the buffering capacity of both the 
intracellular environment and the FBS. 10% FBS has been shown to sequester about 
50% of added [Zn2+] when 10% FBS was added to media7. Fluorescence did not 
increase when more than 50µM ZnSO4 was added, indicating saturation of Fluozin-3 by 
zinc had occurred (data not shown).  
In general, different types of cell and cells at different stages of cellular 
development (naïve, proliferating, effector) load the Fluozin-3 sensor differently19. Total 
Fluozin-3 loading efficiency can be derived from measurements following zinc saturation 
using excess zinc and pyrithione to generate a maximum fluorescent signal (see section 
3.3). Within resting naïve lymphocytes, CD19+ B cells exhibit higher Fmax signals than 
CD4+ cells, which are higher than CD8+ cells (Figure 3.6A). The same hierarchy of 
fluorescence was also observed for Fmin signals (due to background fluorescence of 
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the sensor), which supports the conclusion that B cells load Fluozin-3 more efficiently 
than T cells. This effect was observed over different days with both PBMC and spleen 
derived lymphocytes.  
 The efficiency of AM dye loading is the consequence of 2 separate processes: 1. 
Esterase activity that cleaves the AM group from the dye, making it polar and 
sequestering it inside the cell. 2. Efflux of the dye through ABC transporters and/or 
exocytosis232. In CD8+ T cells (naïve or activated), and activated CD4+ T cells, Fmax 
signals showed a wider distribution than naïve CD4+ T cells, indicating the greater 
variation in the amount of dye retained in the cells. This distribution increased with time 
(data not shown), suggesting that the dye was actively being transported out of the cells. 
That this process was more highly active in activated CD4+ T cells than naïve CD4+ T  
cells (Figure 3.6A) is not surprising given the increased SSC parameter of activated 
CD4+  populations, evidencing a greater number of intracellular vesicles, and the 
generally increased metabolism of proliferating lymphoblasts versus resting naïve 
lymphocytes. However, because the determination of intracellular [Zn2+] is derived from 
a ratio of F, Fmin, and Fmax signals, the degree of saturation of the dye remains the 
important parameter. This ratio is affected by labile [Zn2+] and is independent of dye 
concentration. 
 
3.3 Resting Intracellular Labile [Zn2+] in Different Lymphocyte 
Populations 
To determine the effect of MT gene dose on the resting intracellular [Zn2+] of 
mouse lymphocyte populations, the methods described above were employed to freshly 
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isolated PBMCs taken from male, age-matched MT-KO (n=4), MT-WT (n=4), or MT-
TGN mice (n=4). Cells were stained with anti-CD8 (CD8+ T cells), anti-CD4 (CD4+ T 
cells) or CD19 (B cells) to differentiate cell populations. The Fluozin-3 signal (F, Fmin, 
and Fmax) for one representative mouse from each genotype / cell type is shown in 
Figure 3.6A. The intracellular labile [Zn2+] from each genotype / cell type is shown in 
Figure 3.6B.  
The same hierarchy of intracellular [Zn2+] was observed in each of the 3 
genotypes. CD8+ T cells maintain the highest intracellular labile [Zn2+] which ranges 
from 350 and 400pM. CD4+ T cells maintain a significantly lower concentration that 
ranges from 140 to 220pM. B cells maintain the lowest concentration at 95-130pM. 
These concentrations represent resting cells, the vast majority of which are naïve cells, 
having never encountered their cognate antigen. These zinc levels can be considered a 
baseline at which normal cellular functions are maintained. However, influx of zinc from 
the extracellular environment or intracellular vesicles can quickly raise this 
concentration and act as a zinc signal as part of cellular activation. 
MT genotype did not significantly influence (p<.05) the intracellular [Zn2+]  in any 
of the resting lymphocyte populations tested (MT-WT vs. MT-KO or MT-WT vs. MT-
TGN).  On one hand, this result is somewhat unexpected, given the influence of MT 
gene dose on total serum Zn concentrations in Figure 3.7. However, total serum Zn is 
buffered by plasma proteins, especially albumin 233 and the difference in the labile [Zn2+] 
in serum is likely to be much less. Additionally, given how tightly intracellular [Zn2+] is 
regulated by the ZnT and Zip families of proteins in lymphocytes, modest changes 
(<25%) to extracellular [Zn2+] can be adequately addressed by small changes in 
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transporter activity or expression. Furthermore, baseline MT expression in resting naive 
lymphocytes, especially those from mice, is very low and protein levels are almost 
undetectable 34,35,234. Therefore, it is likely that intracellular MT plays a much less 
significant role in determining intracellular [Zn2+] than other homeostatic mechanisms. 
Fluorescent compensation of overlapping excitation spectra from multiple 
fluorophores is an accepted method of determining relative fluorescence from distinct 
fluorophores. However, it is not without caveats and is based on assumptions including 
a linear relationship between fluorescent intensity and compensation. To make sure that 
fluorescent compensation and/or small sample size did not mask any MT gene dose 
related effects on the intracellular [Zn2+] , CD4+ T cells from mice sacrificed on different 
days over the course of several months were stained using an alexafluor647 labeled 
antibody. There is no spectral overlap between Fluozin-3 and alexafluor647, which 
negates the need for compensation and avoids any compensation derived artifacts. 
Additionally, it was important to validate that the source tissue from which CD4+ T cells 
were taken did not affect intracellular [Zn2+] . The results of this larger study (n=12) 
confirmed earlier findings that MT gene dose does not affect intracellular [Zn2+] in 
resting CD4+ T  cells. Furthermore, cells derived from the spleen or peripheral blood 
displayed similar concentrations of intracellular [Zn2+] . 
 
3.4 Influence of Added Zn or Antioxidant to Culture Media 
The resting concentration of intracellular Zn is tightly controlled primarily by ZnT1 
and ZnT4 which are the predominant zinc exporters expressed in CD4+ T cells235. To 
test the extent to which intracellular labile [Zn2+] could be affected by extracellular 
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concentration, splenocytes from C57BL/6 mice (MT-WT) were cultured in complete 
media with 125µM ZnSO4 for 24 hours (Figure 3.9) The increase in extracellular labile 
[Zn2+] from this treatment is estimated to be about 25 fold. However, intracellular Zn 
increase was only about 50%, from ~200 pM to ~300 pM (Zn+/Zn+). The ability to 
experience only a small increase in intracellular [Zn2+] is due to an increase in ZnT 
expression and is an established mechanism of zinc homeostasis in leukocytes.195. 
When cells were placed back in normal media for 30 minutes after 24 hour incubation 
with increased Zn (Zn+/Zn-), intracellular [Zn2+]  was lowered considerably, even below 
the concentration of cells cultured in normal media for the entire 24 hours (Control). This 
effect has been observed previously in T cells 196 and results from upregulation and 
expression of ZnT family zinc exporters. This observation emphasizes the fact that 
measurement of intracellular [Zn2+] is affected by the [Zn2+]  in the media and buffers 
used during cell loading and analysis. For this reason, cells should be kept in media 
with an equivalent [Zn2+] throughout experimental treatment and measurement. 
Intracellular [Zn2+] is intimately linked to redox potential because the additional 
electron on reduced sulfhydryls (as a free electron or part of the hydrogen atom) is a 
requirement for the coordination and binding of cationic zinc236. Oxidative stress or ROS 
signaling oxidizes intracellular thiols into disulfides that release bound Zn and prohibit 
further Zn binding until a reduced sulfhydryl is regenerated20. In this way, oxidative 
stress decreases the redox and consequent zinc buffering capacity of cells and makes 
them more susceptible to zinc toxicity201. This is especially important in lymphocytes 
where small changes in oxidative stress and zinc status are important for pro-apoptotic 
pathways237,238. For this reason, understanding the relationship of intracellular redox 
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potential during cell culture becomes critically important when measuring or 
manipulating the concentration of intracellular zinc. Removal of cells from the body, 
where partial pressure of oxygen is around 9%, and placement in atmospheric oxygen 
at 19% causes cells to experience an oxidative stress. To counteract this increase in 
redox potential, antioxidants are added to culture media to maintain intracellular 
reduced thiol concentrations 239. For some cell types, 10% FBS adds enough redox 
buffering capacity to maintain healthy cells. However, given the sensitive nature of 
lymphocytes to oxidative stress, additional antioxidant in the form of 2-mercaptoethanol 
(2-ME) is often added. Maintaining an appropriate redox potential is critical to T cell 
functions including proliferation240,241 and differentiation242 and perturbation can 
exacerbate inflammatory autoimmune disease243. Furthermore, maintenance of 
extracellular free thiols has a significant role in shaping T cell responses244-246.  
To determine the effect of additional antioxidant on maintaining intracellular 
[Zn2+] concentration in CD4+ T cells, splenocytes were isolated and cultured in standard 
cell culture media that includes 50µM added 2-ME, 50% antioxidant (25µM 2-ME) or no 
added antioxidant (Control) (Figure 3.9B). It is important to keep in mind that the 10% 
added FBS also acts as an antioxidant and redox buffer so control cells were not 
exposed to non-buffered oxidative stress (which leads to decreased cell viability).  After 
24 hours, there was a strong correlation with added antioxidant and intracellular labile 
[Zn2+] in CD4+ T cells. Cells cultured in 50µM 2-ME maintained the same intracellular 
labile [Zn2+] as freshly isolated cells. Reducing the added 2-ME concentration by 50% 
resulted in 50% increase in intracellular labile [Zn2+] while excluding 2-ME altogether 
resulted in a 2 fold increase. After 24 hours, cell viability for cell cultures without added 
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2-ME began to decline, indicating the effect of the increased oxidative stress and zinc 
concentration led to programmed cell death. For this reason, cells were cultured in 2-
ME for all T cell activation experiments to maintain normal physiological intracellular 
labile [Zn2+].  
Transcriptional control of ZnT1 is mediated through activation of MTF-1 and its 
subsequent binding to MREs in the gene promoter 247. Addition of 125µM ZnSO4 does 
not significantly affect the viability of CD4+ T cells because of expression of 
compensatory Zn regulatory mechanisms 205. Activation of MTF-1 is important for 
protection against zinc toxicity and involves induction of MT1 and MT2 as part of the 
cellular response to increased extracellular [Zn2+].248. As a proof of principle experiment, 
we wanted to determine if differential MT expression could be measured in CD4+ T cells 
from mice with disparate MT gene backgrounds in the context of zinc toxicity. Freshly 
isolated splenocytes from C57BL/6 mice (MT-WT) and MT overexpressing (MT-TGN) or 
MT knockout (MT-KO) congenic mice were cultured for 24 hours in the presence of 
different concentrations of ZnSO4 (1-125µM). After 24 hours, cells were fixed and 
stained for CD4 and MT. Concentrations of zinc between 1 and 12.5µM had no effect on 
MT expression (Figure 3.9B). However, at 125µM added ZnSO4, cells from mice with 
intact MT1 and MT2 genes were positive for MT expression with cells from MT-TGN 
expressing significantly more MT than MT-WT (Figure 3.9A). Cells from MT-KO 
appeared to express more MT after exposure to 125µM Zn. This is likely due to the 
expression a truncated non-functional peptide expressed in the MT-KO mice. The 
premature stop codon that disrupts MT1 and MT2 translation is inserted past the first N-
terminal 5 amino acids of the protein and, consequently, MT-KO mice are able to 
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express a truncated protein with an antigenic epitope 38 that is recognized by the anti-
MT antibody. 
 
3.5 Sub-Cellular Localization of Labile Zn2+ 
 The sub-cellular localization of Zn in lymphocytes is an expanding field that is 
only beginning to be understood (for excellent reviews see 191,192). Like most ions, zinc 
is kept at a significantly lower intracellular concentration (~ 100 - 200pM) than serum 
concentration (5-10 µM). Furthermore, intracellular Zn is partitioned by ZnT proteins 
(SLC30A, Zn exporters) into intracellular vesicles, especially lysosomes or the poorly 
described “zincosomes”235. Release of zinc from vesicles with low pH in CD4+ T cells 
following IL-2 stimulation 8 and in CD8+ T cells following TcR stimulation 15 has been 
reported. Following activation of CD8+ T cells, sub-cellular zinc is increased in the 
cytosol and almost completely released from vesicles via upregulation of Zip8 
expression. During activation of CD4+ T cells however, the degree to which Zn is 
compartmentalized and how this changes over the course of differentiation from naïve 
cell to lymphoblast to effector cell has not been characterized. Furthermore, Aydemir et 
al, speculated that increased expression of MT was responsible for no observed 
increase in cytosolic Fluozin-3 fluorescence in T cells following activation, even though 
the cytosolic [Zn2+] had increased.  
 To investigate the sub-cellular localization of zinc in naïve CD4+ T cells, freshly 
isolated splenocytes were imaged by confocal microscopy. Specifically, splenocytes 
were stained with anti-CD4-alexafluor 647 and loaded with Fluzoin-3 AM and Hoechst 
stain and to visualize the plasma membrane, zinc localization, and nucleus, respectively 
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(Figure 3.11). Naïve CD4+ cells that were freshly isolated from the spleen of MT-KO or 
MT-WT mice both showed similar morphological characteristics including a round shape, 
and a tight ring of cytoplasm around the nucleus. Interestingly, the zinc distribution 
pattern indicates a low level of fluorescence in the cytoplasm with zinc (and sensor) 
being localized to punctate fluorescence points. Addition of zinc/pyrithione caused a 
bright fluorescent signal in all areas of the cell (data not shown) indicating sensor was 
present throughout. Both MT-KO and MT-WT cells showed a similar fluorescence 
pattern and these images reflect the finding of previous reports with both mouse and 
human naïve CD4+ T cells7.  
 To determine the localization of zinc in actively proliferating lymphoblasts, 
splenocytes were activated with anti-CD3/anti-28 in the presence of IL-27 to induce a 
Tr1 effector cell phenotype. Cells were monitored daily for changes in scatter properties 
and surface markers of activation (Figure 4.2A) by flow cytometry. On Day +6, the 
highest proportion (nearly 90%) of CD4+ T cell populations of both MT-WT and MT-KO 
were at a dividing lymphoblast stage of development, determined by CD25+ surface 
activation marker, DDAO-SElow (indicating dye partitioning and cell division), and 
FSChigh /SSChigh properties. Confocal images confirmed the flow cytometry data (Figure 
3.11B). CD4+ lymphoblasts were larger and morphologically irregular, showing a greater 
percentage of cytoplasm and an enlarged nucleus, all of which are expected during 
lymphoblast formation. Interestingly, cells maintained punctate zinc fluorescent patterns, 
indicating that intracellular Zn continues to be muffled (partitioned) into intracellular 
vesicles during activation and proliferation. In general, there were more punctate 
fluorescent vesicles in lymphoblast compared with naïve cells from both strains, which 
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was expected from their increased SSC properties. Furthermore, expression of MT was 
not a requirement of intracellular loading of zinc into vesicles, a mechanism that had 
been hypothesized recently. This does not mean that MT does not increase the kinetics 
or efficiency of the transport of zinc ions into intracellular vesicles, only that MT is not a 
requirement for this process. 
 To further investigate the distribution of zinc, CD4+ T cells were removed from 
inducing conditions on Day +6. At this point, cells were proliferating but no longer being 
subjected to TcR mediated activation (1µg/mL plate bound anti-CD3 in the stimulation 
plate is degraded by day +6). Cells were spun down and resuspended in media alone 
(50% fresh media, 50% existing media) or media + plate bound anti-CD3 [5µg/mL] for 
48 hours. Rested cells decreased their FSC/SSC properties, indicating they reduced 
their cell size but remained significantly larger than naïve CD4+ T cells. Restimulated 
cells retained the lymphoblast phenotype. Both types of cells from both strains also 
retained the punctate zinc fluorescence pattern, indicating labile zinc remained, at least 
in part, in a compartmentalized state during naïve, lymphoblast, and effector cell 
differentiation states. Increased frequency of zinc containing vesicles has been reported 
to be polarized in T cells that have formed an immune synapse 7. Interestingly, punctate 
fluorescent patterns also seemed to be polarized with punctate CD4 fluorescence in the 
majority of cells observed in our system. Given that clustering of immune receptors 
(including CD4) occurs during synapse formation, our data would support the finding 
that labile zinc-containing vesicles may localize to the immune synapse, where 
intracellular labile zinc has been observed to play an important role in modulating TcR 
inducing signaling. 
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3.6 Activation of p38 MAPK 
 The influence of zinc and the regulation of its availability during cell signaling is of 
particular importance in T cell activation. Previous work has described the influence of 
increases in free zinc inhibiting intracellular T cell phosphatases including SHP-1 7, 
PTP1b 249, calcinuerin15, phosphatase and tensin homolog deleted on chromosome 10 
(PTEN)222 and the dual specificity phosphatase MAP Kinase Phosphatase 1 (MKP-1)13 
which dephosphorylates the ERK1/2 and p38. MAPK pathways are of particular 
importance in T cell differentiation fate decisions and inhibiting or activating different 
MAPKs can “push” cells towards different effector phenotypes250 including TH1251, 
TH2252, TH17253 depending on context. Activation of p38 is also important in IL-10 
expression 254and Treg effector function255,256. Of the MAPK family of proteins, p38 is 
the most sensitive to changes in intracellular zinc13 in human T cells.  
To verify that zinc mediated activation of p38 is conserved in mice, we 
investigated the activation of p38 in mouse CD4+ T cells from C57BL/6 (MT-WT) mice 
(Figure 3.12). p38 is activated by phosphorylation by MKK3/6 and inactivated by 
dephosphorylation by MKP-1. In resting naïve CD4+ splenocytes, a baseline activation 
of p38 (p-p38) can be detected. Chelation of intracellular zinc with TPEN decreases the 
activation of p38. Increasing intracellular labile [Zn2+] by increasing extracellular [Zn2+]  
and adding the ionophore pyrithione significantly increases p38 activation. This was 
confirmed by western blot (3.12A) and flow cytometry (3.12 B and C). In the context of T 
cell activation, the diacyl glycerol analog PMA has been shown to activate protein 
kinase C (PKC) and p38 MAPK independent of TcR mediated signaling through LcK or 
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LAT257. To confirm this activation in mice, naïve mouse splenocytes from MT-WT or MT-
KO mice were activated with PMA (100ng/mL) for 60 min. At determined time points, 
cells were fixed and stained for CD4+ before being permeabilized and stained for 
activated p38 (p-p38). As expected, p38 is activated in a time dependent manner by 
PMA, with a peak activation at 15 minutes. After 60 minutes of treatment, activated p38 
levels were significantly lower than starting levels. Interestingly, the activation of p38 in 
CD4+ splenocytes from MT-WT mice was higher than MT-KO mice. Because p38 
activation is sensitive to zinc concentration and intracellular Zn is increased in naïve 
CD4+ T cells following stimulation by PMA194, we hypothesize that the difference in p38 
activation may be dependent on differences in intracellular Zn mediated by MT. We will 
address this hypothesis more thoroughly in Chapter 5. 
 
3.7 Conclusions 
The measurement of intracellular labile [Zn2+] within physiologically relevant 
parameters in live cells is an important tool for understanding the role of zinc in the 
regulation of T cell signaling. The use of Fluozin-3 and the zinc specific chelator TPEN 
and ionophore pyrithione allows the extrapolation of the intracellular concentration and 
comparison of data between experiments and between investigators. To avoid the 
measurement of intracellular labile [Zn2+] affecting the concentration itself, it is important 
to optimize experimental parameters to minimize the effect of the sensor or the 
manipulation of cells during preparation and measurement. An experimental protocol 
that is optimized through careful titration and iteration is an important first step in the 
experimental measurement of intracellular labile [Zn2+] in mouse CD4+ lymphocytes. 
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The parameters described above allow for the detection of subtle changes in 
intracellular labile [Zn2+] while permitting the immunophenotyping of different cell 
populations.  
 Resting levels of intracellular labile [Zn2+] vary between CD8+, CD4+ and CD19+ 
lymphocyte populations. Interestingly these three populations also load and export the 
Fluzoin-3 sensor differently, as evidenced by Fmax signal differences between cell 
types. However, because the determination of intracellular labile [Zn2+] is relatively 
independent of sensor concentration, this differential loading does not interfere with the 
intracellular labile [Zn2+] measurement. The fact that no significant differences in 
intracellular labile [Zn2+] exist between lymphocyte subsets from MT-KO, MT-WT or MT-
TGN mice suggests that under normal, resting conditions zinc homeostasis in 
lymphocytes is primarily maintained by MT independent mechanisms. Furthermore, the 
low expression levels of MT in naïve lymphocytes are unlikely to have an effect on total 
intracellular labile [Zn2+]. Only under conditions of induction does MT in lymphocytes 
appear to play a significant role. This is in line with other studies of MT mediated 
immunomodulation where MT is considered to be a stress response protein and 
phenotypic differences between strains of mice with disparate MT gene doses is only 
revealed after stressful challenge.  
This observation was supported by confocal images that did not show differences 
in intracellular labile zinc distribution between strains. The presence of zinc containing 
vesicles in CD4+ T cells from both MT-KO and MT-WT mice, in all stages of cellular 
activation (naïve, lymphoblast, effector) indicate that cellular zinc is maintained in a non-
steady state with both zinc muffling and buffering contributing to the dynamic control of 
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zinc availability. The small differences in zinc availability afforded by MT may be enough 
to affect intracellular phosphatase activity and the regulation of p38 MAPK. Alternatively, 
the small pool of available MT in naïve lymphocytes may affect the kinetics of zinc 
regulation by facilitating the transfer of Zn to apoproteins more effectively than can be 
accomplished by the free ion alone. p38 MAPK is centrally involved in T cell activation 
and the control of T cell effector function and is very sensitive to intracellular labile [Zn2+], 
even in the absence of other cellular activators. The reduced activation of p38 MAPK in 
cells lacking functional MT1 and MT2 genes following stimulation of CD4+ T cells with 
PMA suggests that MT plays a role in modulating T cell signaling, potentially by 
regulating intracellular zinc. 
 Adding to the complexity of measuring intracellular Zn is the importance of 
controlling for oxidative stress and extracellular zinc concentration during all steps of 
cell isolation, culture, and measurement. The close relationship between intracellular 
redox status and Zn2+ concentration and the role of MT in modulating this intersection is 
the focus of the research described hereafter. It therefore follows that carefully 
controlling experimental conditions involving redox and Zn is fundamentally important 
for allowing MT mediated differences in T cell signaling to be measured.  
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Figure 3.1 Regulation of Protein Function by Intracellular Zn 
Fluctuations 
 
 
 
Different classes of enzymes and signaling proteins are differentially regulated by zinc 
based on affinity for the metal (Kd) and on/off rates (K on/off). The control of intracellular 
[Zn2+] by metallothionein includes potential regulation of important signaling enzymes 
including phosphatases. 
 
  
 
  
Figure 3.2 Structure and Emission Spectrum of Fluozin
 
 
The structure, relevant specifications, and emission spectrum of the zinc specific 
fluorescent chemosensor Fluozin
http://www.lifetechnologies.com/order/catalog/product/F24195
 
  
-3 
-3 AM. Figure adapted from website : 
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Figure 3.3 Measurement of Intracellular [Zn2+] in CD4+ T Cells with 
Fluozin-3 AM 
 
 
 
Peripheral blood mononuclear cells were freshly isolated from a C57BL/6 mouse. Cells 
were loaded with Fluozin-3 AM [0.5µM] and stained with anti-CD4alexafluor647 and 
propidium iodide. For the Fmin sample, cells were treated with TPEN [50µM] for 10 min 
on ice. For the Fmax sample, cells were treated with ZnSO4 [100µM] / Pyrithione [50µM] 
for 10 min on ice. The Fluozin-3 signal for lymphocyte FSC/SSC, propidium iodide 
negative, CD4+ cells are shown (Lines are representative and do not reflect the true 
geometric mean). 
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 Figure 3.4 Effect of Fluozin
Fluorescent Signal 
 
 
Freshly isolated PBMCs from a C57BL/6 mouse were incubated with different 
concentrations of Fluozin-3 AM in complete media for 30 min. Cells were then incubated 
without sensor for 30 min and stained with anti
Lymphocyte FSC/SSC, PI negative, 
incubation concentration on the fluorescent signal in these cells is shown.
 
  
-3 AM Incubation Concentration on 
-CD4 alexafluor647 and propidium iodide. 
CD4+ cells were gated and the effect of probe 
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 Figure 3.5 Relationship between Fluozin
Extracellular ZnSO4 with or without pyrithione
 
 
Mouse PBMCs were isolated by Histopaque1083 centrifugation and loaded with 0.5µM 
Fluozin-3AM. Cells were then treated with 50µM pyrithione (or control) and varying 
ZnSO4 concentrations (0-50µM) in PBS + 1% FBS at 37C for 30 min. Cells were stained 
with anti-CD4 alexafluor647 and propidium iodide. Lymphocyte FSC/SSC, PI negative, 
CD4+ cells were gated and the effect extracellular Zn or pyrithione on Fluozin
fluorescence was determined.
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Figure 3.6  Effect of MT Gene Dose on Intracellular [Zn2+] in Resting 
Lymphocyte Populations 
 
 
 
 
 
 
Freshly isolated PBMCs from C57BL/6 mice (MT-WT, n=4) or congenic strains that 
don’t express MT (MT-KO, n=4) or overexpress MT (MT-TGN, n=4) were incubated with 
Fluozin-3 AM in complete media for 30 min as described in materials and methods. 
Cells were stained with anti-CD8 PerCP, anti-CD4 alexafluor647 or anti-CD19PE and 
propidium iodide. Lymphocyte FSC/SSC, PI negative cells, lymphocyte marker+ cells 
were gated and the Fmin, Fmax and F cell populations for one representative mouse 
from each genotype/cell type are shown in A. Intracellular [Zn2+] was determined for 
each genotype / cell type. Bars indicate mean intracellular [Zn2+]. Error bars indicate 
standard deviation. 
CD8+  CD4+         CD19+ 
MT-KO 
MT-WT 
MT-TGN 
A. 
B. 
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Figure 3.7 Metallothionein Knockout Genotype is associated with 
decreased total serum zinc   
 
 
 
 
Serum was isolated by centrifugation from pre-clotted blood taken by sub-mandibular 
bleed from MT-WT or MT-KO mice (n=3). Total serum zinc was quantified using an Elan 
DRC (dynamic reaction cell) II quadrupole ICP-MS (inductively coupled plasma – mass 
spectrometer).  Statistical significance was determined using a student’s two-tailed T 
test. (*p<.05) 
  
* 
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Figure 3.8 MT Gene Dose Does Not Affect Intracellular Labile [Zn2+] in 
CD4+  Splenocytes 
 
 
 
 
Intracellular labile [Zn2+] was measured from freshly isolated CD4+  splenocytes from 
MT-WT (n=12) or MT-KO mice (n=12) on four different days. Cells were loaded with 
Fluozin-3 AM as previously described. CD4+ T  cells were labeled with an alexafluor647 
conjugated antibody to avoid the need for fluorescent compensation. Each point 
represents a different mouse.  
 
  
 97
Figure 3.9 Intracellular [Zn2+] and Homeostatic Mechanisms are 
Affected by Extracellular Zn and 2-Mercaptoethanol in CD4+ T  cells 
 
A. 
 
 
 
 
B. 
 
 
 
Splenocytes were isolated from C57BL/6 mice (n=3). (A) Cells were cultured in media 
containing 10% FBS (Control) or media with 125µM added ZnSO4 for 24 hours. Zinc 
treated cells were loaded with Fluozin-3 AM and incubated for 30 min in media with 
added Zn (+Zn/+Zn) or control media (+Zn/ Control) while Control cells were kept in 
control media for the duration of the experiment. (B) Cells were cultured in standard cell 
culture media (50µM 2-ME) or media with reduced antioxidant (25µM 2-ME) or no 
antioxidant (Control) for 24 hours before intracellular [Zn2+] was measured. Bars 
indicate mean of 3 separate experiments. Error bars indicate standard deviation. * 
(p<.05)  
* 
* 
*
*
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Figure 3.10 Extracellular Zn Induces Expression of Metallothionein in 
CD4+ T Cells 
 
A. 
 
 
 
 
B. 
 
 
 
Freshly isolated splenocytes from MT-KO mice (n=3), MT-TGN mice (n=3) or MT-
WT (n=3) wildtype congenic control mice were cultured in media with added ZnSO4 
(1-125µM) for 24 hours. Cells were fixed and permeabilized and stained for CD4+  
surface marker and intracellular MT using an alexafluor647 labeled anti-MT 
antibody (UC1MT) or isotype control (MOPC, red line. Expression of MT after 
125µM ZnSO4 is shown in Figure A for one representative mouse from each strain. 
Triangles represent mean MT MFI from 3 mice for each strain. Error bars indicate 
standard deviation. (*) indicates mean is significantly higher than baseline (1µM 
ZnSO4) (p<.05) 
 
  
* 
* 
Extracellular ZnSO4 [µM] 
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Figure 3.11 Imaging Sub-Cellular Localization of Zinc in CD4+ T 
cells from MT-KO and MT-WT Mice 
A. Day 0  
 
 
 
B. Day +6 (anti-CD3/anti-CD28 stimulation + IL-27) 
 
              MT-KO                 MT-WT 
 
  
 
C. Day +8 (+6 days Stimulation, +2 Days Rested/Restimulated) 
 
                  MT-KO        MT-WT 
 
Rested 
Restimulated 
CD4 Fluozin-3 Hoechst Merge CD4 Fluozin-3 Hoechst Merge 
DIC CD4 Fluozin-3 Hoechst Merge DIC CD4 Fluozin-3 Hoechst Merge 
DIC CD4 Fluozin-3 Hoechs
t 
Merge 
MT-KO 
MT-WT 
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Splenocytes were isolated from MT-WT (n=4) or MT-KO (n=4) mice and stimulated 
under Tr1 inducing conditions for 6 days. Cells were then removed and rested in media 
alone or restimulated with anti-CD3 for an additional 2 days. (A). Freshly isolated 
splenocytes were stained for with anti-CD4 (red), and loaded with Hoechst stain (blue) 
and Fluozin-3 AM (green). Cells were then imaged by confocal microscopy. One 
representative field of view is shown for one mouse from each strain. (B) After activation 
and proliferation, cells were removed and stained as described for Day 0. One 
representative cell from each mouse (n=4) from each strain is shown. (C) At day 6, cells 
were either rested for 2 additional days in media alone or restimulated with anti-CD3. 
On day 8, cells were stained and loaded as described above. One representative field 
from 2 mice are shown for each condition / genotype. 
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3.12 Activation of p38 MAPK by Zinc or PMA  
 
A.      B. 
 
C.      D. 
  
 
Naïve splenocytes were isolated from MT-WT (n=1) or MT-KO mice (n=1). Cells were 
exposed to 20µM TPEN or 100µM ZnSO4 / 50µM pyrithione for 20 minutes before being 
lysed in buffer containing phosphatase inhibitors. Cell lysates were separated by SDS-
PAGE and blotted for the presence of phospho-p38 (A). Alternatively, cells were fixed 
with paraformaldehyde after 20 min exposure and stained for CD4. Cells were then 
permeabilized and stained with anti-phospho-p38 or isotype control (B and C) and 
analyzed by flow cytometry. (D) To determine if PMA [100ng/mL] affects p38 activation, 
cells were stimulated before fixation and phospho-p38 was quantified in CD4+ T cells by 
flow cytometry.  
 
 
MT-WT 
MT-KO 
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Chapter 4 
 
Effect of MT Gene Dose on Primary CD4+ T Cell 
Activation in vitro 
 
4.1  Introduction 
An increase in intracellular [Zn2+] 235 and metallothionein (MT) expression35,36 are 
two measurable phenotypic changes that occur during the activation, proliferation and 
differentiation of naïve CD4+ T  cells. Manipulation of MT expression in CD4+ T cells 
using genetic knockout/overexpressing mutants, or siRNA knockdown or knock-in,5 
affects signaling pathways and downstream effector function but the observations from 
different studies are often contradictory and inconclusive. For example, Huh et al 
reported restimulation of CD4+ T cells from MT-WT mice (129S1/SvImJ) resulted in 
higher levels of secreted IL-10 than cells isolated from MT-KO congentic controls 
(129S7/SvEvBrd-Mt1tm1BriMt2tm1Bri) (following differentiation for 5-6 days under TH0 
promoting conditions (plate bound anti-CD3 [10µg/mL] / soluble anti-CD28 [2µg/mL] 2 ). 
Alternatively, Wu et al observed no IL-10 secretion from CD4+ T cells differentiated 
under similar TH0 inducing conditions (plate bound anti-CD3 [1µg/mL] / soluble anti-
CD28 [1µg/mL] from either MT-WT or MT-KO mice. However, addition of IL-27 
promoted a Tr1 phenotype in CD4+ T cells from both strains in their experiments, with 
MT-KO cells producing significantly more IL-105.  
The body of research on the influence of intracellular [Zn2+] on T cell 
differentiation is also inconclusive. As discussed previously, much of the early work 
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involving metal influences on immune functions employed models of complete zinc 
chelation or addition of a 50 fold excess in vitro or in vivo which makes interpretation of 
biologically relevant influences of zinc within the normal, healthy range of fluctuation 
difficult. Recently, with the use of more sensitive zinc probes including Fluozin-3 AM, 
the effect of smaller changes in intracellular labile [Zn2+] have been explored. In general, 
increased [Zn2+] is associated with increased proliferative capacity7 and increased 
signaling and expression of IL-28,222 and IFN-gamma15. However, these effects are still 
context specific and the role of zinc in T cell activation appears to be more nuanced 
than a simple positive correlation between [Zn2+] and proliferation and TH1 
differentiation.  
To date there is no published study that carefully and systematically 
characterizes the changes in intracellular labile [Zn2+] during naïve CD4+ T cell 
activation through proliferation and effector differentiation. Our first specific aim is to test 
the hypothesis that MT gene dose affects intracellular labile [Zn2+] during naïve CD4+ T 
cell activation. This will be addressed by stimulating naïve splenocytes from MT-WT or 
MT-KO mice for 6 days with plate bound anti-CD3 and soluble anti-CD28 antibodies in 
the presence or absence of IL-27. The intracellular labile [Zn2+], MT expression, and 
presence of the surface marker of activation (CD25a) will be assessed by flow 
cytometry every 24 hours to assess differences between strains and inducing conditions. 
After establishing the expression of MT, our second specific aim is to test the 
hypothesis that MT provides a redox sensitive mobilizable zinc pool in activated CD4+ T 
cells. This will be addressed by measuring the release of bound intracellular zinc upon 
exposure to hydrogen peroxide and comparing the rate and amount of zinc released in 
 104
CD4+ T cells from MT-WT and MT-KO mice. To determine if differences in release of 
intracellular zinc are due to total redox buffering capacity, intracellular thiols and the 
oxidation of an ROS sensor will be measured in CD4+ T cells from each strain. 
 
4.2  Effect of the Cytokine Environment on Intracellular 
[Zn2+] and MT Expression During CD4+ T Cell Primary 
Activation 
Primary activation of CD4+ T cells is believed to occur primarily in in the 
secondary lymphoid tissues following interaction with pathogen activated dendritic cells 
158
. Recognition of the unique peptide/MHC complex on the surface of the antigen 
presenting cell (APC) occurs by dual recognition and the strength of this interaction 
affects T cell signaling258. For T cell activation to proceed to proliferation rather than cell 
death, co-activation through expression of B7 on the APC signaling through CD28 on 
the T cell is a requirement259. To model these interactions in vitro, antibodies against 
molecular components associated with TcR (CD3) and CD28 are employed. Successful 
activation of T cells requires polarization of the TcRs and associated co-activating 
receptors to a single region of high density, often referred to as the immune synapse. 
This is replicated by the interface of the T cell and the plate bound anti-CD3 antibody. 
The bivalent nature of antibodies allows subsequent crosslinking of CD28 by anti-
CD28260.  
 The choice of concentrations of anti-CD3 and anti-CD28 are important when 
studying T cell signaling. Higher concentrations can overstimulate cells, leading to cell 
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death while lower concentrations can lead to insufficient levels of activation and 
proliferation. The choice of 1µg/mL anti-CD3 and anti-CD28 for activation of T cells in 
vitro in the following study was based on previous studies that revealed an effect of MT 
gene dose on T cell activation5 and titration in the lab to assess the relationship 
between antibody concentration and cell proliferation (data not shown). The reasoning 
behind this choice of conditions was based on the risk of higher concentrations of 
antibody potentially masking differences in MT mediated effects by overstimulating cells 
and lower concentrations resulting in sub-optimal activation. 
 In addition to stimulation through the TcR and CD28, CD4+ T cells receive 
signals about the status of their extracellular environment through cytokine receptors. 
As discussed in the introduction (1.2.2), integration of all three signals leads to a choice 
of T cell differentiation fate. Of particular interest is signaling through IL-27, which 
induces MT expression and results in a Type 1 regulatory T cell effector phenotype 
(Tr1).  
Induction of the Tr1 phenotype via anti-CD3/anti-CD28 activation and addition of 
exogenous IL-27 [50ng/mL] was compared with induction of the TH0 T cell phenotype 
via activation through anti-CD3/anti-CD28 stimulation alone. Under both conditions, 
expression of the activation marker CD25a (high affinity receptor for IL-2) was increased 
within 24 hours and >95% of CD4+ T cells were CD25+ after 5 days, indicating CD4+ T  
cell activation is not delayed under TH0 conditions. (Figure 4.1A, 4.1B)) The increase in 
intracellular [Zn2+], however, is delayed under TH0 inducing conditions and is not 
significantly increased above naïve baseline concentration until day 6 (Figure 4.1C). 
This is in contrast to Tr1 inducing conditions where intracellular labile [Zn2+] was 
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significantly higher after day 4 and remained significantly higher than THO conditions 
through day 6.  
Expression of MT following CD4+ T cell activation has been reported for different 
stimulation conditions including concanavalin A35, super antigen loaded APCs 36 and 
anti-CD3/ anti-CD28 5,36. To avoid confounding effects of post-transcriptional regulation 
of MT mRNA, we choose to verify the expression of MT by immunohistochemistry and 
flow cytometry. Similar to intracellular labile [Zn2+], MT expression was significantly 
higher by day 3 under Tr1 conditions (Figure 4.1E). Interestingly, the increase in 
intracellular MT preceded the increase in intracellular [Zn2+], indicating MT induction is 
not dependent on increased [Zn2+] . However, the largest increases in MT and [Zn2+] 
under both inducing conditions appeared on day 6, suggesting a potential induction of 
MT when [Zn2+] reaches a certain threshold, similar to what was seen by MT induction 
in naïve CD4+ T  cells following addition of extracellular ZnSO4 to the culture media 
(Figure 3.10). Interestingly, intracellular [Zn2+] was not higher in all Tr1 cells compared 
with TH0 cells, indicated by the considerable overlap of the distribution of Fluzoin-3 
fluorescence (Figure 4.1D). This wide distribution of intracellular [Zn2+] illustrates the 
heterogeneity of the CD4+ T  cell population, even when all cells are stimulated under 
the same conditions. 
 The effect of IL-27 on the intracellular [Zn2+] and MT expression in CD4+ T cells 
demonstrates that both of these parameters are potential points of regulation by 
cytokine signaling during activation. The expression of MT in the IL-27 treated cultures 
before a detectable increase in intracellular [Zn2+] suggests that MT may be induced by 
metal independent mechanisms. IL-27 is associated with pro-inflammatory effects261 in 
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inflammatory autoimmune arthritis and may induce MT via pathways that are similar to 
pro-inflammatory IL-6. MT induction was not completely independent of zinc, however, 
and maximal MT expression coincided with the highest observed concentration of 
intracellular [Zn] under both conditions, underscoring the strong and direct relationship 
between zinc, MTF-1, and MT expression. It is important to note that induction of MT by 
IL-27 and Zn was complimentary and produced a T cell phenotype with an increased 
pool of intracellular MT (Figure 4.1F). This difference has the potential to position Tr1 
cells to respond differently to oxidative signaling upon further reactivation. 
 
4.3  Effect of MT Gene Dose on Intracellular [Zn2+] and MT 
Expression During CD4+ T Cell Primary Activation 
Upon establishing the increase in intracellular [Zn2+] and intracellular MT 
expression following activation of CD4+ T cells, the effect of MT gene dose on 
intracellular [Zn2+] was determined.  Intracellular [Zn2+] in MT knockout mice (MT-KO) 
and MT-WT congenic controls were compared during naïve CD4+ T cell activation under 
Tr1 inducing conditions described above. Mice lacking functional MT1 and MT2 genes 
displayed the same pattern of activation as wildtype controls including increased 
FSC/SSC and CD25 expression (Figure 4.2A). Furthermore, there were no differences 
in the intracellular [Zn2+] between the strains at any of the timepoints tested (Figure 
4.2D), indicating MT did not significantly affect zinc homeostasis under these culture 
conditions. The expression of MT was verified by intracellular immunofluorescence  
(Figure 4.2C). In the MT-KO cells, the expression of non-functional truncated MT 
peptides is under the same transcriptional control as native MT1 and MT2 genes, and is 
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significantly increased by day 3. This supports the previous observation that MT is 
induced by IL-27 independently of zinc and this expression can be measured by day 3 
after activation. 
Ultimately, the intracellular labile [Zn2+] in CD4+ T cells associates very strongly 
with the developmental state (p<.001) (Figure 4.3) of the cells.  When cells are removed 
from activation conditions and rested for an additional 48 hours, both the intracellular 
[Zn2+] and MT expression decrease but remain significantly above levels seen in naïve 
cells. The observation that MT expression parallels intracellular Zn increases is 
expected given the established nature of Zn mediated regulation of MT. The 
observation that MT gene dose did not affect intracellular [Zn2+] during primary 
activation implies that regulation of intracellular [Zn2+]  is controlled primarily by 
mechanisms that are independent of MT. However, the mechanisms underlying primary 
and secondary activation of T cells are fundamentally different. During secondary 
activation, effector T cells respond much more quickly to stimulation than naïve cells. 
Effector cells also require a lower threshold for stimulation and respond with intracellular 
redox signaling cascades (through the generation of ROS and RNS) that are more 
robust than those seen during primary activation. Taken together, this data suggests 
that MT does not play a significant role in affecting the ability of naïve CD4+ T cells to 
become activated, develop into a lymphoblast phenotype, increase intracellular [Zn2+] , 
or proliferate. 
 
4.4 Effect of MT Gene Dose on Redox Mobilizable 
Intracellular Labile Zinc Pool 
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The increased intracellular pool of Zn-MT in the Tr1 phenotype provides a 
potential reservoir of redox mobilizable labile Zn. To assess whether this zinc pool could 
be released and affect intracellular labile [Zn2+] in response to ROS, extracellular H2O2, 
as prototype oxidant, was added to Tr1 induced CD4+ T cells loaded with Fluozin-3. 
Addition of H2O2 increased intracellular [Zn2+] in a dose dependent manner over a period 
of 8 minutes (Figure 4.4A). This increase was unaffected by increased extracellular Zn 
during the time tested (data not shown), indicating the increased intracellular [Zn2+] was 
not due to increased zinc influx. Additionally, H2O2 had no affect on the fluorescence of 
Fluozin-3 under the conditions tested based on Fmax measurements (data not shown.) 
The H2O2 induced release of Zn2+ was significantly greater in Tr1 cells from MT-WT 
mice compared with cells from MT-KO mice (Figure 4.4B). The effect of MT gene dose 
was significant for both the total increase in intracellular [Zn2+]  (Figure 4.4 C) and the 
fold increase when compared with baseline [Zn2+]  (Figure 4.4D) for the range of H2O2 
tested. In addition to the differences in the total amount of zinc released, the rate of 
release (V0) following initial exposure to H2O2 was greater in cells expressing MT 
(Figure 4.4E) for each of the concentrations tested. Taken together, this evidence 
supports previous observations that MT is preferentially oxidized in the presence of 
H2O2 compared with other Zn bound proteins21. It is important to note that cells were 
incubated in media containing 10% FBS (with no 2-ME) during oxidative release of Zn 
which acts as a buffer to reduce the concentration of H2O2 and subsequent oxidative 
stress experienced by the cells. This was necessary to avoid the confounding effects of 
decreasing intracellular [Zn2+] when cells are moved from a normal [Zn2+] (3µM) to a low 
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zinc environment (Figure 3.9A). This means that the intracellular release of zinc in 
response to extracellular oxidant is even more sensitive than the figures suggest.  
To determine if the source of the released zinc was primarily reduced thiols, Tr1 
cells from MT-WT and MT-KO mice were treated with the thiol specific oxidant DTDP 
[50µM] and the release of labile Zn2+ was monitored by measuring Fluozin-3 
fluorescence. After 3 min of DTDP exposure, the increase in intracellular [Zn2+] was 
significantly greater in cells that expressed MT (Figure 4.4F). The robust release of Zn 
upon oxidant exposure in cells that don’t express functional MT indicates that MT is not 
the only redox sensitive mobilizable pool of intracellular Zn. However, the presence of 
Zn-MT ensures a greater increase in intracellular Zn following oxidant exposure and a 
more efficient transformation of an oxidant signal into Zn signal. The MT specific 0.3nM 
intracellular [Zn2+] increase following exposure to 40µM H2O2 has the potential to 
significantly inhibit the intracellular phosphatase activity 8,12 that contributes to activation 
of MAPKs and affects downstream events including cytokine secretion. 
 
4.5 Effect of MT Gene Dose on Cellular Redox Buffering 
Capacity 
The influence of MT expression on oxidant induced zinc release could be 
explained by the preferential oxidation of zinc-thiolate bonds in MT, or by an increased 
redox buffering capacity in MT-KO cells. Either scenario would likely result in an 
increased release of Zn from MT-WT cells in response to oxidant. To examine the latter 
possibility, total free thiols in Tr1 cells from MT-KO and MT-WT controls were 
determined by CPM assay using reduced glutathione as a reference243. The 
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concentration of free thiols was within the range of previously reported for C57BL/6 
mice240 and was not significantly different between MT-WT and MT-KO mice (Figure 
4.5A). This suggests that the expression of MT did not significantly affect the total free 
thiol status of the cell. This is not unexpected, given that reduced glutathione (GSH) is 
considered the primary intracellular redox buffer and is found in 100,000 fold molar 
excess compared with MT in T cells.  
To determine if MT gene dose contributed to a difference in redox buffering 
capacity, MT-WT and MT-KO cells were loaded with CM-H2DCFDA and exposed to 
50µM H2O2 for 1 hour. This dye is sensitive to oxidation by different species of ROS 
including superoxide, hydrogen peroxide and peroxynitrite and is a good general 
indicator of oxidative stress262.  MT gene dose did not significantly contribute to a 
difference in the total redox buffering capacity, evidenced by a similar level of oxidation 
of the fluorescent probe upon exposure to extracellular H202 (Figure 4.5B). As indicated 
by the similar levels of total thiols, this observation supports the conclusion that CD4+ T 
cells maintain redox homeostasis primarily through non-MT based thiols, most notably 
GSH. However, the oxidation of GSH to GSSG controls the release of zinc from MT 263. 
For this reason, when MT is present in the free thiol pool, it significantly changes the 
zinc release potential in response to ROS, even in the presence of a significant molar 
excess of GSH. 
 
4.6  Conclusions 
In vitro stimulation of CD4+ T cells with anti-CD3 and anti-CD28 results in a 
predictable and reproducible activation and differentiation pattern that includes 
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development of a lymphoblast phenotype during proliferation. This metabolically active 
phenotype maintains a significantly higher intracellular labile [Zn2+] than naïve or 
effector cells and this increase is not affected by MT gene dose but is affected by the 
presence of IL-27. Zinc alone does not control T cell fate decisions, however, and the 
increased labile [Zn2+] is likely part of a larger pattern of activation including transcription 
factor expression and chromatin remodeling. The significant difference in intracellular 
[Zn2+] between Tr1 and TH0 inducing conditions implicates Zn as a potential regulatory 
mechanism for the differentiation of the Tr1 phenotype. This observation has not been 
reported previously. Furthermore, the intracellular signaling events that precede the Tr1 
phenotype occur in an environment of increased zinc beginning 2 days before 
significant proliferation occurs. This is in contrast to TH0 development where 
intracellular [Zn2+] is not significantly increased until proliferation begins. 
MT expression in the context of CD4+ T cell activation and proliferation appears 
to be controlled by zinc dependent and independent mechanisms. Increased MT is 
generally associated with cell proliferation, most likely through the increased cellular 
redox potential that accompanies increased cellular metabolism 123. In CD4+ T cell 
activation, an initial increase in MT expression precedes an increase in intracellular 
[Zn2+] and did not occur without the addition of IL-27. This indicates MT is regulated 
prior to cell proliferation and lymphoblast development, potentially influencing fate 
decisions of CD4+ T cells before they gain effector function. Indeed, MT is associated 
with increased Repressor of GATA (ROG) and decreased expression of Tbet2 during T 
cell activation, both of which would be regulated during the activation window that 
overlaps with MT expression.  
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Following the significant increase in intracellular [Zn2+] that occurs on day +6 post 
activation in Tr1 cells, MT expression is robust. The overlap of increased MT together 
with an increased [Zn2+] means the pool of readily oxidizable thiols (MT) is larger and is 
more significantly saturated with zinc. At this point, CD4+ T cells are poised to release 
zinc in response to an oxidant signal. Indeed, exposure of these cells to ROS resulted in 
significant release of thiol bound zinc and a consequent increase in the intracellular 
labile [Zn2+]. Although this effect is not specific for MT, and is observed in MT-KO cells, 
the expression of MT results in a significantly faster and larger zinc increase. 
Furthermore, the presence of MT during cellular redox signaling would facilitate the 
transfer of zinc to apo-enzymes more efficiently than in a system without MT 79,121. This 
would amplify the effect of MT on zinc mediated regulation of signaling pathways and 
suggests a mechanism where even low nanomolar concentrations of MT could have a 
significant impact on signaling through both kinetic and thermodynamic control of zinc 
availability.   
In terms of global redox regulation, the expression of MT does not appear to 
significantly contribute to the total free thiol concentration or the general redox buffering 
capacity of CD4+ T cells, even after its induction by IL-27 and increased intracellular 
[Zn2+]. This observation implies MT mediated effects on T cell signaling are not 
accomplished through the dampening of ROS or RNS signals through reaction with MT, 
but rather through the control of zinc in response to these signals.  
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Figure 4.1 IL-27 affects intracellular [Zn2+] and MT expression in CD4+ 
T cell during primary activation  
 
A.      B. 
 
C.      D. 
   
E.      F. 
  
 
Mononuclear cells were isolated from spleens of C57BL/6 mice (n=7) and stimulated for 
6 days in the presence of anti-CD3 and anti-CD28 with IL-27 (Tr1) or without cytokines 
(TH0). (A,B) Cell activation was monitored by measuring the frequency of CD25a 
expression within the CD4+  cell population for 6 days. (C,D) Intracellular [Zn2+] and 
(E,F) [MT] were measured from CD4+ PI- cells every 24 hours for 6 days. Histograms 
are representative of 1 Tr1 and TH0 sample from day 6. Groups were analyzed by two-
tailed T test followed by Bonferoni correction. *p<.05 
  
* 
* 
* 
* 
* 
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Figure 4.2 Effect of MT Gene Dose on the Activation and Intracellular 
[Zn2+] of CD4+ T cells 
 
A.           MT-WT            MT-KO 
 
 
 
B.           C. 
 
 
D.  
 
  
* 
Mononuclear cells were isolated from 
spleens of MT-WT (n=6) or MT-KO 
mice (n=6) and stimulated for 6 days in 
the presence of anti-CD3 and anti-
CD28 with IL-27 (A) Cell activation was 
monitored by measuring FSC/SSC, 
frequency of CD25a expression and 
MT expression within the CD4+ cell 
population (B). The mean % of CD25 
expressing cells, (C) MT expression 
and (D) intracellular labile [Zn2+] for 
each strain over 6 days of activation is 
shown. Error bars indicate standard 
deviation. Groups were analyzed by 
two-tailed T test followed by Bonferoni 
correction. *p<.05  
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Figure 4.3 Developmental State but not MT Gene Dose Affects 
Intracellular [Zn2+] in CD4+ T cells 
 
 
 
Mononuclear splenocytes from MT-KO mice (n=11) or MT-WT congenic wildtype 
control mice (n=11) were cultured under Tr1 inducing conditions for 6 days and then 
rested for an additional 2-3 days. Intracellular [Zn2+]  was measured at day 0, day 6, and 
day 8 corresponding to different stages of differentiation: naïve, lymphoblast and 
effector, respectively. Error bars indicated standard deviation. groups were analyzed by 
two way ANOVA followed by Tukey’s test. *p<.05 ***p<.001 
 
  
 
*** 
    *** 
 
* 
* 
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Figure 4.4 Metallothionein Gene dose Affects Thiol Oxidation 
Mediated Release of Zn in CD4+ T cells 
 
A.      B. 
 
 
C.      D. 
 
 
E.      F. 
 
 
Intracellular [Zn2+] was measured in Tr1 induced CD4+ T  cell lymphoblasts from 
metallothionein knockout mice (MT-/-) (n=3) or congenic wildtype controls (MT+/+) (n=3) exposed 
to different concentrations of H202 for 8 minutes to determine the amount and rate of intracellular 
Zn2+ release. (a) The change in Fluozin-3 fluorescence from wildtype CD4+ PI- cells before and 
after exposure to H202 [40-5µM] or (b) for metallothionein knockout (MT-/-) CD4+ T cells 
compared with wildtype controls exposed to [40µM] H202. (c) The average net increase or (d) 
fold increase in intracellular [Zn2+] after 8 minutes of H202exposure for each strain from 3 
independent experiments is compared with H202 exposure. (e) The slope of the increase in 
[Zn2+] for the initial 60 seconds of H202exposure is also compared. (f) The fold-increase in 
intracellular [Zn2+] after 140 seconds of DTDP exposure [50µM] for each strain from 3 
independent experiments is compared with H202 exposure. Arrows indicate addition of treatment. 
*p<.05 
H2O2 [µM] H2O2 [µM] 
H2O2 [µM] 
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Figure 4.5 Metallothionein Gene Dose Does Not Significantly Increase 
Total Redox Buffering Capacity of CD4+ T Cells 
 
A. 
 
 
B. 
 
 
Mononuclear cells were isolated from spleens of metallothionein knockout (MT-/-)(n=3) 
or wildtype controls (MT+/+)(n=3) and allowed to differentiate into lymphoblasts under 
Tr1 inducing conditions. CD4+ T cells were negatively selected by magnetic separation. 
(a) Tr1 CD4+ cell lysate was analyzed for the presence of free thiols by CPM assay and 
total protein by BCA. (b) Cells were exposed to 50µM H202 to determine the redox 
buffering capacity. Bars indicate standard deviation. 
  
Control 
H202 
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Chapter 5  
Effect of MT gene dose on reactivation of CD4+ 
effector T cells in vitro 
 
5.1  Introduction 
The generation of ROS following TcR engagement is a critical component of 
effective T cell signaling and a requirement for proliferation and development of 
function168. CD4+ T lymphoblasts produce superoxide and hydrogen peroxide through 
discrete enzymatic mechanisms following stimulation through the TcR. These ROS 
signals are separated temporally, as evidenced by differential oxidation of two different 
intracellular oxidation probes, DCFDA and DHF218. More recently, the source of these 
signals has been revealed to be a phagocyte-type p47 NADPH oxidase264  and 
mitochondrial complex III144. The NADPH oxidase can be activated by a PMA 
dependent pathway in CD4+ T cells 264,265 and is required for direct Treg mediated 
suppression of CD4+ T cells266, highlighting an important experimental model of ROS 
generation in CD4+ T cells.  
A hallmark of T cell activation is the increase in intracellular calcium following 
signaling through the TcR, first from intracellular stores and later through CRAC 
channels230,267. This calcium signal, in addition to activating calcinuerin, via calmodulin, 
is a requirement of inducible nitric oxide synthase (iNOS) activation in CD4+ T cells268,269. 
The resulting nitric oxide (NO) signal is implicated in cytokine production 270,271 and 
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turning off Th17 T cell responses while increasing development of Th1 effector 
cells272,273.  NO regulation in T cells occurs, in part, through the activation of soluble 
guanyl cyclase which up regulates cGMP274. NO can also affect cAMP and cGMP levels 
indirectly by releasing zinc signals which inhibit phosphodiesterases 6. 
 The ROS and RNS signaling pathways converge when they are converted or 
transduced into a zinc signal by interaction with MT, or alternatively through the 
interaction of superoxide O2- or hydrogen peroxide (H2O2) with NO 275 to form 
peroxynitrite which oxides MT even more readily. This mechanism of signal transduction 
is less studied than the direct interaction of ROS and NO with signaling proteins during 
T cell activation and differentiation. However, there is a large body of evidence that 
suggests NO and ROS induced changes in intracellular [Zn2+] are mediated through 
MT61,115,127,276-278. In this way, by expressing cytosolic MT, CD4+ T cells can poise 
themselves to effectively transduce ROS and RNS signals into Zn signals. The 
presence of MT also has a synergistic effect on this level of Zn regulation by lowering 
the kinetic barrier to Zn binding to apoenzymes279. This is supported by recent studies 
indicating that selenium promotes T cell responses following TcR stimulation280,281 
because selenium is an efficient catalyst for oxidant mediated Zn2+ release from MT and 
transfer to apoenzymes121,132. For redox signaling cascades to immediately follow TcR 
and co-stimulatory activation in T cells requires metabolic reprogramming and enzyme 
expression to already be in place at the time of activation. For this reason, naïve CD4+ T 
cells do not immediately generate ROS following activation. However, as part of 
adaptive immunity and secondary immune responses, effector T cells express these 
proteins and remain poised to generate ROS signals. 
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 The origins of redox signals in T cells are spatially and temporally separated, 
adding to the complexity of signal integration and suggesting a kinetic rather than a 
strictly thermodynamic component to oxidant reactivity. Enzymes associated with the 
plasma membrane generate three distinct types of ROS signals: 1. rapid hydrogen 
peroxide production independent of Fas or NADPH oxidase; 2. sustained hydrogen 
peroxide production dependent on both Fas and NADPH oxidase; 3. delayed 
superoxide production that is dependent on Fas ligand and Fas and independent of 
NADPH oxidase264. In addition to these ROS signals, mitochondrial signals originating 
from complex III144 or an ADP-dependent glucokinase GDP2k211 also produce 
superoxide required for efficient T cell activation. 
Both ROS and RNS can directly modify signal transduction pathways through 
reversible oxidation or nitrosation of cellular target proteins. This process is important in 
regulating MAPK signaling162,282, JAK/STAT signaling 283 and NF-κB signaling284. It is 
not clear, however, if MT affects ROS and RNS signaling directly by preventing 
oxidative modification of signal transduction pathways, or if MT acts indirectly by 
releasing intracellular Zn, which, in turn, modifies signal transduction pathways. 
In specific aim 3 in this chapter, we address the hypothesis that the MT bound 
redox sensitive zinc reservoir is mobilized during T cell activation. This will be 
investigated by stimulating CD4+ Tr1 cells from MT-WT and MT-KO mice and comparing 
the intracellular increases in ROS and [Zn2+] using appropriate intracellular sensors. In 
specific aim 4 we address the hypothesis that the consequence of an MT associated 
increased intracellular [Zn2+] during CD4+ Tr1 secondary activation is a subsequent 
increase in p38 activation. This will be investigated by fixing cells at defined time points 
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following stimulation and measuring intracellular phospho-p38 by flow cytometry. 
Alternatively, cells will be lysed and intracellular total p38 and phospho-p38 will be 
analyzed by western blotting. In specific aim 5, we will address the hypothesis that MT 
gene dose affects cytokine secretion patterns in CD4+ Tr1 cells and that these effects 
are mediated, in part, through zinc. 
 
5.2   Tr1 Cells Produce ROS in Response to TcR or PMA 
Stimulation  
 To determine whether ROS production following TcR stimulation of CD4+ Tr1 
cells is affected by MT, we loaded cells with the oxidative sensor CM-H2DCFDA and 
stimulated cells using anti-CD3 and anti-IgG as previously described 218. Oxidation of 
the CM-H2DCF probe was significantly higher after 30 minutes of stimulation and 
persisted for at least 2 hours, indicating cells produced a robust intracellular ROS 
signaling response following TcR stimulation (Figure 5.1A). Similar to the response to 
extrinsic oxidative stress, oxidation of the probe was not significantly higher in cells that 
did not express MT, supporting the previous observation that maintaining cellular redox 
buffering capacity does not require MT. Despite the similar strength of the ROS signal, 
the increase in intracellular zinc was higher in cells expressing MT by 1 hour of 
stimulation (Figure 5.1B). This increase was not affected by the addition of 20µM ZnS04 
to the media for this time period, indicating the difference in zinc signaling was not due 
to differential zinc influx from the extracellular environment (data not shown). Taken 
together, these experiments reinforce the hypothesis that the total redox potential of 
CD4+ T r1 cells is not significantly influenced by MT expression. This suggests that the 
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reversible oxidative modifications to signaling proteins including MAPK would not be 
directly affected by the presence of MT. The degree of oxidation under these conditions 
would be regulated thermodynamically by the redox state of the intracellular 
environment, which is influenced by intracellular antioxidants including GSH and 
thioredoxin (Trx). Furthermore, oxidation would be regulated kinetically by the presence 
of antioxidant enzymes including superoxide dismutase and catalase. The consequence 
of the oxidation of these intracellular thiols would eventually lead to oxidation of MT, 
given MT’s extremely low redox potential (-366mV) and interaction with GSSG to 
release bound zinc263. When MT expression is high, as in the case of Tr1 cells, the 
concentration of zinc released from MT is sufficient to significantly effect total 
intracellular labile [Zn2+]. During the initial reactivation of T cells, this process appears to 
dominate the control of intracellular [Zn2+] before other mechanisms of zinc homeostasis 
are upregulated.  
 
5.3 Effect of MT Gene Dose on p38 MAPK Activation 
The co-stimulatory effect of zinc on p38 MAPK signaling in CD4+ T cells has 
been observed following signaling through the T cell receptor13, IL-1beta receptor 195 
and IL-2 receptor 8,285. To determine if increased p38 MAPK activation is associated 
with MT mediated zinc release, we activated CD4+ Tr1 cells through the TcR and 
analyzed total p38 and activated p38 (phospho-p38) over a 2 hour time period by 
western blot (Figure 5.2A,B). The ratio of phospho-p38 / total p38 was slightly increased 
20 min after activation before dropping off precipitously by 30 min in both strains. This 
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proof of principle study supports previous observations of increased p38 activation in 
MT-WT compared with MT-KO CD4+ T cells (Figure 3.12D). 
As an alternative strategy to investigate the mechanisms of MT dependent zinc 
mediated p38 MAPK activation, we employed the diacyl glycerol analog PMA. PMA 
does not induce a Zn influx from the extracellular environment but does induce ROS 
production in CD4+ effector T cells168,264,265. Taken together, this model allows us to 
investigate the effect of ROS and zinc release from MT on p38 activation. 
To further investigate p38 activation, Tr1 cells from MT-WT (n=4) and MT-KO 
mice (n=4) were activated with PMA [100ng/mL] over a one hour period (Figure 5.3A). 
Cells were fixed at different time points following activation and permeabilized to stain 
for intracellular phospho-p38 before being analyzed by flow cytometry286. Observed 
differences in phospho-p38 were not due to differences in total p38 between the strains 
or at different time points (Figure 5.2C). Activation of Tr1 cells led to a similar pattern of 
p38 activation compared with naïve cells, except that the peak activation was higher (5 
fold increase in phospho-p38 compared with a < 2 fold increase) and took longer to 
occur (20 minutes compared with 10 min). Similarly, both MT-WT and MT-KO show 
equivalent levels of phospho-p38 before activation but Tr1 cells from MT-WT mice 
exhibit a significantly stronger activation of p38 by 20 minutes after treatment (p<.05) 
and maintain a higher level of activation at 60 minutes post stimulation.  
The MT associated increase in p38 activation was prevented after pre-treatment 
of cells with the antioxidant N-acetylcysteine (NAC) [20M] which reduced p38 activation 
significantly in both strains (Figure 5.3B). Addition of NAC is associated with preventing 
oxidative Zn release from MT287 and supports the hypothesis that the difference in p38 
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activation between MT expressing and MT-KO cells is due to increased zinc. The 
addition of 25mM NAC was chosen because it is a more than sufficient concentration to 
block ROS (and subsequent zinc release) signaling. The observation that p38 activation 
was still slightly increased in Tr1 cells in the presence of a large molar excess of 
antioxidant indicates ROS independent pathways, which have been reported 
previously257, play a role in p38 activation. 
To further investigate the mechanism responsible for the MT mediated increase 
in p38 activation, intracellular labile [Zn2+] was chelated or increased to determine if the 
increased p38 activation phenotype could be rescued from MT-KO Tr1 cells or visa 
versa. Addition of modest concentrations of extracellular Zn [20µM] did not affect PMA 
activation in either strain (Figure 5.3 C). Typically, changes in extracellular Zn (<25µM) 
do not significantly affect intracellular [Zn2+] within the one hour window of p38 
activation unless cells are pre-exposed to periods of Zn depletion (and upregulate Zn 
importers) or activation is achieved through an activated APC presenting a strong 
agonistic peptide for TcR binding7. To overcome this membrane transport limitation, 
pyrithione was added in addition to increased Zn, which significantly increased p38, 
MAPK activation in both strains and rescued MT-KO Tr1 cells to WT levels of activation. 
Chelation of intracellular Zn with TPEN [5µM] significantly reduced p38 activation and 
prevented differential activation in the two strains. Like NAC pretreatment, addition of 
TPEN during PMA stimulation did not completely prevent p38 activation, providing 
further evidence for Zn independent pathways of p38 activation. 
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5.4 Effect of MT Gene Dose or Added Zn on Cytokine 
Secretion  
  Expression of MT has been linked to both increased and decreased expression 
of the important immuno-regulatory cytokine IL-10 2,5. To determine if the influence of 
MT on IL-10 secretion is Zn dependent, we measured the intracellular [Zn2+] and 
cytokine secretion in Tr1 differentiated splenocyte cultures from MT-WT and MT-KO 
mice. Upon restimulation, in contrast to primary stimulation, the increase in intracellular 
[Zn2+] in CD4+ Tr1 cells was immediate (Figure 4b) and was significantly increased in 
the MT-WT cells from 0-6 hours post restimulation (Figure 5.1B, 5.4A). The metabolic 
reprogramming during primary activation and effector T cell development accounts for 
the faster response to secondary activation. This reactivation includes ROS generation 
and subsequent zinc release, which accounts for at least part of the initial increase in 
zinc. Tr1 cells display higher FSC/SSC and CD25+ expression than naïve T cells as 
well, indicating a change in phenotype that accompanies effector cell development. At 
later timepoints (12-48 hours), there were no significant differences in intracellular [Zn2+] 
between the two strains. Redox control of zinc bound to protein-thiols becomes less 
important in determining intracellular labile [Zn2+] as Zn influx through expression of Zip 
proteins becomes the driving factor in intracellular Zn homeostasis 15,36, which was seen 
during blast development in naïve T lymphocytes earlier.  
Secretion of IL-10 was detected by 6 hours post stimulation and was greater in 
Tr1 induced MT-/- splenocyte cultures compared with wildtype controls (Figure 5.4B). 
This difference was significant after 6 hours, and again at 24 and 48 hours and 
represents a general pattern of increased IL-10 secretion in MT-KO cells5. Secretion of 
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IFN-gamma during the same time frame was not significantly affected by MT gene dose 
(Figure 5.5C).  
To determine if differences in cytokine secretion between the two strains could 
be prevented by treatment with zinc, Tr1 CD4+ T cell cultures were incubated in 
increased extracellular Zn for 48 hours during restimulation. 20µM ZnSO4 represents the 
maximum [Zn] that does not affect Tr1 viability within a 48 hour period of cell culture 
(data not shown). Exposure to [20µM] ZnSO4 during activation significantly increased 
the intracellular [Zn2+] by 48 hours in the MT-KO CD4+ Tr1 cells compared control [Zn2+]. 
(Figure 5.5A). Interestingly, MT-WT cells maintained Zn homeostasis in the presence of 
increased extracellular Zn. The MT-KO Tr1 cell culture produced more IL-10 compared 
with MT-WT cells under conditions of normal zinc during restimulation, similar 
observations from splenocyte cultures, albeit with a higher final concentration of IL-10. 
The addition of 20µM ZnSO4 and the resulting increase in intracellular labile [Zn2+] in 
MT-KO Tr1 cells correlated with a significant decrease in IL-10 secretion (Figure 5.5B). 
This observation supports the hypothesis that an increased concentration of zinc can 
impair IL-10 secretion from Tr1 cells. In contrast to IL-10, IFN secretion was not 
significantly different between the strains under either of the conditions tested.  
  
5.5 Effect of MT Gene Dose on Adaptive Immune Responses 
Interpretation of the effects of MT gene dose on the development of CD4+ T cell 
subsets in vivo during adaptive immune responses is difficult because of the complex 
nature of immune responses. The potential effects of intracellular versus extracellular 
pools of MT, which act to modulate intracellular zinc and influence chemotaxis, 
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respectively, compound this complexity. In this way, it is difficult to know whether the 
effect of MT gene dose on the development of CD4+ T regulatory cells in vivo is 
mediated through the intracellular signaling within the cells, altered APC activity that 
differentially activates CD4+ T  cells, or even a modified extracellular chemokine 
environment that influences lymphocyte trafficking patterns. Furthermore, these 
mechanisms of action are not mutually exclusive and may all play a role in shaping the 
development of CD4+ T cells during an adaptive immune response.  
 One of the paradigms that emerges from studies involving MT mediated 
immunomodulation is the association of MT with the control of inflammation and the 
reducing the pathophysiology of inflammatory autoimmune diseases150,152,288. Genome 
wide association studies (GWAS) have even revealed an association between 2 
polymorphisms in the MT1a gene in an Italian Central female population that is 
associated with reduced induction of MT. The consequence of this reduced MT pool is 
lower inflammatory status in the population and increased longevity 197. This 
observation supports the in vitro observations discussed above where decreased 
release of zinc from MT in MT-KO cells was associated with greater expression of the 
potent anti-inflammatory cytokine IL-10.   
 As discussed previously, one of the major sources of IL-10 in vivo is CD4+ 
CD25+FoxP3+ T regulatory cells 289. To determine if MT gene dose affects the 
circulating frequency of Treg cells in vivo, PBMCs were isolated from MT-KO (n=3), MT-
WT (n=3) and MT-TGN mice (n=3) and the percentage of CD25+FoxP3+ cells within 
the total CD4+ T cell population was determined (Figure 5.6) Even with a small sample 
size, a significant difference in circulating frequency of Tregs was observed between 
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MT-KO and MT-WT mice (p<.05). In line with in vitro observations, MT-KO mice had a 
significantly higher frequency of Tregs (1.7%) compared with MT-WT mice (0.9%). The 
frequency of MT-TGN Treg cells was closer to MT-WT levels, but the small sample size 
and large variation in the MT-TGN population limits the interpretation of this study.  
 An alternative, less direct way to study the effect of MT gene dose on CD4+ T cell 
adaptive immune responses is to measure the humoral response to immunization with a 
T dependent antigen290. Immunization with type II chicken collagen is an established 
method for inducing an autoimmune arthritis phenotype in mice220 and represents a T 
cell dependent antigen291. Age-matched male mice were grouped by MT gene dose. 
MT-KO (n=7), MT-WT (n=8), and MT-TGN (n=8) mice were immunized with type II 
sternal chicken collagen in complete Freund’s adjuvant (CFA) (Day 0) and immunized 
with booster injections of collagen in incomplete Freund’s adjuvant (IFA) on day +14 
and day +55. Serum was collected by sub mandibular bleed on day 22, day 43, and day 
77. Total IgG in the serum was not different between the strains at any of the time 
points tested (data not shown). On day 22, the anti-collagen specific IgG response was 
greater in MT-TGN compared with MT-WT (Figure 5.7A). Interestingly, this supports 
observations from a previous study where both MT-KO and MT-TGN mice develop 
more robust immune responses to challenge with Listeria monocytogenes 292. 
 Cytokines secreted by CD4+ T cells affect the sub type of IgG expressed in 
response to antigenic challenge293. On day 43, serum was collected and the anti-
collagen IgG sub type response was measured. The concentration of IgG1 and IgG2b 
sub types of anti-collagen IgG were significantly higher (p<.05) in MT-TGN mice than 
MT-WT while the IgG2a response was roughly equivalent for all three strains. Increased 
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IgG1 is associated with TH2 responses and is induced by IL-4 and inhibited by IFN-
gamma294. Alternatively, increased IgG2a is induced by IFN-gamma and inhibited by IL-
4 and is associated with TH1 responses.215. IgG2b is induced by TGF-beta and is 
selectively increased in the serum of individuals suffering from rheumatoid arthritis216. 
For MT-WT and MT-KO mice, the concentration of the 3 anti-collagen IgG sub-types 
present was not significantly different (.05µg/mL and .08µg/mL, respectively). The 
concentration of anti-collagen IgG2b in the serum of MT-TGN was the highest of any 
response tested. 
 The similar level of IgG2a response to collagen between the strains supports the 
in vivo CD4+ cytokine secretion studies that indicate IFN-gamma secretion is not 
significantly influenced by MT. The observation that IgG1 and IgG2b responses were 
significantly greater in MT-TGN compared with MT-WT, but are not significantly greater 
than MT-KO responses, is difficult to interpret. The important mechanisms underlying 
MT mediated immunomodulation may be different for the different genotypes. For 
example, the important mechanism responsible for the influence of MT mediated 
differences in MT-KO CD4+ T cells may be the lack of a redox mobilizable pool of 
intracellular Zn while in MT-TGN mice, it may be a sufficient concentration of 
extracellular MT to interfere with lymphocyte trafficking patterns. The results from the 
humoral response to collagen emphasize the point that there is no linear relationship 
between MT gene dose and T helper or humoral response patterns.  
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5.6  Conclusions 
 Recent studies investigating the role of ROS produced in response to TcR 
stimulation in CD4+ T cells support the role of MT as an important redox mobilizable 
zinc pool with the potential to modify T cell signal transduction. Furthermore, oxidative 
signaling helps define the context in which MTs divergent roles in Zn buffering (zinc 
binding or zinc release) influence T cell function. In the absence of oxidative signaling, 
MT acts to bind and sequester Zn ions. The effect of increased MT expression in the 
absence of an oxidative signal is a decrease in intracellular labile [Zn2+] via binding of 
free Zn ions to unsaturated MT. The effect of MT expression during T cell signaling, 
however, appears to have the opposite effect, where MT expression increases 
intracellular labile [Zn2+]. Additionally, the role of MT in modifying zinc dependent signal 
transduction pathways is not limited to release of Zn ions. MT facilitates the transfer of 
Zn to apo-proteins, even those with a lower binding affinity for zinc through a network of 
cooperative binding reactions involving selenium. Even when intracellular oxidants react 
with species other than MT, including glutathione or other protein thiols, the resulting 
disulfides are molecular targets for reduced or zinc bound MT. The complexity and 
unique biochemistry of MT’s 20 vicinal cysteine residues impart this unique redox 
property that centrally places MT at the intersection of redox state and labile intracellular 
[Zn2+]. 
 The consequence of increased intracellular labile [Zn2+] on the modification of T 
cell signaling pathways is only beginning to be understood. The role of zinc as a 
cofactor and allosteric regulator of enzyme activity is well established. It has been 
discovered only recently, however, that the inhibition (IC50) values of relevant signaling 
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phosphatases are within the range of intracellular zinc fluctuations. This suggests that 
these signaling phosphatases are points of zinc-controlled regulation. In T cells, protein 
tyrosine phosphatases including MKP-1 are exceptionally sensitive to reversible 
inhibition by zinc. The effect of this inhibition is increased activation of phosphorylated 
MKP-1 substrates, including p38 MAPK. The regulation of p38 MAPK in the context of 
different MT gene backgrounds supports the role of zinc as an activator of p38 via 
inhibition of MKP-1. Furthermore, the MT associated increase in p38 activation can be 
inhibited by chelating zinc, or by loading the intracellular environment with a molar 
excess of the anti-oxidant NAC.  
 Studies investigating the role of MT in CD4+ T cell mediated inflammatory 
autoimmune diseases have revealed a strong relationship between MT and the control 
of inflammation. There exists substantial contradiction in the literature regarding the 
effect of MT on the IL-10 expression and secretion from regulatory T cells, specifically 
Tr1 cells. Our findings suggest MT expression, in the context of Tr1 stimulation, is 
associated with an increase in intracellular labile [Zn2+] and a decrease in IL-10 but no 
significant effect on IFN-gamma.  
Previous studies have established the requirement of p38 activation for IL-10 
expression, which suggests that MT-WT Tr1 cells should secrete more IL-10 than MT-
KO based on p38 activation measurements. However, p38 is significantly activated 
following TcR or PMA stimulation of Tr1 cells from both MT-WT and MT-KO mice and 
cells from both strains secrete IL-10. The decrease in IL-10 secretion from MT-KO Tr1 
cells following addition of Zn implies the regulation of IL-10 secretion, apart from 
sufficient activation of p38, is mediated by a zinc sensitive mechanism. This mechanism 
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may be inhibition of STAT3 activation, which has been observed in MT-WT Tr1 cells 
and is a known effect of zinc during TH17 development (Figure 5.7). 
The association of the MT-KO genotype with increased IL-10 extends to the 
frequency of IL-10 producing Treg cells in vivo. Furthermore, the function of MT in 
modulating bioavailable zinc release and the association of this function with 
inflammation was discovered independently of a Zn-MT-inflammation hypothesis, based 
on the results of a GWAS study looking at IL-6 and control of inflammation. Taken 
together, these results suggest that MT’s role in influencing the intracellular labile [Zn2+] 
contributes to its effect on CD4+ T cell function. 
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Figure 5.1 Metallothionein Gene Dose Affects Intracellular [Zn2+] in Tr1 
Cells Following TcR Stimulation  
 
A. 
 
B. 
 
 
 
Tr1 induced splenocytes from metallothionein knockout (MT-/-)(n=4) or wildtype controls 
(MT+/+)(n=4) were stimulated with hamster anti-CD3 and anti-hamster IgG for 0-120 
minutes. Cells were loaded with CMH2DCFDA and labeled with anti-CD4 and propidium 
iodide. (A) The average fold change in  CMH2DCFDA fluorescence or (B) intracellular 
[Zn2+]  in treated CD4+ PI- T cells compared with untreated control cells each strain at 
30, 60 and 120 minutes is shown. Error bars indicate standard deviation. *p<.05 **p<.01 
* 
** 
* 
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Figure 5.2 Activation of p38 MAPK in Tr1 Cells Following TcR 
Stimulation 
 
A. 
 
B. 
 
C. 
 
CD4+ Tr1 cells from MT-WT (n=3) or MT-KO mice (n=3) were stimulated with hamster 
anti-CD3 and anti-hamster IgG for 0-120 minutes. Cell lysates from 3 samples per time 
point were pooled and protein concentration was measured by Bradford assay. (A) 24µg 
of cell lysate from each time point for each strain were then separated by SDS-PAGE 
and probed for phospho-p38 or total p38. Primary antibody binding was detected by 
chemiluminescence (B) The ratio of band intensity for phospho-p38 / total p38 over time 
is shown. (C) Total p38 was measured in MT-WT (n=3) and MT-KO (n=3) separately for 
each time point by western blot. Bars indicate mean band intensity. Error bars indicate 
standard deviation.
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Figure 5.3 p38 MAPK Activity is Affected by MT Gene Dose or Zn in 
PMA Stimulated Tr1 Cells 
 
A.      B. 
 
 
C. 
 
 
Tr1 induced splenocytes from metallothionein knockout (MT-/-)(n=4) or wildtype controls 
(MT+/+)(n=4) were stimulated with 100ng/mL PMA for 0-60 minutes. (A.) Cells were fixed 
and permeabilized and stained for CD4 and phospho-p38. (B.) Before PMA induced 
activation, cells were pretreated with N-acetyl cysteine [25mM] for 1 hour and then 
exposed to PMA [100ng/mL] (NAC) or PMA without pretreatment (Stim) or PBS alone 
(Control). (C) During PMA induced activation, cells were treated with a Zn chelator 
(TPEN, [5µM]) or Zn + ionophore (Zn-pyrithione [20µM]) or extracellular Zn alone (Zn-
SO4  [20µM]) or without PMA (control). The difference in phospho-p38 at 20 min post 
activation is shown. Error bars indicate standard deviation. *p<.05 **p<.01 ***p<.001 
* 
* 
 
*** 
* 
* 
*** 
* 
* 
* 
** 
** 
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Figure 5.4 MT Gene Dose Affects Intracellular Labile [Zn2+] and IL-10 
Secretion from Tr1 Cells after TcR Restimulation 
 
A. 
 
B. 
 
C.  
 
 
Tr1 induced splenocytes from metallothionein knockout (MT-/-)(n=4) or wildtype controls 
(MT+/+)(n=4) were restimulated with anti-CD3 for 48 hours. Cells were spun down at 
different time intervals and cells were loaded with Fluozin-3 and stained for CD4 and 
propidium iodide and (a) intracellular [Zn2+] was measured in CD4+ PI- cells. 
Supernatants from different timepoints were analyzed for the presence of (b) IL-10 and 
(c) IFN-gamma by ELISA. Error bars indicate standard deviation. Groups were analyzed 
by two-tailed T-test with Bonferoni correction for multiple comparisons *p<.05 
* * 
* 
* 
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Figure 5.5 Increasing [Zn2+] Reduces IL-10 Secretion in Tr1 Cells from 
MT-KO mice 
 
A.       B. 
 
 
C.  
 
 
To determine if the effects of MT gene dose on Tr1 cytokine secretion are affected by 
[Zn2+], 20µM ZnSO4 was added to the media. Tr1 cells from metallothionein knockout 
(MT-/-)(n=3) or wildtype mice (MT+/+)(n=3) were restimulated with anti-CD3 [5µg/mL] for 
48 hour with or without added ZnSO4. Intracellular [Zn2+]  in CD4+ PI- Tr1 cells after 48 
hour restimulation was measured by flow cytometry. The concentration of secreted (B) 
IL-10 or (C) IFN-gamma in the culture media after 48 hours of restimulation was 
determined by ELISA. Bars indicate mean of 3 separate experiments. Error bars 
indicate standard deviation. *p<.05  
  
* * 
* 
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Figure 5.6 MT Gene Dose Affects Circulating Treg Frequency 
 
A.     B. 
  
 
Peripheral Blood Mononuclear Cells were isolated from heparinized blood collected 
from MT-KO (n=3), MT-WT (n=3), and MT-TGN (n=3) mice. Cells were fixed and 
stained for the surface markers CD4 and CD25a. Cells were permeabilized and stained 
for the intracellular transcription factor FoxP3. Cells were gated on a lymphocyte scatter 
gate and CD4+ marker. Tregs were identified as CD4+ CD25hiFoxP3+ cells. (A) One 
representative mouse from each genotype is shown. (B) The frequency of Tregs / total 
CD4+ T  cells was plotted for each genotype. Points indicate frequencies in individual 
mice. Error bars indicate standard deviation. Groups were analyzed by one way ANOVA 
followed by Tukey’s post test. *p<.05   
MT-KO 
MT-WT 
MT-TGN 
* 
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Figure 5.7 MT Gene Dose Affects the Humoral Response to Type II 
Collagen 
 
A.      B. 
 
C.      D. 
 
 
 
The humoral response to type II chicken collagen was assessed in MT-WT (n=7) MT-
TGN (n=8) or MT-KO (n=8) mice. Mice were immunized with Type II collagen in CFA at 
Day 0 and given a booster immunization in IFA on day +14 and day +55. Serum was 
collected 22 days, 43 or 77 days after primary immunization and measured by ELISA. 
(A) Total anti-collagen IgG response on Day 22 and Day 77 are shown. (B-D) IgG 
subtype anti-collagen specific responses on day 43 are shown. Error bars indicate 
standard deviation. *p<.05, 1 way ANOVA followed by Tukey’s Test. 
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Figure 5.8 Model: MT Transduces ROS Signals into Zn Signals and 
Affects CD4+ T  Cell Signaling 
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Chapter 6  
6.1 Conclusions 
 The unique biochemistry of MT has always posed a challenge to studies 
designed to decipher its biological functions. Recently, with improved intracellular zinc 
sensors and techniques for investigating the redox state of MT in biological tissues, a 
role for MT at the intersection of redox and zinc biology has emerged. Specifically, the 
ultra low redox potential and unique zinc binding characteristics of MT suggest that it is 
capable of transducing intracellular oxidant signals into zinc signals by releasing bound 
zinc and increasing intracellular [Zn2+]. Concurrently, a role for zinc in the modulation of 
T cell receptor signaling has been observed. In light of the recent observation that 
robust ROS production occurs following activation of CD4+ T cells, the aims of this 
thesis were to address the following general questions:  
1. When is MT expressed in CD4+ T cells and is its expression affected by cytokine 
inducing conditions?  
2. Does MT expression position CD4+ T cells to respond differently to ROS in terms 
of intracellular zinc release? 
3. Is activation of the zinc sensitive MAPK p38 affected by MT gene dose? 
4. Does MT affect cytokine secretion patterns and are those effects zinc 
dependent? 
 To better understand the timing of MT expression and changes in intracellular 
[Zn2+] during T cell activation, both parameters were measured over the course of 
primary T cell activation for 6 days. Prior to activation, resting naïve lymphocytes from 
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both MT-WT and MT-KO mice maintain a similar intracellular [Zn2+], despite the fact that 
serum [Zn2+] is higher in MT-WT mice. This coincides with very low levels of MT 
expression and suggests that under normal resting conditions MT does not play a 
significant role in zinc homeostasis in lymphocytes. Upon activation however, MT 
expression can be seen by day 3 and peaks on day 6, which coincides with the highest 
observed concentration of intracellular [Zn2+]. Interestingly, MT expression did not affect 
the intracellular [Zn2+] during this window of primary activation, suggesting other 
homeostatic zinc mechanisms dominate the control of intracellular [Zn2+] during this time. 
Both MT expression and intracellular [Zn2+] are affected by the presence of IL-27 during 
this activation, however, indicating zinc is a potential point of regulatory control in 
determining CD4+ T cell fate during primary activation and differentiation. Specifically, 
the Tr1 effector phenotype inducing cytokine IL-27 promoted an increase in MT 
compared to TcR and CD28 co-stimulation without IL-27. These observations revealed 
definitively that MT is expressed following CD4+ T cell activation and its expression is 
increased when activation occurs in the presence of IL-27. 
 When the release of zinc following exposure to different concentration of H2O2 
was compared between Tr1 cells expressing MT (MT-WT) and congenic MT knockout 
cells, a significant association between MT expression and increased release of zinc 
was observed. This difference was not due to total intracellular redox buffering capacity 
between the two genotypes, but rather was a consequence of the intracellular reduced 
thiol pool in MT-WT cells being comprised, in part, of MT. These results indicate that the 
expression of MT in Tr1 cells positions these cells to respond to ROS by efficiently 
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releasing zinc and increasing their intracellular labile [Zn2+]. This result suggests a 
mechanism for MT mediated immunomodulation through the control and release of zinc. 
 The consequences of increased intracellular [Zn2+] during T cell activation are 
complex, given the greater than 3000 known proteins that have at least one zinc binding 
domain. However, one general paradigm that has emerged recently is the inhibition of 
intracellular phosphatases by labile zinc, even at very low concentrations. One example 
of a zinc-sensitive phosphatase that is expressed in CD4+ T cells and is important in T 
cell signaling following activation is MKP-1. One of the substrates of this enzyme is the 
p38 family of MAP kinases. Reactivation of Tr1 cells produces a robust ROS signal that 
is associated with an increase in intracellular [Zn2+]. Similar to exposure to H2O2, cells 
that express MT release significantly more labile zinc following stimulation through the 
TcR and this is associated with an increased activation of p38. MT gene dose does not 
affect p38 activation when zinc is removed through chelation or added through the 
presence of an ionophore, however, suggesting the mechanism of MT mediated p38 
regulation is zinc dependent.  
 The regulation of intracellular phosphatases and T cell signaling pathways by 
zinc released from MT has the potential to affect CD4+ T cell effector function. To 
determine if there are differences in Tr1 cytokine secretion patterns between MT-WT 
and MT-KO CD4+ T cells, IL-10 and IFN-γ were measured following restimulation of Tr1 
cells. While IFN-γ secretion was similar between the two strains, IL-10 secretion was 
significantly increased in MT-KO cells compared with wildtype controls. Interestingly, 
wildtype levels of IL-10 secretion could be rescued by increasing the extracellular zinc 
concentration, once again suggesting that MT mediated affects on CD4+ effector 
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function are, in part, zinc dependent.  Taken together, these observations demonstrate 
a novel mechanism of MT mediated immunomodulation. By facilitating the release of 
zinc following TcR activation and the production of ROS, the potential of MT to affect 
intracellular phosphatase activity and associated CD4+ T cell signaling pathways has 
been established. Furthermore, this mechanism has implications for MT mediated 
immunomodulation during inflammatory immune responses where oxidative stress is 
increased in the local environment. This type of pre-exposure to ROS prior to secondary 
activation would allow MT to prime CD4+ T cells by increasing their intracellular [Zn2+] 
before signaling through the TcR. This has potential to alter the kinetics of signaling and 
potentially exacerbate inflammatory conditions by inhibiting intracellular phosphatases 
responsible for regulating TcR signaling. Additionally, this higher intracellular [Zn2+] 
would impart a cytoprotective effect on intracellular thiols, preventing further oxidation 
and preserving the proliferative capacity. 
 
6.2 Future Directions 
 The experimental observations presented in this thesis open the door to further 
investigation into the role of MT in modifying intracellular signaling pathways in CD4+ T 
cells. As a first step, the degree of MT oxidation by intracellular ROS can be 
investigated. Expression of the CFP-MT-YFP FRET sensor in CD4+ T cells would allow 
the direct visualization of zinc release from MT by taking advantage of the structural 
changes in MT following zinc release and the resulting decreased FRET ratio. This 
would further confirm MT as the source of increased intracellular [Zn2+] following CD4+ T 
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cell activation and control for the possibility that MT facilitates the release of zinc from 
another intracellular source. 
 The observation of increased p38 activation as a consequence of an MT 
mediated increase in intracellular [Zn2+] and inhibition of the MKP-1 phosphatase 
warrants further investigation. As a proposed next step, the relationship between zinc 
concentration and global T cell phosphatase activity, measured by conversion of PNPP 
or other suitable substrate, should be assessed in the presence and absence of MT in a 
cell free system. Equivalent phosphatase activity in experiments with equivalent zinc 
concentrations, irrespective of the presence of MT, would demonstrate that the effect of 
MT on phosphatase activity is mediated through labile zinc and not through an 
interaction with MT directly.  
 Another important future direction of this research involves the contribution of 
CD4+ T cells to MT mediated immunomodulation in vivo. While CD4+ T cells are a 
requirement for the pathogenesis of several pro-inflammatory autoimmune diseases, it 
is not clear if MT mediated differences in disease pathology occur through an effect of 
CD4+ T cell effector function. Employing a conditional knockout or knockdown model 
that takes advantage of the Cre-lox system to specifically prevent expression of MT in 
CD4+ T cells would address this question.  
 A more complete understanding of the role of MT and its influence on the 
regulation of labile zinc during T cell activation is an important step in determining how 
CD4+ T cell responses are shaped during adaptive immune responses. This is 
especially true in for the development and function of protective type 1 regulatory T cells, 
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which could lead to therapeutic opportunities to more effectively control inflammatory 
autoimmune diseases. 
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Chapter 7 
Appendix 
7.1 Functional Phenotyping of T Cell Populations using SPR 
Based Immuno Microarrays 
 
7.1.1 Introduction 
The circulating population of peripheral T lymphocytes rapidly and frequently 
traffics throughout the body and is exposed to many different tissue microenvironments. 
Functional and phenotypic characterization of these T cells can indicate prior exposure 
to vaccines 295 infectious agents 296, and toxicants297.  Furthermore, detection of certain 
self-antigen-specific T cells can help to confirm the presence of autoimmune disease 298 
and may also reflect the propensity to develop autoimmune disease before the onset of 
symptoms. Detecting and characterizing antigen-specific T cells in peripheral blood, 
however, is a laborious, time-consuming, and costly activity. As a consequence, these 
types of analyses are usually done only after the appearance of clinically observable 
disease symptoms. At that point, damage to tissues may have progressed far enough to 
make treatment less effective than it might have been if started earlier.  
The detection of antigen-specific T cells has previously been accomplished by 
specific labeling with fluorescently tagged oligimerized major histocompatibility complex 
(MHC) proteins that have been loaded with antigen-derived peptides (p/MHC). Cells 
that bind these complexes are subsequently identified by flow cytometry 299. The allelic 
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form of the p/MHC complex must, in most cases, match the patient’s MHC to promote a 
constructive interaction between the T cell receptor (TCR) and the fluorescently labeled 
p/MHC. Because MHC molecules in the human population are extremely polymorphic300, 
the patient’s MHC must be determined before T cell analysis can proceed. In flow 
cytometry, this approach is limited by the number of different fluorescent labels that can 
be differentiated in a single assay, as well as significant labor and reagent requirements 
for screening assays. By using pre-determined spatial coordinates rather than 
fluorescent tags on a sensor chip to identify specific interactions, microarrays are not 
constrained to the same multiplexing limits as flow cytometry. However, traditional 
fluorescence based cellular microarrays still require a labeling step during sample 
preparation to generate signal and remain technically challenging 301,302.  
GCSPRI cellular microarrays retain the increased multiplexing capacity 
afforded by other microarray systems and do not require cells to be labeled. Cell binding 
to the sensor chip is quantified by measuring the change in SPR resonance angle at 
spatially defined regions of interest (ROIs) on the sensor chip (Chabot et al. 2009). 
Binding of a cell causes the resonance angle to shift, which results in a signal that is 
proportional to the number of cells captured 303.  In a GCSPRI system, the evanescent 
wave vector extends only about 200nm from the chip surface into the dielectric medium 
above 304 meaning that only cells directly in contact with the chip surface actually 
contribute to the GCSPRI measurement. This results in sufficient sensitivity to detect a 
single human T cell captured by an immobilized antibody ROI 303. The incorporation of 
microfluidics makes this an ideal assay platform because small volumes of sample can 
be recirculated over the sensor surface to facilitate increased sampling of the cell 
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suspension. A GCSPRI sensor chip with 1 cm2 active sensor surface area is capable of 
presenting more than 103 ROIs for potential cell capture in a 50µl flow cell volume 303. 
The capacity to interrogate hundreds of peptide-MHC combinations in parallel in a 
single sample would allow screening for T cells that are specific for many putative 
disease-associated peptides in combination with multiple allelic variations of the MHC 
class I and class II molecules.  
Using the dual mode GCSPRI/SPCE based microarray described in this report, 
T cell subsets bound to the chip surface can be assessed for cytokine secretion by co-
immobilizing cell capture ligands and anti-cytokine antibodies on the same ROI 
microspot.  After cells are selectively immobilized and enumerated by GCSPRI and 
cultured on the microarray, ROIs can be probed for the presence of secreted cytokines 
using secondary antibodies conjugated to a fluorescent tag. Low levels of fluorescence 
generated in this assay can be detected because of the increased signal to noise ratio 
resulting from surface plasmon coupled emission (SPCE) (Figure 7.1). By using the 
appropriate excitation wavelength, fluorophores within 200nm of the sensor chip surface 
are excited by both the excitation laser and the surface plasmon, rather than by the 
laser alone. Interaction of the fluorescent emission with the surface plasmon 
concentrates the fluorescence towards the path of the detector, increasing optical 
collection efficiency 305. Together, increased excitation and collection efficiency improve 
the sensitivity of SPCE and allow for T cell activation status in response to stimulation to 
be characterized. By automating this process with programmed microfluidics, a dual 
mode GCSPRI/SPCE T cell detection/phenotyping assay is capable of assaying for the 
presence of hundreds of different antigen-specific T cells simultaneously and, when 
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present on the ROI in sufficient numbers, determining the functional status of the 
immobilized cells.  
 
7.1.2 Protocol Optimization 
 In GCSPRI systems, the change in SPR angle over time is based on local 
refractive index changes that occur above the spatially defined ROIs on the biosensor 
chip 306 and is proportional to the density of cells bound to specific ROIs 303.To validate 
the utility of GCSPRI as a T cell detection platform, we compared two independent 
measurements of cell capture on the same GCSPRI chip. A CD4+ T  cell population was 
fluorescently labelled with the succinimidyl ester DDAO-SE, and then captured on 20 
ROIs containing different concentrations of anti-CD3 antibody to facilitate a range of cell 
binding densities. Immobilization of antibodies for cell capture was mediated through a 
dithiobis-succinimidyl propionate (DSP) modified surface which acted as crosslinker 
between the gold chip and cell capture antibody. This surface was chosen for 
preliminary experiments because it is easily fabricated and results in uniform and 
reproducible immobilization of protein 307.The resulting GCSPRI angle shift was 
compared to the fluorescent signal for each ROI (Figure 7.3C). The high degree of of 
correlation (r2= 0.9178) between the two measurements indicates that SPR angle shift 
provides an accurate measurement of captured cell populations that is comparable to 
direct detection of fluorescently labelled cells. 
Non-specific binding (NSB) of protein and non-specific adhesion (NSA) of cells 
will influence the sensitivity of GCSPRI measurements by adding to background noise. 
Ideally, modifying the gold surface with a crosslinker will result in a more homogenous 
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and reproducible deposition of the capture ligand. This should lead to more target 
molecules or cells bound per unit area (higher activity), more reproducible analyte 
capture (less inter-assay variation), and a surface that is less sensitive to temperature 
and redox changes.  
  To test the activity of capture ligands immobilized via different surface 
modifications, we compared changes in the SPR angle using the Flexchip 8500 
GCSPRI instrument after recirculation of CH7C17 T cells that recognize the 
influenza peptide (HA 306-318) presented by HLA-DR1 (HA-DR1). Anti-CD3 
antibodies or HA-DR1 p/MHC complexes with a C-terminal cysteine were 
immobilized via passive physical adsorption to unmodified gold as a control surface 
strategy. Alternatively, immoblilization on the chip was facilitated using a 2-
(pyridinyldithio) ethylcarbamoyl dextran (PDEC dextran) which forms a covalent 
bond to the capture ligand through a free sulfhydrl group and represents the use of a 
hydrogel matrix modification. Biotinylated anti-CD3 antibodies or HA-DR1 p/MHC 
complexes with a C-terminal biotin were also immobilized via a neutravidin modified 
gold surface that utilizes a self assembled monolayer (SAM) of alkane-dithiols as a 
crosslinker (Figure 7.2A). Cell capture activity of the immobilized HA-DR1 p/MHC 
complex was similar for both the biotin-neutravidin surface and sulfhydryl-PDEC 
dextran surface immobilization strategies. However, the PDEC dextran coated 
surface showed significantly lower non-specific binding to bovine serum albumin 
(BSA) negative control ROIs compared with the other surfaces tested (Figure 7.2B).  
Most non-specific cell and protein binding occurs through electrostatic or 
hydrophobic interactions with the surface 308 and the neutral, hydrophilic PDEC 
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dextran appeared to resist NSB which reduced background to less than 10% of 
signal. The coefficient of variation (CV) for p/MHC mediated cell capture on the 
PDEC dextran surface (CV<0.05) was lower than unmodified gold (CV<0.20) or 
neutravidin (CV<0.21) and is an indirect indicator of reproducible ROI spotting of the 
capture ligands.  
  The effect of sample flow rate was tested to determine the rate that produces 
the highest specific signal to background ratio. It has been reported by other groups 
that the rate constant for cell adhesion (e.g. the number of cells captured per unit 
time) increases with velocity under the range of flow conditions used in cellular 
microarray assays 309. As the flow rate increases under these conditions, the 
encounter rate between cell surface markers and capture ligands increases but the 
duration of the interactions decreases. At very high flow rates, the adhesion rate 
begins to plateau as the two effects counterbalance each other 310. We observed that 
faster sample flow rates increased the rate of cell adhesion up to a flow rate of 500µl 
min-1 (Figure 7.3A) for our system. Flow rates below 100 µl min-1 resulted in higher 
background signals at control ROIs due to increased non-specific cell adhesion, 
which lowerd the sensitivity of antigen-specific cell detection.  
 Optimal flow rate for the removal of non-specific cell adhesion by washing the 
chip surface with media was also investigated. At flow rates between 100 and 1000µl 
min-1, removal of cells specifically bound to capture ligands was negligible, indicating 
that T cell capture via immobilized p/MHC or antibodies is a durable event. Removal of 
non-specifically bound cells was essentially equivalent for all flow rates above 1,000µl 
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min-1 after 15 min of wash (data not shown). For this reason, a flow rate of 1000µl min-1 
was used for removal of unbound cells.  
 Using these flow-rate parameters, we investigated the amount of time needed to 
generate a maximum SPR angle shift at a given ROI. Using a sample flow rate of 500µl 
min-1 we found that a maximum SPR angle shift of between 320 and 400 resonance 
change units (RCU) was generated within 30 minutes of sample exposure at anti-CD3 
or anti-CD28 containing ROIs (Figure 7.3B) on the dual mode GCSPRI/SPCE system. 
Variation in the rates of cell capture was observed when replicate ROIs were positioned 
near the center of the chip and near the flow cell edge, presumably due to laminar flow 
patterns. This positional effect disappeared when ROIs were placed more than 2mm 
from the flow cell edge and cell capture rates between 5 replicate ROIs placed at this 
minimum distance from the flow cell edge were similar (CV < 0.05) (data not shown). 
This spacing requirement was used in all cell capture microarray experiments reported 
here.  
 
7.1.3 Antigen Specific T cell Capture and Functional Characterization 
One application of GCSPRI technology is to interrogate a heterogeneous 
population of T cells and determine the presence of low-frequency T cells with specific 
antigen reactivity. To assess the limits of antigen-specific cell detection sensitivity, 
CH7C17 T cells were recirculated over a PDEC dextran biosensor chip as either a 
homogenous population, or in a mixed population with Jurkat T cells that do not 
recognize the HA-DR1 p/MHC construct. To test for non-specific binding to the DR1 
MHC, we included a tetanus toxin derived control peptide also presented by DR1. There 
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was a strong linear correlation (r2= 0.93) between antigen-specific T cell density and 
SPR angle shift (RCU). At the lower limit of detection, 0.1% HA-DR1 specific T cells in 
the pool of 6 x 106 total T cells resulted in cell capture signal that was significantly 
above signal from control peptide ROIs after 30 minutes of sample recirculation (Figure 
7.4).  
Another approach to further characterize T cells in a mixed population using 
SPR-based microarrays combines GCSPRI-based cell detection with an SPCE-based  
fluorescent measurement of cytokine secretion by captured cells. To test this application, 
we investigated whether T cell populations primed under different inducing conditions 
could be differentiated by a GCSPRI/SPCE cellular microarray. Jurkat T cells were 
exposed to TH1 inducing conditions (pre-cultured with anti-CD3, anti-CD28, IL-12 and 
IFN-gamma), TH2 inducing conditions (pre-cultured with anti-CD3, anti-CD28, IL-10 and 
IL-4), or control conditions (no stimulation) for 24 hours, followed by culture in media 
without cytokines for 24 hours. T cells were then stimulated with phytohemaglutanin 
(PHA) and captured on a dual mode GCSPRI/SPCE microarray sensor chip or 
incubated in wells for supernatant analysis by ELISA. For microarray experiments, 
antibodies against the T cell specific markers CD3 and CD28 were co-immobilized with 
a panel of anti-TH1 cytokine monoclonal antibodies to interrogate cell secretion. The 
fluorescent secretion signal was normalized to the density of captured cells at each ROI 
to determine a ratio of cytokine secretion per unit density of captured cells for each T 
cell sub population. In these experiments, cell capture signal for each of the three cell 
populations was roughly equivalent (CV < 0.08) because cells were passed over the 
chip surface until a monolayer of cells were immobilized on ROIs (Figure 7.5A). 
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Adjacent ROIs comprised of anti-TH1 cytokine antibody alone were not fluorescent, 
indicating secretion signals are specific to cells immobilized at a particular ROI (data not 
shown). 
In TH1 cytokine secretion experiments, IL-2 secretion was increased when cells 
were exposed to TH1 versus control or TH2 inducing conditions and measured by 
SPCE or ELISA (Figure 7.5). This observation shows that the measured increase in IL-2 
after pre-incubation with TH1 inducing conditions is independent of the assay format 
used to detect it. IFN-gamma secretion was also higher after TH1 compared with TH2 
inducing conditions for both SPCE and ELISA based measurements. However, IFN-
gamma levels were significantly higher for control versus TH2 conditions for both SPCE 
based assays but not in the supernatant used in the ELISA analysis. Similarly, 
increased secretion of TNF-alpha was observed after cells were induced under TH1 or 
control conditions compared with TH2 conditions and measured by SPCE. This 
difference was also not observed when the supernatant was measured by ELISA, 
where TNF-alpha secretion was only higher in TH1 compared with control conditions. 
We believe the differences in TH1 cytokine secretion profiles from SPCE versus ELISA 
experiments may reflect an additional stimulatory effect of cell capture by surface 
immobilized antibodies in the presence of PHA which is absent from cell incubation in 
wells. Furthermore, if higher levels of CD3 or CD28 surface expression correlate with 
increased IFN-gamma and TNF-alpha secretion, selecting these cells from the larger 
population could be responsible for the increased cytokine levels observed in the control 
induced populations in SPCE assays but not in ELISA experiments. In the ELISA 
experiments, secretion from these cells may have been diluted out in the larger 
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population and prevented differences being detected between TH2 and control induced 
populations. Alternatively, differences in microarray and ELISA cytokine profiles could 
be due, in part, to the release and capture of intra-cellular cytokines during cell lysis in 
microarray experiments. 
 Cells immobilized on anti-CD3 containing ROIs also produced less IL-2 after 
TH1 inducing conditions, and less TNF-alpha after control conditions compared by anti-
CD28. Additionally, cells induced under TH2 versus control conditions secreted more IL-
2 when captured by anti-CD28 (Figure 7.5C), but less IL-2 under TH2 versus control 
conditions when captured by anti-CD3 (Figure 7.5B). Preferential selection of cells 
expressing higher levels of CD3 or CD28 surface markers cannot explain the 
differences in secretion profiles under the same inducing conditions, indicating that the 
ligand used for capture can have an effect on captured cell activity. The significant 
differences in the functional phenotypes of T cells exposed to different inducing 
conditions and captured at either anti-CD3 or anti-CD28 containing ROIs demonstrates 
that T cell programming can be affected by exposure to different microenvironments, 
and that this programming contributes to a functional status that is distinct from the 
surface phenotype of the cell.  
 
7.1.4 Conclusions 
Because many autoimmune diseases are T cell mediated, detection and 
characterization of self-antigen reactive T cells is a more direct approach to specifically 
characterize an autoimmune disease and may be provide better predictive indicator of 
patient risk 311. The frequency of a diabetes antigen-associated CD8+ T cells in NOD 
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mice, for example, ranges from 0 – 0.76% of total CD8+ T cells in peripheral blood 312 
and correlates to disease with high specificity. The GCSPRI cellular microarray 
described here is sufficient to detect an antigen-specific T cell population in NOD mice 
after cells are positively selected for CD4 expression. The efficient screening of some T 
cell mediated autoimmune diseases, however, may require detection of very rare T cell 
populations and may have to overcome difficulties associated with very low avidity TCR 
– p/MHC interactions. To improve the detection sensitivity of a GCSPRI cellular 
microarray, strategies aimed at preventing non-specific cell binding or increasing the 
activity of the p/MHC reagents should be explored. Another potential approach would be 
to improve the molecular flexibility of the immobilized p/MHC complex by tethering it to a 
more flexible crosslinking surface. This could increase cell capture efficiency and result 
in more densely bound cells at p/MHC ROIs and a higher signal to noise ratio 301. Self-
assembled monolayers of functionalized oligo ethylene glycols may provide a 
scaffolding to optimize these parameters. Because the current GCSPRI optical 
configuration is sufficient to detect a single cell bound to an ROI, the challenge of 
improving sensitivity primarily involves reducing NSB and NSA to increase the signal to 
noise ratio. Lower background will result in higher sensitivity and a more accurate 
detection and quantification of specific cell populations. NSB reduction should also 
improve sensitivity of fluorescence based cell secretion assays by improving signal to 
noise ratio. 
In some cases, detection of self-antigen reactive T cells alone may not be 
sufficient to predict or diagnose disease onset. CD4+ GAD65 reactive T cells, for 
example, can be found at equivalent frequencies in healthy and type 1 diabetic 
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populations and it is their preferential activation in diabetic patients that is believed to be 
associated with disease 313. In these cases, characterizing the activation status of 
specific T cell subsets may be needed to overcome high false-positive rates that would 
be associated with a T cell screening assay that only measured the presence of self-
antigen reactive T cells. In rheumatoid arthritis patients, the ability to differentiate T cells 
based on their effector status and functional capacity has shown more promise in 
identifying individuals at risk to develop disease than the detection of antigen-specificity 
of T cells or the presence of peripheral blood cytokines alone 314.  
The diagnostic information gained by interrogating circulating populations of 
lymphocytes is not limited to autoimmune disease. For example, exposure to various 
environmental stressors such as toxic heavy metals has been demonstrated to affect T 
cell development and the response to activation signals 315. By integrating information 
about the presence of antigen-specific T cells and the functional status of immune cell 
subsets, GCSPRI/SPCE may therefore be able to screen for exposure to different 
environmental stressors. In this report, we have established the utility of GCSPRI for the 
detection of T cells on a p/MHC microarray. We have also established that mixed 
populations of T cells can be selectively sorted and detected and that selected 
populations can be interrogated for functional effector status by using SPCE.  The broad 
applications of this combination T cell detection / functional characterization platform 
could extend from early diagnosis of T cell mediated autoimmune disease to exposure 
to environmental stresses or evaluation of therapeutic efficacy. 
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Figure 7.1. Schematic Representation of Surface Plasmon Coupled 
Emission Instrumentation 
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Figure 7.2. Surface Modification of SPR Sensor Chip 
 
A. 
 
B. 
 
 
(A) Three distinct surface modification strategies were employed to test the specific 
activity of antibodies and p/MHC complexes to capture T cells on the microarray surface. 
As a control strategy (unmodified gold), antibodies were passively adsorbed to the gold 
sensor chip surface while p/MHC complexes with a C terminal cysteine residue (p/MHC 
– C) were covalently linked through a gold-thiolate bond. To evaluate a dextran 
hydrogel modification (PDEC Dextran), reduced antibodies and p/MHC – C complexes 
were immobilized through free sulfhydryl groups to modified dextran. To evaluate an 
self-assembled monolayer approach (1,9 Nonanedithiol Neutravidin), biotin labeled 
antibodies or p/MHC complexes were immobilized through neutravidin that was cross-
linked to the gold surface through a 1,9 nonanedithiol monolayer and maleimide 
interaction. Diagram is not drawn to scale. (B) CH7C17 HA peptide specific T cells (1 x 
106 cells ml -1) in RPMI 1640 were recirculated over SPR sensor chips modified with 
neutravidin or PDEC dextran or left unmodified. The net SPR angle shift (RCU) after 
recirculation is shown. Bars are averages of 3 ROI ± S.D. # indicates a significant 
difference between groups (p≤ .05). 
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Figure 7.3 Cell Capture Kinetics  
 
A. 
 
 
B. 
 
 
C. 
 
 
  
* 
(A)Anti-CD3 antibody (squares), HA-DR1 
monomers (triangles), or TT-DR1 
negative control monomers (circles) were 
immobilized on a SPR sensor surface in 
regions of interest. HA peptide specific 
CH7C17 cells (2 x 106 cells ml-1) were 
passed over a PDEC dextran treated 
SPR sensor chip for 10 minutes at 
indicated flow rates. The net shift in SPR 
angle from before and after cell sample 
exposure was divided by the time of 
sample exposure to determine cell 
capture rate. Points are the average of 3 
separate ROIs and error bars indicate ± 
S.D. (B) Anti-CD3 antibodies (circles), 
anti-CD28 antibodies (squares) or 
isotype matched negative control 
antibodies (triangles) were immobilized 
on a DSP modified GCSPRI sensor chip. 
Chips were washed with PBS (10 min) 
and a media baseline was established (5 
min). Chips were exposed to a 
suspension of Jurkat E6 T cells (2 x 106 
cells ml-1) at 500 µl min-1 for 40 minutes. 
Each line represents one ROI on the 
microarray. Arrows indicate the duration 
of cell suspension exposure to the 
sensor chip surface. (C) Jurkat E6 T 
cells (1 x 106 cells ml-1) were 
fluorescently labeled with DDAO-
SE and passed over a SPR 
sensor chip microarray containing 
a dilution series of anti-CD3 
antibody spotted in 
quadruplicate(left). The net shift in 
GCSRPI angle (RCU) was 
compared to fluorescence (AFU) 
measured by SPCE for 20 
individual regions of interest 
(ROIs) (right). Linear correlation is 
represented as r2. 
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Figure 7.4 Limits of HA-DR1 reactive T cell detection by GCSPRI 
microarray. 
 
 
 
CH7C17 HA-DR1 reactive T cells were mixed with Jurkat E6 T cells and the percentage 
of reactive cells in a cell sample of 6 x 106 total cells was varied from 100 to 0.01%. (A) 
A mixed T cell suspension was recirculated over a PDEC dextran modified SPR 
biosensor chip for 30 minutes and net GCSPRI angle shift (RCU) at ROIs containing 
cognate p/MHC (HA / DR1), negative control p/MHC (TT / DR1), or anti-CD3 antibody 
was determined. Bars are the average of 3 separate experiments ± S.D.. (B) Images of 
representative ROIs after T cell sample exposure from each condition are shown. 
#indicates a significant difference between groups (p≤ .05). 
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Figure 7.5 Cytokine release from T cells exposed to different inducing 
conditions can be differentiated by GCSPRI/SPCE microarray 
 
 
 
Jurkat E6 T cells were stimulated under TH1 or TH2 inducing conditions or control 
conditions (no stimulation) for 48 hours and then cultured for 24 hours in media without 
cytokines. (A) Cells were then captured at ROIs containing anti-CD3 or anti-CD28 
antibody and anti-TH1 cytokine antibodies and incubated on the chip in the presence of 
PHA for 3 hours to allow for cytokine secretion and capture. Cells were then lysed and 
ROIs were probed for the presence of secreted cytokines using fluorescently labeled 
secondary antibodies. (B,C) Fluorescence per unit of cell density was measured using a 
ratio of the surface plasmon coupled emission (SPCE) measurement (AFU) divided by 
the GCSPRI measurement (RCU). (D) Cells were incubated in wells of a 24 well tissue 
culture plate in the presence of PHA for 3 hours before cells were spun down and the 
supernatant was analyzed for the presence of 3 cytokines by ELISA. Bars are the 
average of 3 independent experiments ± S.D. #indicates a significant difference between 
groups (p≤ .05), ##(p≤ .002) 
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